University of Bristol, Population Health Sciences, Bristol Medical School, Canynge Hall, 39 Whatley Road, BristolUK, BS8 2PS Show
Lancaster University, International Observatory on End of Life Care, Furness College, LancasterUK, LA1 4YG Amelia O Clive, Email: [email protected], Email: ku.oc.oohay@ebmocsnudailema. Disclaimer University of Bristol, Academic Respiratory Unit, BristolUK University of Bristol, Population Health Sciences, Bristol Medical School, Canynge Hall, 39 Whatley Road, BristolUK, BS8 2PS Lancaster University, International Observatory on End of Life Care, Furness College, LancasterUK, LA1 4YG Amelia O Clive, Email: [email protected], Email: ku.oc.oohay@ebmocsnudailema. Corresponding author.Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This article is an update of "Interventions for the management of malignant pleural effusions: a network meta‐analysis" in volume 2016, CD010529. AbstractBackgroundMalignant pleural effusion (MPE) is a common problem for people with cancer and usually associated with considerable breathlessness. A number of treatment options are available to manage the uncontrolled accumulation of pleural fluid, including administration of a pleurodesis agent (via a chest tube or thoracoscopy) or placement of an indwelling pleural catheter (IPC). This is an update of a review published in Issue 5, 2016, which replaced the original, published in 2004. ObjectivesTo ascertain the optimal management strategy for adults with malignant pleural effusion in terms of pleurodesis success and to quantify differences in patient‐reported outcomes and adverse effects between interventions. Search methodsWe searched CENTRAL, MEDLINE (Ovid), Embase (Ovid) and three other databases to June 2019. We screened reference lists from other relevant publications and searched trial registries. Selection criteriaWe included randomised controlled trials of intrapleural interventions for adults with symptomatic MPE, comparing types of sclerosant, mode of administration and IPC use. Data collection and analysisTwo review authors independently extracted data on study design, characteristics, outcome measures, potential effect modifiers and risk of bias. The primary outcome was pleurodesis failure rate. Secondary outcomes were adverse events, patient‐reported breathlessness control, quality of life, cost, mortality, survival, duration of inpatient stay and patient acceptability. We performed network meta‐analyses of primary outcome data and secondary outcomes with enough data. We also performed pair‐wise meta‐analyses of direct comparison data. If we deemed interventions not jointly randomisable, or we found insufficient available data, we reported results by narrative synthesis. For the primary outcome, we performed sensitivity analyses to explore potential causes of heterogeneity and to evaluate pleurodesis agents administered via a chest tube only. We assessed the certainty of the evidence using GRADE. Main resultsWe identified 80 randomised trials (18 new), including 5507 participants. We found all except three studies at high or unclear risk of bias for at least one domain. Due to the nature of the interventions, most studies were unblinded. Pleurodesis failure rate We included 55 studies of 21 interventions in the primary network meta‐analysis. We estimated the rank of each intervention's effectiveness. Talc slurry (ranked 6, 95% credible interval (Cr‐I) 3 to 10) is an effective pleurodesis agent (moderate certainty for comparison with placebo) and may result in fewer pleurodesis failures than bleomycin and doxycycline (bleomycin versus talc slurry: odds ratio (OR) 2.24, 95% Cr‐I 1.10 to 4.68; low certainty; ranked 11, 95% Cr‐I 7 to 15; doxycycline versus talc slurry: OR 2.51, 95% Cr‐I 0.81 to 8.40; low certainty; ranked 12, 95% Cr‐I 5 to 18). There is little evidence of a difference between the pleurodesis failure rate of talc poudrage and talc slurry (OR 0.50, 95% Cr‐I 0.21 to 1.02; moderate certainty). Evidence for any difference was further reduced when restricting analysis to studies at low risk of bias (defined as maximum one high risk domain in the risk of bias assessment) (pleurodesis failure talc poudrage versus talc slurry: OR 0.78, 95% Cr‐I 0.16 to 2.08). IPCs without daily drainage are probably less effective at obtaining a definitive pleurodesis (cessation of pleural fluid drainage facilitating IPC removal) than talc slurry (OR 7.60, 95% Cr‐I 2.96 to 20.47; rank = 18/21, 95% Cr‐I 13 to 21; moderate certainty). Daily IPC drainage or instillation of talc slurry via IPC are likely to reduce pleurodesis failure rates. Adverse effects Adverse effects were inconsistently reported. We performed network meta‐analyses for the risk of procedure‐related fever and pain. The evidence for risk of developing fever was of low certainty, but suggested there may be little difference between interventions relative to talc slurry (talc poudrage: OR 0.89, 95% Cr‐I 0.11 to 6.67; bleomycin: OR 2.33, 95% Cr‐I 0.45 to 12.50; IPCs: OR 0.41, 95% Cr‐I 0.00 to 50.00; doxycycline: OR 0.85, 95% Cr‐I 0.05 to 14.29). Evidence also suggested there may be little difference between interventions in the risk of developing procedure‐related pain, relative to talc slurry (talc poudrage: OR 1.26, 95% Cr‐I 0.45 to 6.04; very‐low certainty; bleomycin: OR 2.85, 95% Cr‐I 0.78 to 11.53; low certainty; IPCs: OR 1.30, 95% Cr‐I 0.29 to 5.87; low certainty; doxycycline: OR 3.35, 95% Cr‐I 0.64 to 19.72; low certainty). Patient‐reported control of breathlessness Pair‐wise meta‐analysis suggests there is likely no difference in breathlessness control, relative to talc slurry, of talc poudrage ((mean difference (MD) 4.00 mm, 95% CI –6.26 to 14.26) on a 100 mm visual analogue scale for breathlessness; studies = 1; participants = 184; moderate certainty) and IPCs without daily drainage (MD –6.12 mm, 95% CI –16.32 to 4.08; studies = 2; participants = 160; low certainty). Overall mortality There may be little difference between interventions when compared to talc slurry (bleomycin and IPC without daily drainage; low certainty) but evidence is uncertain for talc poudrage and doxycycline. Patient acceptability Pair‐wise meta‐analysis demonstrated that IPCs probably result in a reduced risk of requiring a repeat invasive pleural intervention (OR 0.25, 95% Cr‐I 0.13 to 0.48; moderate certainty) relative to talc slurry. There is likely little difference in the risk of repeat invasive pleural intervention with talc poudrage relative to talc slurry (OR 0.96, 95% CI 0.59 to 1.56; moderate certainty). Authors' conclusionsBased on the available evidence, talc poudrage and talc slurry are effective methods for achieving a pleurodesis, with lower failure rates than a number of other commonly used interventions. IPCs provide an alternative approach; whilst associated with inferior definitive pleurodesis rates, comparable control of breathlessness can probably be achieved, with a lower risk of requiring repeat invasive pleural intervention. Local availability, global experience of agents and adverse events (which may not be identified in randomised trials) and patient preference must be considered when selecting an intervention. Further research is required to delineate the roles of different treatments according to patient characteristics, such as presence of trapped lung. Greater attention to patient‐centred outcomes, including breathlessness, quality of life and patient preference is essential to inform clinical decision‐making. Careful consideration to minimise the risk of bias and standardise outcome measures is essential for future trial design. Plain language summaryInterventions for the management of fluid around the lungs (pleural fluid) caused by cancer Review question We reviewed the evidence on the effectiveness of different methods to manage a build‐up of fluid around the lungs in people where this is caused by cancer. Background Malignant pleural effusion (MPE) is a condition that affects people with cancer of the lining of the lung. This can cause fluid to build up in the space between the outside of the lungs and rib cage (pleural cavity), often resulting in breathlessness. Treatment options focus on controlling symptoms. These include removal of the fluid using a temporary chest drain, a camera examination of the pleural cavity (thoracoscopy) or a semi‐permanent chest drain tunnelled under the skin (an indwelling pleural catheter). Introducing a chemical into the pleural cavity can also be used to prevent the fluid coming back (pleurodesis). We wanted to find out which method was the most effective for preventing fluid re‐accumulation (pleurodesis failure) and which was best in terms of side effects (including pain and fever) and other important outcomes such as breathlessness and quality of life. Study characteristics We collected and analysed relevant studies to answer this question. We were interested in high quality research, so only searched for randomised controlled trials (in which participants are randomly allocated to the treatments being tested). We analysed most data using 'network meta‐analysis', which allows lots of different interventions to be compared in one analysis. This analysis ranks the interventions in order of their effectiveness. Certainty of the evidence We rated the certainty of the evidence from studies using four levels: very low, low, moderate or high. Very low‐certainty evidence means that we are very uncertain about the results. High‐certainty evidence means that we are very confident in the results. Many of the studies were of low quality and the individual studies were quite different to each other. This made it difficult to reach definite conclusions. Key results From our searches in June 2019, we found 80 studies (18 new) involving 5507 participants (2079 new). In the network meta‐analysis, we found that giving talc through a chest tube after draining the fluid (talc slurry) resulted in fewer pleurodesis failures than other commonly used methods, such as the medicines doxycycline or bleomycin through a chest tube (low certainty). Using a thoracoscopy procedure to remove the fluid and blow talc into the chest (talc poudrage) is likely to be as effective as talc slurry (moderate certainty). We had a low level of certainty that the risk of having a fever is similar between treatments. There may be little difference between treatments in the chance of having pain (low certainty for bleomycin, IPCs and doxycycline; very‐low certainty for talc poudrage). Using an IPC, which allows intermittent drainage of fluid at home, may relieve breathlessness as much as a talc slurry procedure (low certainty). There may be little difference in the risk of death between treatments when compared to talc slurry (low certainty for bleomycin and IPC without daily drainage; very low certainty for talc poudrage and doxycycline). The chance of needing another invasive procedure to remove fluid was lower after having an IPC than after talc slurry pleurodesis (moderate certainty). Conclusions The available evidence shows that talc poudrage and talc slurry are effective ways of managing MPEs, with lower pleurodesis failure rates than a number of other commonly used methods. However, it is also important to consider global experience of these agents and knowledge of their safety and side effects when selecting the most appropriate pleurodesis method. IPCs are less likely to prevent pleural fluid from re‐accumulating than talc slurry, but may be as good at helping breathlessness. People who have an IPC are less likely to need another invasive procedure in the future to manage the pleural effusion. Further research is required to look at particular patient groups and explore outcomes such as breathlessness and quality of life in more detail. Ideally a fuller understanding of the potential harms of the treatments from the patients' perspective would also be beneficial. Summary of findingsBackgroundMalignant pleural effusion (MPE) is a common clinical problem, with an estimated annual incidence of at least 150,000 in the USA (). Fifteen percent of people diagnosed with cancer will develop pleural effusion during the course of their disease as a result of malignant infiltration of the pleura. It often confers a poor prognosis (). Breathlessness results from compression of the underlying lung and impaired diaphragmatic and chest wall movement and is often relieved by pleural fluid aspiration. This is the first update of the review published in Issue 5, 2016 (), which replaced the original review published in 2004 (). Description of the conditionMPE is a condition whereby excess fluid accumulates in the pleural cavity. It is thought to be caused by a combination of direct pleural tumour invasion, resulting in increased permeability of the pleural microvessels and obstruction of local lymph drainage channels causing reduced fluid re‐absorption (). The most common primary sites which metastasise to the pleura are lung cancer in men and breast cancer in women, but other primary sites include lymphoma, genitourinary and gastrointestinal malignancy (; ). In addition, the pleura may be the primary site of the malignancy, as is the case in mesothelioma. In the majority of cases, the diagnosis of pleural malignancy is made by cytological analysis of the pleural fluid or pleural biopsy. Depending on the clinical situation, confirmation of malignancy elsewhere and an otherwise unexplained (usually exudative) effusion may also be attributed to malignancy. Survival of these patients varies widely (; ). Tools have been developed to aid estimation of an individual's prognosis, which may in turn help with selection of the most appropriate management strategy (; ). Description of the interventionA number of different approaches may be used to manage MPE and the chosen method is likely to depend on clinical factors, patient preferences and local availability of the various techniques. Instillation of a sclerosant into the pleural cavity through an intercostal chest drain, after complete fluid drainage has been the mainstay of treatment for many years (known as 'bedside' or 'slurry' pleurodesis). This technique aims to fuse the pleural layers together by means of local inflammation induced by the pleurodesis agent, thereby preventing pleural fluid re‐accumulation. The optimal management strategy to maximise pleurodesis success in terms of the size of chest drain, patient positioning, use of analgesia and type of sclerosant has historically been the subject of debate (). Thoracoscopy is a method which can be used to drain an effusion and, during the same procedure, deliver a sclerosant into the pleural cavity with a view to achieving pleurodesis (). Thoracoscopy can either be performed under moderate sedation (medical thoracoscopy), or as a surgical procedure under general anaesthetic (video‐assisted thoracoscopic surgery (VATS)). In both techniques, the pleural fluid is drained and the pleural cavity is visualised using a fibreoptic camera. Loculations can be broken down and biopsies may be taken to gain a histological diagnosis. At the end of the procedure, a temporary chest tube is left in place to allow the lung to re‐expand. An alternative approach in the management of MPE is the use of indwelling pleural catheters (IPCs). These are long‐term chest tubes which are tunnelled under the skin and therefore allow regular, intermittent fluid drainage to be performed in the community, potentially minimising recurrent hospital attendances. They have an established role in the management of pleural effusions in people with trapped lung, but are increasingly being used for the primary management of malignant effusions as an alternative to chemical pleurodesis (; ; ). Spontaneous pleurodesis may occur, allowing the drain to be removed without recurrence of the effusion (). In certain clinical scenarios, none of the above options may be suitable and simple pleural fluid aspiration or medical management of a patient's breathlessness (e.g., using opiates) may be deemed more appropriate. This may be the case for people in the terminal phase of their illness where invasive techniques may be considered to confer unnecessary discomfort. How the intervention might workPleurodesis aims to induce inflammation between the pleural layers causing them to become adhered. This effectively obliterates the pleural space and by so doing, prevents fluid recurrence. For pleurodesis to be successful, the visceral and parietal pleural surfaces must be opposed, hence if lung expansion is incomplete, pleurodesis is more likely to fail. Trapped lung (also known as 'entrapped' or 'non‐expandable' lung) can occur when full lung expansion is limited by either a visceral pleural peel or endobronchial obstruction. In this situation, even once the fluid is drained, visceral and parietal pleural apposition does not readily occur, with attempts at inflating the lung potentially distressing for patients. This results in pleurodesis attempts being less effective and often limits the treatment options to either an IPC or surgery. IPCs allow regular, intermittent pleural fluid drainage, which relieves the pressure on the diaphragm and chest wall, and promotes lung re‐expansion. By so doing, breathlessness is improved and, in a small proportion of people, autopleurodesis may occur (). Why it is important to do this reviewDue to wider availability of pleural interventions, such as thoracoscopy under sedation and IPCs, the management options available to people with MPE are expanding. This review will help to define the most effective pleurodesis approach, primarily addressing the type of agent used. Given the availability of many pair‐wise comparisons for the method of pleurodesis administration, type of pleurodesis agent and approaches to IPC use, this is a multiple interventions review. We performed network meta‐analysis (NMA) to synthesise all the available evidence and determine a treatment hierarchy. In 2019, the National Institute for Health and Care Excellence (NICE) in the UK commissioned the priority updating of this review to inform the guideline Lung cancer: diagnosis and management [NG122] (). ObjectivesTo ascertain the optimal management strategy for adults with malignant pleural effusion in terms of pleurodesis success and to quantify differences in patient‐reported outcomes and adverse effects between interventions. MethodsCriteria for considering studies for this reviewTypes of studiesWe included reports of randomised controlled trials (RCTs) in this review. This included randomised cross‐over trials and cluster randomised trials, although we did not identify any studies of these types. We included both single‐ and multicentre studies. We excluded studies that were stated to be randomised, but were at high risk of bias for adequate sequence generation or allocation concealment. Types of participantsInclusion
Exclusion
Types of interventionsWe identified studies comparing the following.
We generated a network of interventions, including comparisons between the types of sclerosant, mode of administration and IPC use. We assumed that any participant meeting the inclusion criteria could be, in principle, randomised to any of the eligible interventions. This is referred to as the interventions being 'jointly randomisable'. However, if we considered an intervention was not jointly randomisable, for example the treatment was specific to a certain tumour type, we reported the results separately from the network (). Interventions of direct interestWe included RCTs that evaluated one or more of the following intrapleural interventions: talc poudrage, talc slurry, bleomycin, tetracycline, doxycycline, iodine, C parvum, IPC (both daily drainage and without daily drainage), talc administered via IPC, mitoxantrone, mustine, mepacrine, interferon, triethylenethiophosphoramide and adriamycin compared with another intervention or placebo. If we identified other sclerosants that we were not aware of, we considered them as eligible and included them in the network after assessing their comparability with the prespecified set of competing interventions. We reported the findings for these interventions in the results and the conclusions of the review. Types of outcome measuresPrimary outcomesEfficacy of pleurodesis was our primary outcome measure. Definitions of pleurodesis failure varied between studies and although current practice would define this by a lack of recurrence of symptoms or need for a repeat pleural intervention to manage the effusion, some older studies used less clinically relevant definitions (e.g. re‐accumulation of effusion on imaging). We still included these studies in the review, and documented the method used to define pleurodesis for all studies in the assessment of the risk of bias. For the purposes of the primary outcome, we used the following hierarchy of preferences to judge pleurodesis failure (if a study reported more than one definition of pleurodesis failure, the highest of these according to this hierarchy was used):
For studies evaluating IPCs, we judged that an effective pleurodesis was achieved when there was cessation of pleural fluid drainage or device removal due to cessation of drainage, or both. Similarly, we selected the time point used to define pleurodesis efficacy using the following hierarchy of preferences:
For participants who died before the time point at which pleurodesis efficacy was assessed, we classified these according to their last known pleurodesis outcome prior to their death (i.e. their last observation carried forward). If these data were not provided, we used the available reported data. Secondary outcomes
Search methods for identification of studiesTrials that compared at least two of the interventions (including placebo) were eligible. We included all possible comparisons formed by the interventions of interest. Electronic searchesTo identify studies for inclusion in this review, we searched the following databases:
The search strategies can be viewed in . There were no language restrictions. We included single and multicentre studies. Searching other resourcesWe screened the reference lists from the included studies for additional publications. We searched the reference lists from relevant chapters in key resources, such as the British Thoracic Society Pleural Disease Guidelines (). We searched clinicaltrials.gov (www.clinicaltrials.gov), and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/) for ongoing trials. Data collection and analysisSelection of studiesOne author screened all titles and abstracts retrieved by the search for relevance (AOC). For the 2020 update, this was performed by two authors (AOC and AD) using the platform. We identified potentially eligible studies and obtained the full papers. Two review authors (AOC and NAM or AD) independently assessed each full text for inclusion in the review and resolved any disagreement through discussion or by a third review author (NP). Data extraction and managementTwo review authors (two of AOC, RB, NP and NAM up to 2016; two of AOC, AD and RB; and NP and NAM from 2016 to 2020) extracted data from each included study. We resolved disagreements through discussion and referral to one of the other review authors. If a review author was involved in one of the included studies, they did not perform the data extraction for that study. Data collected included the following.
We requested additional data from the study authors as required. One review author (AOC or AD) entered outcome data suitable for pooling into Cochrane's statistical software (). Where we performed a NMA, we transferred data to the WinBUGS software (). Assessment of risk of bias in included studiesWe limited inclusion to studies that were randomised as a minimum. Two review authors (two of AOC, RB, NP and NAM up to 2016; two of AOC, AD, RB, NP and NAM from 2016 to 2020) independently assessed risk of bias for each study, using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (), with any disagreements resolved by discussion. In our original protocol, we had planned to include sample size in our risk of bias assessment. However, in view of Cochrane guidance stating imprecision should not be considered a risk of bias, we did not perform this assessment (). We assessed the following for each study. Random sequence generation (checking for possible selection bias)We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random‐number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process, that is, at high risk of bias (e.g. odd or even date of birth; hospital or clinic record number). Allocation concealment (checking for possible selection bias)The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies at high risk of bias that did not conceal allocation (e.g. open list). Blinding of participants and personnel (checking for possible performance bias)We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated there was blinding of participants and key study personnel and unlikely blinding could be broken, or no blinding or incomplete blinding but the outcome not likely to be influenced by lack of blinding); unclear risk of bias (insufficient information to permit judgement of low or high risk of bias); high risk of bias (no blinding or incomplete blinding, which is likely to influence the trial outcome or blinding attempted but likely it could have been broken and the outcome is likely to be influenced by lack of blinding). Blinding of outcome assessment (checking for possible detection bias)We assessed the methods used to blind outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was not blinded but the review authors judged that the outcome measurement was not likely to be influenced by lack of blinding or blinding of outcome assessment was ensured); unclear risk of bias (study provided an inadequate description to permit judgement of low risk or high risk); high risk of bias (no blinding of outcome assessment and outcome likely to be influenced by lack of blinding, or there was blinding of the outcome assessment but likely that the blinding could have been broken). Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)We assessed the methods used to deal with loss to follow‐up (LTFU) for each of the given studies. Due to the challenges of inevitable missing outcome data given the predictable attrition of patients due to death in the palliative care population, we took into account whether missing data had been justified, whether the rate was similar in the different treatment arms, whether the treatment being evaluated was felt to have an impact on the degree of missing outcome data and whether an intention‐to‐treat (ITT) analysis had been attempted. We assessed the methods used to deal with incomplete data as: low risk (rate of missing data were balanced between the treatment arms, seemed reasonable and had been justified; data had been analysed according to the participants' randomised treatment allocation; a suitable imputation method may have been used to account for missing data); unclear risk of bias (insufficient information given to allocate trial to high‐ or low‐risk group); high risk of bias (imbalanced missing outcome data between the treatment arms or missing outcome data felt to be related to the true outcome; reasons for LTFU poorly justified; no attempt at ITT analysis; inappropriate imputation used). Selective outcome reportingWe assessed the studies for selective outcome reporting using the following criteria: low risk of bias (all outcomes predefined and reported, e.g. in a published protocol, or all clinically relevant and reasonably expected outcomes were reported); uncertain risk of bias (unclear whether all predefined and clinically relevant outcomes were reported); high risk of bias (one or more clinically relevant and reasonably expected outcome was not reported and data on these outcomes were likely to have been recorded). Other sources of biasThis section was used to report other biases, which were detected but did not fit into the above categories (e.g. industry bias, academic bias or other methodological flaws that may have caused bias). We assessed the methods used to deal with other sources of bias as: low risk of bias (the trial appeared free from other potential biases); unclear risk of bias; high risk of bias (other source of bias was identified). Measures of treatment effectRelative treatment effectsFor proportions (dichotomous outcomes), such as pleurodesis efficacy and mortality, we calculated the odds ratio (OR) with 95% confidence intervals (CIs). For continuous data (such as length of hospital stay and cost), we planned to use the mean difference (MD) with 95% CIs and the number needed to treat for an additional beneficial efficacy outcome (NNTB), and the number needed to treat for an additional harmful outcome (NNTH) for adverse effects. We planned to treat ordinal outcome measures (e.g. breathlessness scales and quality of life data) as continuous so long as the scale was sufficiently long. If different scales were used by the included studies, we planned to use the standardised mean difference (SMD) in meta‐analyses. We presented results from both pair‐wise standard meta‐analysis (both random and fixed effect) and NMA (random effects only) as summary relative effect sizes (OR, MD or SMD with 95% CIs) for each possible pair of treatments (). Relative treatment rankingBased on the results of the NMA, we estimated the rank of each competing intervention's effectiveness. We presented estimated ranks (medians) with 95% credible intervals (Cr‐Is) (representing uncertainty about the true rank) produced from the Bayesian analyses (). Unit of analysis issuesIf repeated observations on the same participants occurred during the trial (e.g. pleurodesis success rate at different time points), we analysed these separately. We used only one measure per participant for the primary endpoint (according to the hierarchy of preferences detailed above ). For the purpose of meta‐analysis, if a study had multiple doses for a certain substance, we combined and compared all relevant experimental intervention groups with the combination of all relevant control groups. We reported any evidence for effects of the different doses descriptively. For cross‐over trials, we planned to analyse data using pair‐wise meta‐analysis, taking into account the cross‐over design. If meta‐analysis had been performed containing cluster randomised trials and the presented results had not accounted for clustering, then we planned to make an appropriate adjustment, as described in the Cochrane Handbook for Systematic Reviews of Interventions (). We treated multi‐arm studies as multiple independent two‐arm studies in the standard pair‐wise meta‐analysis. In the NMA, we accounted for the correlation between the effect sizes from multi‐arm studies. In meta‐analysis of continuous outcomes, we pooled differences in change from baseline, rather than differences in final values (). Dealing with missing dataWe attempted to contact the authors of included studies to clarify any missing data. We imputed missing standard deviations (SD) based on the mean SDs from the other included studies if SDs for mean scores had not been reported and it had not been possible to obtain the information from the study authors. We only included data for those participants whose results were known if an ITT analysis was not reported by the study. However, we assessed the potential impact of these missing data in the 'Risk of bias' table. For continuous outcomes, where baseline and final values were reported without a SD of change score or correlation coefficient, we imputed correlation coefficients based on other studies in order to estimate the SD of change. Assessment of heterogeneityAssessment of clinical and methodological heterogeneity within treatment comparisonsWe extracted data from study reports regarding clinical heterogeneity such as details on the intervention and control treatments, participant characteristics and the outcomes evaluated. We assessed the presence of clinical heterogeneity within each pair‐wise comparison by comparing the study population characteristics across all eligible trials. We only performed meta‐analysis when considered reasonable based on the degree of heterogeneity. Assessment of transitivity across treatment comparisonsWe assessed the assumption of transitivity by comparing the distribution of the potential effect modifiers across the different pair‐wise comparisons (). Assessment of reporting biasesWe performed searches in multiple databases to ensure all potentially eligible studies were identified (). The review authors were alert to duplicated publication of results when analysing the studies to ensure each participant was only included once in the analysis. If unpublished studies were identified, we tried to obtain sufficient information in order for them to be included in the analysis. The same applied for data published in abstract format. In studies published in a language other than English, we made every effort to obtain a translation of at least the abstract. If sufficient information was available, we included the study in the analysis. Data synthesisMethods for direct treatment comparisonsSince we expected some clinical heterogeneity between studies (e.g. due to different definitions of pleurodesis success, different time points and doses used), we believed that the assumption of a single fixed intervention effect across included studies was unlikely to be valid. Our primary analyses therefore employed random‐effects models. Since pooled effect estimates from random‐effects models give relatively more weight to smaller studies, which is often considered undesirable, we performed sensitivity analyses using fixed‐effect meta‐analysis models. We performed standard pair‐wise meta‐analysis using a random‐effects model in Cochrane's statistical software, , for every treatment comparison with two or more studies. For binary outcome data, we meta‐analysed ORs. For continuous data, we planned to use the MD or SMD and perform a check to identify if continuous outcome data were skewed. If this was the case, we planned to analyse the data on a log scale. If we assessed studies as unsuitable for meta‐analysis, or insufficient studies were identified for meta‐analysis to be performed, we planned to present data by means of a narrative synthesis. If sufficient data were available, we used similar analysis methods to analyse the adverse effects data. Alternatively, we summarised this qualitatively. Methods for indirect and mixed comparisonsWherever possible, we performed a multiple‐intervention, NMA of primary and (separately) of each secondary outcome measure. We used a Bayesian random‐effects model, fitted using the WinBUGS software (; ). We assumed binomial likelihoods for count data, and modelled log ORs as random effects across studies. We assigned vague prior distributions with mean 0 and SD of 100 to all mean log ORs and to baseline event rates in each study on the logit scale. We assumed a common between‐studies SD within a network, represented by the parameter Tau which was assigned a Uniform (0.2) prior distribution. For each NMA, we used the Stata software to generate a network plot (using the networkplot command) and inconsistency plot (using the ifplot command) (). Subgroup analysis and investigation of heterogeneityAssessment of statistical heterogeneityIn pair‐wise meta‐analyses, we estimated the between‐study SD (Tau2) separately for each intervention comparison. We also reported the I2 statistic for each pair‐wise meta‐analysis, which is an estimate of the proportion of variability in effect estimates that is due to heterogeneity (). The assessment of statistical heterogeneity in the NMA was based on the magnitude of and Cr‐Is for the between‐studies SD (Tau), which was assumed to be common across all comparisons within a network. As described below, reasons for heterogeneity were investigated using subgroup or sensitivity analyses. Assessment of statistical inconsistencyInconsistency in the network refers to differences between the direct and indirect effect estimates for the same comparison (). We used both a loop‐specific approach and a global approach to evaluate these effects. To evaluate the presence of inconsistency locally we used the loop‐specific approach. This assesses the consistency assumption in each closed loop of the network separately. We identified all the triangular loops (comprising three direct treatment comparisons, all compared with each other) and all the quadratic loops (involving four comparisons) in the network. We compared the differences between the direct and indirect estimates for these loops to generate inconsistency factors, with 95% CIs, calculated and displayed graphically using the 'ifplot' command in Stata (; ). We assumed the estimated between‐study SD (Tau) from the Bayesian analysis of the full network for each loop. We used the magnitude of the inconsistency factors to infer the presence and degree of inconsistency in each loop. In addition to this, we used a global approach, involving formally comparing the fit of the NMA model (which assumes consistency) with that of an 'inconsistency' model (in which all consistency constraints are removed). The inconsistency model used is equivalent to fitting a random‐effects meta‐analysis model for all pair‐wise comparisons, with a shared between‐studies variance parameter but no assumptions about direct and indirect evidence forming coherent 'loops'. We calculated the mean residual deviance and the deviance information criterion (DIC) for each model (mean residual difference +pD). If the DIC for the inconsistency model was more than five units higher than that of the consistency model, this was viewed as evidence of inconsistency (). We further examined differences in the estimated between‐study SD parameter (Tau) across the two models: a reduced estimate of Tau in the inconsistency relative to the NMA model may also be indicative of inconsistency (). Further, for the main analyses, we plotted the mean residual deviance contributions of each data point under the inconsistency versus NMA models. This allows identification of specific data points for which the inconsistency model has improved fit, that is, data points that are potentially inconsistent with the network (). Assessment of statistical imprecisionWe evaluated precision of results, and subsequent rankings, based on their 95% CIs (for pair‐wise analysis) or Cr‐Is (for Bayesian NMA). Sensitivity analysisSensitivity analysis and investigation of heterogeneity and inconsistencyWe conducted subgroup or sensitivity network meta‐analyses by re‐running the model on restricted numbers of studies according to the following potential effect modifiers, which we felt could be sources of inconsistency or heterogeneity, or both:
In the protocol, we planned to investigate different tumour types, age of participants and baseline performance status, although there were insufficient data on this in the included studies to perform these subgroup analyses. We performed a post‐hoc sensitivity NMA evaluating only pleurodesis agents delivered via a chest tube (as opposed to being given at thoracoscopy). We removed the trials evaluating talc poudrage and IPC use from the main network and repeated the analysis. We performed sensitivity analyses of direct evidence on pleurodesis failure using fixed‐effect meta‐analysis models, since pooled effect estimates from random‐effects models give relatively more weight to smaller studies, which is often considered undesirable. We performed an additional post‐hoc pair‐wise meta‐analysis comparing ipsilateral repeat invasive pleural intervention rates (where data were available). Summary of findings and assessment of the certainty of the evidenceWe created 'summary of findings' tables for the most clinically relevant outcomes: pleurodesis failure and breathlessness. We summarised adverse event data for procedure‐related pain and fever. Data on mortality were also included. We included the need for an additional invasive pleural procedure, due to failure of the initial intervention for pleural fluid control, as this is an important outcome of relevance to both patients and clinicians. We used talc slurry as our reference comparator. We graded evidence relating to the most commonly compared interventions with the most widespread availability. We calculated anticipated absolute effect estimates using data from NMA for pleurodesis failure, pain, mortality and fever. We used pair‐wise analysis results for breathlessness and repeat pleural intervention. We followed the approach proposed by Yepes‐Nunez and colleagues and the methods and recommendations described in Chapter 14 of the Cochrane Handbook of Systematic Reviews of Interventions (; ). Two review authors (AD and AOC) rated the quality of the direct and indirect evidence using GRADE methodology. We considered study limitations (overall risk of bias), assessments of inconsistency (heterogeneity), indirectness and intransitivity, imprecision and publication bias. We justified and documented judgements, which have been incorporated into the reporting of results for each outcome. We reached an overall judgement on the certainty in the estimate of the effect across these considerations, classified as 'high', 'moderate', 'low' or 'very low'. Our 'interpretation of findings' reflects this certainty of evidence outcome and, where available, this was combined with the overall ranking of each intervention in our NMA. ResultsDescription of studiesResults of the searchWe performed the literature search in June 2019, covering the period from April 2015 when searches for the previous edition of this review were conducted (Figure 1). We identified 1396 records from database searches before exclusion of three duplicates. We identified one additional record from references listed in a systematic review (, referenced in ). From trials registry searches, we identified 21 records. Open in a separate window 1 Study flow diagram. We screened 1415 abstracts, of which 156 full‐text articles were retrieved and assessed for eligibility. A total of 18 studies met eligibility criteria (see table). The 18 studies identified in our updated literature search were combined with the 62 studies from the previous Cochrane Review (). From the combined total of 3065 records screened and 363 full‐text reviews across the two searches, we included 80 studies (5507 participants randomised between 1977 and 2018) in this review. We excluded 15 studies (four identified from the 2019 literature search), following an initial assessment that they were eligible for inclusion (see table). Thirteen texts are awaiting classification (see table). Eight studies are ongoing (see table). Included studiesForty‐six studies analysed the efficacy of a variety of pleurodesis agents. Twenty‐seven trials evaluated talc, which was the most studied agent. Bleomycin and tetracycline were other commonly studied agents. Eight studies evaluated IPCs. Four studies compared IPCs with talc slurry (; ; ; ), and one with doxycycline pleurodesis (). Techniques to optimise outcomes from IPCs were also considered; two examined IPC drainage regimens (daily drainage versus symptom‐guided or alternate day regimens) (; ), and one randomised participants to talc slurry administered via IPC or IPC with saline placebo (). Five studies evaluated the mode of administration of the pleurodesis agent; four compared talc poudrage with talc slurry (; ; ; ), and one compared instillation of tetracycline thoracoscopically or through an intercostal cannula (). Some studies evaluated alternative techniques to improve pleurodesis success rates; one study examined catheter size (); one examined a combination of chest drain size and analgesia (non‐steroidal anti‐inflammatory drugs (NSAIDs) versus opiates) (); three evaluated the duration of drainage after pleurodesis (; ; ); one evaluated the duration of drainage prior to instillation of the sclerosant (); one assessed whether participant rotation improved pleurodesis rate (); and one evaluated the effect of talc particle size (). Three studies evaluated intrapleural fibrinolytics (; ; ). One RCT evaluated administration of three different doses of silver nitrate through a chest tube (), and one evaluated two different doses of iodine through a chest tube (). Three studies compared surgical techniques to talc pleurodesis; one comparing talc pleurodesis with pleurectomy (), and two comparing talc slurry with thoracoscopic mechanical pleurodesis (TMP) (; ). Additionally, we identified eight studies of agents specifically for the treatment of effusions due to lung cancer (; ; ; ; ; ; ; ). There were a number of methodological differences between the included studies. Fifty‐nine of 80 studies included all tumour types. Two included all except mesothelioma; one included only mesothelioma; one included all except lymphoma and small cell lung cancer; two included only adenocarcinoma; eight included only breast cancer; and seven studies included only participants with lung cancer. The time point at which pleurodesis was evaluated varied widely between studies, from one to 12 months. In addition, the methods used to define pleurodesis failure varied. Nineteen of the 80 studies used radiological criteria only to define a pleurodesis failure. The remaining 61 studies incorporated symptomatic recurrence or need for a repeat pleural intervention into their definition. Six studies evaluating IPCs defined pleurodesis success by cessation of drainage from the catheter. Pleurodesis techniques were not standardised. Studies used a variety of chest drain sizes and durations of drainage after sclerosant administration. Participants with trapped lung were excluded from 38/80 studies. Excluded studiesWe excluded 15 studies in total after initially being considered eligible for inclusion, but with reasons for exclusion identified later ( table). Three studies included data for participants with ascites, which could not be separated from participants with pleural effusions (; ; ). Ten studies were not randomised (high risk of bias for sequence generation) and therefore excluded as per protocol (; ; ; ; ; ; ; ; ; ). One study combined data for adults and children (). One study, initially included as an ongoing study, was published during the process of this review. On full‐text review of the published paper, it did not meet criteria for inclusion, as the primary outcome was recruitment rate for a future multicenter phase 3 trial (). Studies awaiting classificationThirteen texts are awaiting classification ( table). Ongoing studiesEight studies are ongoing ( table). Risk of bias in included studiesA summary assessment of the risk of bias is presented in the table, Figure 2 and Figure 3. Three studies were at low risk of bias in all domains (; ; ). Open in a separate window 2 Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Open in a separate window 3 Risk of bias summary: review authors' judgements about each risk of bias item for each included study. AllocationAll 80 studies were stated to have been randomised. Forty‐seven of these documented adequate sequence generation. The most commonly used methods were computer or telephone randomisation services, block randomisation, stratification, opaque sealed envelopes or a random number generator. Since we excluded studies with inadequate methods of sequence generation as per the protocol, sequence generation was unclear in the remaining 33 studies. Allocation concealment was at low risk of bias in 42 studies. Since we excluded studies with inadequate allocation concealment, as per the protocol, allocation concealment was unclear for the remaining 38 studies. BlindingBlinding of participants and personnel (performance bias)Due to the nature of many of the interventions evaluated in this review, blinding of the participants and clinicians was often not possible. Thus, 49/80 studies were at high risk of bias for this domain. Many of the pleurodesis agents have differing visual appearances and those studies randomising participants to different modes of administration, an IPC or surgery could not feasibly be blinded. We assessed nine studies as low risk of performance bias and 22 as unclear. Blinding of outcome assessment (detection bias)The assessment of pleurodesis success could often not be blinded, as it was reliant on symptom reporting from unblinded participants, in association with the radiological findings of effusion recurrence. Few studies reported whether the radiological assessments were performed using a blinded method. Thirty‐one of 80 studies were at high risk of detection bias, and a further 33 of 80 studies had an unclear risk of bias for this domain. Sixteen studies were low risk of detection bias. Incomplete outcome dataMost studies were at low risk of bias because although there was some inevitable attrition due to death, the rates were comparable for the treatment arms. We classified 13 studies at high risk of bias; nine due to very high attrition rates (; ; ; ; ; ; ; ; ); one due to very imbalanced LTFU between the treatment arms (); in one the number randomised was not stated (); for one the numbers provided did not add up (); and one excluded participants from the analysis who discontinued treatment due to an allergic reaction (). The risk of bias was unclear in six (: number of randomised participants not stated, only stated number of participants analysed; : unable to access tables, and numbers only given as percentages, rather than absolute values; : duration of trial follow‐up unclear; and : numbers of participants LTFU not stated; : withdrawals not stated, and unclear how many participants included in final outcome analysis). Selective reportingMost studies were at low risk of bias for selective outcome reporting. We classified two studies as unclear; one as minimal raw data were presented in the text and the tables could not be accessed (), and the other because pleurodesis success data were not collected in an RCT of talc and tetracycline pleurodesis (although the study was not designed to evaluate this) (). Nine studies were at high risk; four provided minimal or no data regarding adverse effects or survival, or both (; ; ; ); one did not report data on 15/100 participants randomised (); one did not report pleurodesis outcomes for 11/40 participants and did not give information on LTFU (); one did not report how long participants were followed up for or state the time at which pleurodesis failure was assessed (); and two did not report on a stated outcome (: time to pleural effusion relapse; : breathlessness). Other potential sources of biasWe classified 11/80 studies at high risk of bias in the 'other' domain. The risk of bias was unclear in three studies. This was for a variety of reasons (see table). The remaining studies had a low risk of bias for this domain. Effects of interventionsSee: Table 1; Table 2; Table 3; Table 4; Table 5; Table 6 Summary of findings for the main comparisonPleurodesis failure rate in adults with malignant pleural effusion Patient or population: adults with malignant pleural effusion Open in a separate window aDowngraded one level: evidence of indirectness. Of the studies evaluating talc slurry, 13/19 excluded trapped lung and 12/19 used a clinical definition of pleurodesis success. Of the studies in the network evaluating bleomycin, 9/21 excluded trapped lung and 12/21 used a clinical definition of pleurodesis success and variability in the dose of bleomycin noted. Summary of findings 2Adverse effects: procedure‐related fever in adults with malignant pleural effusion Patient or population: adults with malignant pleural effusion Open in a separate window aDowngraded one level for imprecision due to wide credible intervals of all network estimates. Summary of findings 3Adverse effects: procedure‐related pain in adults with malignant pleural effusion Patient or population: adults with malignant pleural effusion Open in a separate window aDowngraded one level for imprecision due to wide credible intervals of network estimates. Summary of findings 4Patient‐reported control of breathlessness in adults with malignant pleural effusion Patient or population: adults with malignant pleural effusion Open in a separate window aDowngraded one level for study limitations: lack of blinding of participants and clinicians (due to nature of trial interventions) leading to increased risk of bias in VAS score reporting. Summary of findings 5Overall mortality in adults with malignant pleural effusion Patient or population: adults with malignant pleural effusion Open in a separate window aDowngraded one level for imprecision due to wide credible intervals of all network estimates. In the talc poudrage to talc slurry comparison 3/7 RCTs included only people with breast cancer. Summary of findings 6Patient acceptability: need for repeat invasive pleural intervention in adults with malignant pleural effusion Patient or population: adults with malignant pleural effusion Open in a separate window aDowngraded one level: evidence of indirectness: people with trapped lung excluded by , but not or . Primary outcome: pleurodesis failure ratePair‐wise (direct) meta‐analysisResults of the direct, pair‐wise random‐effects meta‐analysis of the main pleurodesis techniques for the primary outcome of pleurodesis failure are presented in Table 7. Few studies made the same direct comparisons; meta‐analysis was therefore only possible for 12 direct comparisons. Results are also displayed for an additional 30 direct comparisons that were each made in only one study (Table 7). 1Direct meta‐analysis of pleurodesis failure using the random‐effects model showing the odds ratios (95% CI) of the rows compared to the columns AdriamycinAutologous bloodBleomycinC parvumDoxycyclineIFNIPC – daily drainageIPC – not daily drainageIodineMepacrineMitoxantroneMustinePlaceboSilver nitrateTMPTalc poudrageTalc slurryTalc via IPCTetracyclineAutologous bloodNANANANANANANANANANANANANANANANA/NA/BleomycinNANANA///NANA///NANANANA//NA/C parvumNANA0.55 (0.01 to 57.48); n = 2; Tau2 = 10.59; I2 = 94%NA/NANANANANANA/NANANANANANA/DoxycyclineNANA0.67 (0.24 to 1.86); n = 2; Tau2 = 0; I2 = 0%1.91 (0.43 to 8.48); n = 1NANANA/NANANANANANANA/NANANAIFNNANA3.25 (1.54 to 6.89); n = 1NANANANANANANANANANANANANANANANAIPC – daily drainageNANANANANANANA/NANANANANANANANA/NANAIPC – not daily drainageNANANANA4.28 (1.59 to 11.54); n = 1NA3.23 (1.79 to 5.85); n = 2; Tau2 = 0; I2 = 0%NANANANANANANANANA//NAIodineNANA0.65 (0.22 to 1.96); n = 2; Tau2 = 0.16; I2 = 25%NANANANANANANANANANANANA//NANAMepacrineNANA0.16 (0.03 to 0.89); n = 1NANANANANANANA/NA/NANANA/NA/Mistletoe (viscum)NANA0.19 (0.02 to 1.62); n = 1NANANANANANANANANANANANANANANANAMitoxantroneNANA3.18 (1.17 to 8.65); n = 1NANANANANANA7.61 (0.35to 163.82); n = 1NANA/NANANANANANAMustine2.71 (0.1 to 74.98); n = 1NANA10.80 (1.64 to 70.93); n = 1NANANANANANANANANANANA/NANA/PlaceboNANANANANANANANANA14.4 (1.37 to 150.81); n = 11.33 (0.56 to 3.17); n = 1NANANANANA/NA/Silver nitrateNANANANANANANANANANANANANANANANA/NA/TMPNANANANANANANANANANANANANANANANA/NANATalc poudrageNANA0.1 (0.02 to 0.48); n = 2; Tau2 = 0; I2 = 0NA0.02 (0.00 to 0.47); n = 1NANANA0.57 (0.08 to 3.80); n = 1NANA0.13 (0.02 to 0.71); n = 1NANANANA/NA/Talc slurryNA0.69 (0.24 to 1.95); n = 10.82 (0.37 to 1.82); n = 5; Tau2 = 0.1; I2 = 12%NANANA0.30 (0.08 to 1.14); n = 1 0.18 (0.07 to 0.45); n = 2; Tau2 = 0.26; I2 = 61% 0.85 (0.24 to 3.08); n = 2; Tau2 = 0; I2 = 0%0.48 (0.14 to 1.60); n = 1NANA0.07 (0.00 to 1.51); n = 15.82 (0.21 to 158.82); n = 12.28 (0.83 to 6.23); n = 2; Tau2 = 0; I2 = 0%1.24 (0.92 to 1.65); n = 4; Tau = 0; I22 = 0%NANA/Talc via IPCNANANANANANANA 0.36 (0.18 to 0.73); n = 1 NANANANANANANANANANANATetracycline0.90 (0.05 to 16.59); n = 10.71 (0.14 to 3.60); n = 12.00 (1.07 to 3.75); n = 5; Tau2 = 0; I2 = 0%3.18 (0.52 to 19.64); n = 1NANANANANA1.60 (0.12 to 20.99); n = 1NA0.37 (0.10 to 1.35); n = 2; Tau2 = 0; I2 = 0%0.30 (0.05 to 1.94); n = 10.60 (0.15 to 2.47); n = 1NA12.10 (1.32 to 111.30); n = 10.78 (0.19 to 3.13); n = 1NANATriethylenethiophosphoramideNANANA NANANANANANA4.95 (1.02 to 24.10); n = 1NANA0.34 (0.03 to 3.69); n = 1NANANANANANA* Indicates that the comparison included a three‐arm study. Open in a separate window IFN: interferon; IPC: indwelling pleural catheter; n: number of studies included in the pair‐wise comparison; NA: no direct pair‐wise comparison available; TMP: thoracoscopic mechanical pleurodesis. In most cases, there was no evidence against the null hypothesis of no true difference between interventions (Table 7). However, in 14/42 direct comparisons made, the OR and 95% CI lay away from the null value of 1, giving evidence against the null hypothesis of no difference. A number of interventions had a higher pleurodesis failure rate than talc poudrage. This included tetracycline (pleurodesis failure of tetracycline versus talc poudrage: OR 12.10, 95% CI 1.32 to 111.30; studies = 1; participants = 33; Analysis 4.1; bleomycin: OR 9.70, 95% CI 2.10 to 44.78; studies = 2, participants = 57; Analysis 1.1; doxycycline: OR 42.69, 95% CI 2.13 to 856.61; studies = 1, participants = 31; Analysis 8.1; mustine: OR 8.00, 95% CI 1.40 to 45.76; studies = 1, participants = 37; Analysis 16.1). 1.1 Analysis Comparison 1 Bleomycin, Outcome 1 Pleurodesis failure rate. 4.1 Analysis Comparison 4 Tetracycline, Outcome 1 Pleurodesis failure rate. 8.1 Analysis Comparison 8 Doxycycline, Outcome 1 Pleurodesis failure rate. 16.1 Analysis Comparison 16 Mustine, Outcome 1 Pleurodesis failure rate. The evidence suggests that participants treated with an IPC had more pleurodesis failures than those receiving talc slurry. Two studies compared talc slurry to IPCs without daily drainage (OR 0.18, 95% CI 0.07 to 0.45; studies = 2, participants = 249; Analysis 2.1; ; ). One study compared talc slurry to daily IPC drainage (: OR 0.30, 95% CI 0.08 to 1.14; participants = 55; Analysis 2.1). Two studies comparing IPCs without daily drainage to IPCs with daily drainage suggested a higher pleurodesis failure rate in those without daily drainage (OR 3.23, 95% CI 1.79 to 5.85; participants = 236; Analysis 6.1; ; ). Results from one study suggest that talc administration via IPC may result in fewer pleurodesis failures than drainage alone (OR 0.36, 95% CI 0.18 to 0.73; participants = 139; Analysis 25.1; ). 2.1 Analysis Comparison 2 Talc slurry, Outcome 1 Pleurodesis failure rate. 6.1 Analysis Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 1 Pleurodesis failure rate. 25.1 Analysis Comparison 25 Talc via indwelling pleural catheter (IPC), Outcome 1 Pleurodesis failure rate. There was evidence that tetracycline, mitoxantrone and interferon were less effective (i.e. associated with a higher likelihood of pleurodesis failure) than bleomycin (tetracycline: OR 2.00, 95% CI 1.07 to 3.75; studies = 5, participants = 220; Analysis 4.1; mitoxantrone: OR 3.18, 95% CI 1.17 to 8.65; studies = 1, participants = 85; Analysis 17.1; interferon: OR 3.25, 95% CI 1.54 to 6.89; studies = 1, participants = 160; Analysis 12.1). Bleomycin and triethylenephosphoramide were less effective than mepacrine (bleomycin: OR 6.40, 95% CI 1.12 to 36.44; studies = 1, participants = 36; Analysis 1.1; triethylenephosphoramide: OR 4.95, 95% CI 1.02 to 24.10; studies = 1, participants = 29; Analysis 13.1). 12.1 Analysis Comparison 12 Interferon (IFN), Outcome 1 Pleurodesis failure rate. 13.1 Analysis Comparison 13 Triethylenethiophosphoramide, Outcome 1 Pleurodesis failure rate. 17.1 Analysis Comparison 17 Mitoxantrone, Outcome 1 Pleurodesis failure rate. There was generally little evidence of statistical heterogeneity between studies making direct comparisons. However, the comparison between C parvum and bleomycin estimated a very high level of heterogeneity (Tau2 = 10.59, I2 = 94%) because the two included studies had conflicting results (C parvum versus bleomycin: OR 0.05, 95% CI 0.01 to 0.29 in ; OR 5.69, 95% CI 1.38 to 23.48 in ; Analysis 5.1). The number of participants in the comparison was small (98 participants randomised across the two studies; 78 of whom had sufficient data to be included in the primary outcome analysis) and was at high risk of bias for two domains and unclear risk of bias for a further two. only included people with adenocarcinoma or bronchogenic carcinoma, whereas included all cell types. The evidence suggests that there may be some heterogeneity in the direct comparison of IPC without daily drainage and talc slurry (I2 = 61%, Chi2 = 2.58, P = 0.11; studies = 2; participants = 249; Analysis 6.1). 5.1 Analysis Comparison 5 C parvum, Outcome 1 Pleurodesis failure rate. demonstrates no obvious difference in the distribution of potential effect modifiers between direct comparisons. Sensitivity analysis of the direct comparisons using the fixed‐effect meta‐analysis model did not reveal any clinically or statistically meaningful differences (see ). Network meta‐analysisSelection of trials for inclusion in the network meta‐analysisWe evaluated and assessed all the interventions from the included studies for inclusion in the network. We considered a number of interventions were not jointly randomisable and hence we did not include them. These interventions included specific surgical techniques (), different talc particle sizes (), interventions to improve the efficacy of pleurodesis (; ; ; ; ; ; ; ; ; ; ), tumour‐specific intrapleural therapy (; ; ; ; ; ; ; ), different doses of silver nitrate (), and different doses of iodine (). For computational reasons, we could not include one intervention (combined tetracycline and bleomycin) in the NMA: this combination was evaluated in only one trial, with no pleurodesis failures occurring in the relevant study arm. Inclusion of this trial led to convergence problems (). We did not include an additional study in the analysis as there were no pleurodesis failures in either study arm (). Such studies cannot statistically contribute to the estimate of relative intervention effects (). We included 55 studies in the primary NMA. Most studies included all cell types. Twenty‐six of 55 excluded participants with trapped lung. Pleurodesis was defined using symptom recurrence and radiology in 37/55 studies and usually defined within four months of the intervention. It was difficult for us to assess whether the distribution of potential effect modifiers was comparable for all the direct treatment comparisons because there were few studies per direct comparison (at most five studies per comparison, seen in the bleomycin versus talc slurry and bleomycin versus tetracycline comparisons) (see ). The final network can be seen in Figure 4. Open in a separate window 4 Network plot of the pleurodesis efficacy network. The nodes are weighted according to the number of participants randomised to the intervention. The edges (line thicknesses) are weighted according to the number of studies included in each comparison. IFN: interferon; IPC: indwelling pleural catheter without daily drainage; thioTEPA: triethylenephosphoramide; TMP: thoracoscopic mechanical pleurodesis. Results from network meta‐analysisEstimated ORs for the pleurodesis failure outcome generated by the NMA, which comprised 55 studies of 21 agents and included 3758 participants, are shown in Table 8. The estimated ranks for each of the interventions in terms of pleurodesis success (i.e. lowest chance of failure) are shown in Figure 5. The summary of findings from the NMA of pleurodesis failure rate are shown in Table 1. Open in a separate window 5 Estimated (95% credible interval (Cr‐I)) ranks for each of the pleurodesis methods from the main network. IFN: interferon; IPC: indwelling pleural catheter without daily drainage; thioTEPA: triethylenephosphoramide; TMP: thoracoscopic mechanical pleurodesis. 2Results of network meta‐analysis for pleurodesis failure showing the odds ratios (95% Cr‐I) of the agents in the rows compared to the agents in the columns AdriamycinAutologous bloodBleomycinC parvumDoxycyclineIFNIPC – daily drainageIPC – not daily drainageIodineMepacrineMistletoe (viscum)MitoxantroneMustinePlaceboSilver nitrateTMPTalc poudrageTalc slurryTalc via IPCTetracyclineAutologous blood1.16 (0.02 to 101.8)NA//////////////////Bleomycin1.17 (0.02 to 83.72)1.02 (0.22 to 4.72)NA/////////////////C parvum0.65 (0.01 to 49.54)0.56 (0.09 to 3.38)0.56 (0.18 to 1.60)NA////////////////Doxycycline1.32 (0.02 to 107.3)1.14 (0.19 to 7.07)1.12 (0.37 to 3.51)2.02 (0.53 to 8.43)NA///////////////IFN3.93 (0.05 to 379)3.39 (0.35 to 33.19)3.34 (0.63 to 18.08)6 (0.85 to 45.87)2.98 (0.39 to 22.38)NA//////////////IPC – daily drainage1.25 (0.02 to 111.4)1.10 (0.16 to 7.49)1.08 (0.26 to 4.46)1.94 (0.36 to 11.11)0.96 (0.20 to 4.53)0.32 (0.04 to 2.90)NA/////////////IPC – not daily drainage3.93 (0.06 to 325.5)3.43 (0.60 to 19.68)3.39 (1.10 to 10.68)6.09 (1.44 to 27.74)3.02 (0.85 to 10.54)1.01 (0.13 to 7.78)3.14 (1.07 to 9.35)NA////////////Iodine0.63 (0.01 to 49.04)0.55 (0.09 to 3.16)0.54 (0.18 to 1.54)0.98 (0.22 to 4.29)0.48 (0.11 to 2.05)0.16 (0.02 to 1.15)0.50 (0.09 to 2.53)0.16 (0.04 to 0.65)NA///////////Mepacrine0.48 (0.01 to 38.24)0.41 (0.06 to 2.59)0.41 (0.11 to 1.37)0.73 (0.14 to 3.64)0.36 (0.07 to 1.74)0.12 (0.01 to 0.94)0.38 (0.06 to 2.13)0.12 (0.02 to 0.55)0.75 (0.15 to 3.54)NA//////////Mistletoe (viscum)0.18 (0.001 to 26.42)0.15 (0.006 to 3.25)0.15 (0.008 to 2.15)0.27 (0.01 to 4.85)0.14 (0.006 to 2.39)0.05 (0.002 to 1.03)0.14 (0.005 to 2.82)0.05 (0.002 to 0.8)0.28 (0.01 to 4.96)0.38 (0.02 to 7.19)NA/////////Mitoxantrone5.62 (0.08 to 485.4)4.77 (0.65 to 38.43)4.7 (1.21 to 20.78)8.5 (1.58 to 53.76)4.22 (0.73 to 25.95)1.4 (0.17 to 13.52)4.38 (0.64 to 32.63)1.39 (0.25 to 8.62)8.71 (1.62 to 54.36)11.54 (2.37 to 70.61)31.44 (1.59 to 841.9)NA////////Mustine3.41 (0.06 to 246.5)2.96 (0.40 to 21.37)2.92 (0.70 to 12.46)5.26 (1.14 to 25.88)2.6 (0.46 to 14.5)0.88 (0.09 to 7.84)2.72 (0.39 to 18.45)0.86 (0.15 to 4.86)5.41 (0.98 to 30.75)7.2 (1.2 to 46.5)19.36 (0.93 to 502.7)0.62 (0.08 to 4.26)NA///////Placebo8.53 (0.13 to 713.2)7.21 (0.99 to 57.97)7.09 (1.74 to 33.09)12.82 (2.33 to 82.88)6.33 (1.09 to 40.23)2.12 (0.24 to 21)6.58 (0.98 to 49.75)2.09 (0.38 to 13.13)13.15 (2.39 to 83.82)17.44 (3.70 to 101.1)47.4 (2.32 to 1298)1.51 (0.37 to 6.14)2.43 (0.35 to 18.64)NA//////Silver nitrate1.28 (0.02 to 123.1)1.10 (0.09 to 11.67)1.08 (0.13 to 8.03)1.96 (0.20 to 17.79)0.96 (0.09 to 9.07)0.33 (0.02 to 4.24)1.0 (0.08 to 10.47)0.32 (0.03 to 2.9)1.999 (0.2 to 18.56)2.67 (0.26 to 26.41)7.21 (0.24 to 243.8)0.23 (0.02 to 2.44)0.37 (0.03 to 3.75)0.15 (0.01 to 1.59)NA/////TMP0.22 (0.003 to 21.16)0.19 (0.02 to 1.61)0.19 (0.03 to 1.04)0.34 (0.05 to 2.47)0.17 (0.02 to 1.15)0.06 (0.005 to 0.61)0.17 (0.02 to 1.26)0.06 (0.008 to 0.34)0.35 (0.05 to 2.34)0.46 (0.06 to 3.52)1.23 (0.05 to 36.67)0.04 (0.004 to 0.33)0.06 (0.007 to 0.55)0.03 (0.003 to 0.22)0.17 (0.01 to 2.46)NA////Talc poudrage0.26 (0.004 to 18.64)0.23 (0.04 to 1.05)0.22 (0.08 to 0.50)0.4 (0.10 to 1.41)0.2 (0.05 to 0.64)0.07 (0.009 to 0.40)0.21 (0.04 to 0.82)0.07 (0.02 to 0.20)0.41 (0.12 to 1.29)0.55 (0.13 to 2.18)1.45 (0.09 to 30.25)0.05 (0.008 to 0.21)0.08 (0.02 to 0.31)0.03 (0.01 to 0.14)0.2 (0.03 to 1.7) 1.19 (0.19 to 6.77)NA///Talc slurry0.52 (0.01 to 38.37)0.45 (0.10 to 1.93)0.45 (0.21 to 0.91)0.8 (0.24 to 2.76)0.4 (0.12 to 1.24)0.13 (0.02 to 0.81)0.41 (0.12 to 1.43)0.13 (0.05 to 0.34)0.82 (0.28 to 2.47)1.1 (0.32 to 4.02)2.93 (0.19 to 60)0.10 (0.02 to 0.41)0.15 (0.03 to 0.66)0.06 (0.01 to 0.27)0.41 (0.05 to 3.43)2.38 (0.5 to 11.99)2.00 (0.98 to 4.79)NA//Talc via IPC1.41 (0.02 to 153.1)1.22 (0.11 to 13.48)1.2 (0.16 to 9.03)2.17 (0.25 to 20.7)1.08 (0.13 to 8.46)0.36 (0.03 to 4.94)1.12 (0.16 to 8.14)0.36 (0.07 to 1.85)2.22 (0.26 to 20.4)2.96 (0.32 to 30.36)7.996 (0.29 to 276.8)0.26 (0.02 to 2.74)0.41 (0.04 to 4.61)0.17 (0.01 to 1.81)1.1 (0.07 to 20.18)6.47 (0.56 to 79.51)5.39 (0.77 to 46.87)2.7 (0.41 to 18.65)NA/Tetracycline1.52 (0.03 to 100.3)1.32 (0.28 to 5.82)1.3 (0.60 to 2.73)2.34 (0.72 to 7.62)1.16 (0.31 to 4.01)0.39 (0.06 to 2.36)1.20 (0.26 to 5.33)0.38 (0.1 to 1.31)2.4 (0.7 to 8.26)3.19 (0.86 to 12.47)8.54 (0.54 to 176.8)0.28 (0.06 to 1.18)0.45 (0.11 to 1.73)0.18 (0.04 to 0.76)1.2 (0.18 to 8.71)6.95 (1.15 to 43.49)5.85 (2.28 to 16.87)2.91 (1.2 to 7.01)1.08 (0.13 to 8.3)NATriethylenethiophosphoramide2.63 (0.03 to 310.8)2.23 (0.15 to 34.02)2.21 (0.22 to 23.08)3.98 (0.32 to 52.04)1.96 (0.15 to 25.22)0.66 (0.04 to 11.71)2.05 (0.15 to 28.96)0.65 (0.05 to 8.08)4.08 (0.34 to 52.3)5.41 (0.69 to 47.85)14.73 (0.42 to 634.9)0.47 (0.04 to 5.52)0.75 (0.05 to 11.16)0.31 (0.03 to 3.16)2.04 (0.1 to 45.98)11.87 (0.71 to 208.7) 9.95 (0.95 to 121.2)4.95 (0.49 to 52.69)1.83 (0.09 to 36.76)1.7 (0.16 to 18.73)Results that are significant at the conventional level of P < 0.05 are in bold. Open in a separate window IFN: interferon; IPC: indwelling pleural catheter; NA: not applicable; TMP: thoracoscopic mechanical pleurodesis. Based on the NMA, there was evidence that talc poudrage results in fewer pleurodesis failures than bleomycin, tetracycline, mustine, interferon, IPC not daily drainage, mitoxantrone and placebo (Table 8). The estimated (posterior median) rank of talc poudrage was third of 21 interventions, but with a much tighter Cr‐I than those interventions with median rank of 1 or 2 (estimated rank 3, 95% Cr‐I 1 to 6). We had a moderate level of certainty in the network estimate of the pleurodesis failure rate of talc poudrage compared to talc slurry. We downgraded evidence by one level for serious study limitations due to an overall high risk of bias for trials forming direct and indirect evidence loops in the talc poudrage to talc slurry comparison. There was little evidence of a difference between these two interventions in the primary NMA (talc poudrage versus talc slurry: OR 0.50, 95% Cr‐I 0.21 to 1.02). Restricting analysis only to studies at low risk of bias provided greater certainty that these interventions have a comparable pleurodesis failure rate (OR 0.78, 95% Cr‐I 0.16 to 2.08). The OR and 95% Cr‐I for IPC (without daily drainage) compared to talc slurry demonstrates that IPCs are likely to have a higher pleurodesis failure rate than talc slurry (OR 7.60, 95% Cr‐I 2.96 to 20.47). Our level of certainty in this result is moderate. We downgraded one level for inconsistency, due to a high I2 value (I2 = 61%) in the IPC without daily drainage to talc slurry comparison. Talc slurry was associated with fewer pleurodesis failures than mitoxantrone and placebo (talc slurry versus mitoxantrone: OR 0.10, 95% Cr‐I 0.02 to 0.41; talc slurry versus placebo: OR 0.06, 95% Cr‐I 0.01 to 0.27). We had a low level of certainty that talc slurry may result in fewer pleurodesis failures than bleomycin and doxycycline (bleomycin versus talc slurry: OR 2.24, 95% Cr‐I 1.10 to 4.68; doxycycline versus talc slurry: OR 2.51, 95% Cr‐I 0.81 to 8.40). We downgraded by one level in the bleomycin to talc slurry comparison for serious study limitations due to an overall high risk of bias for trials forming direct and indirect evidence loops, and by one level for evidence of indirectness (due to variation in the dose of bleomycin used and different approaches between studies to inclusion of patients with trapped lung and definition of pleurodesis failure). We downgraded evidence in the doxycycline to talc slurry comparison for imprecision (due to the wide Cr‐I around the effect estimate) and indirectness (as there was no direct evidence comparing doxycycline and talc slurry, and evidence forming indirect evidence loops were based on few studies). The NMA provides some evidence that mistletoe (viscum) may be associated with fewer pleurodesis failures than placebo, mitoxantrone and IPC without daily drainage, with ORs and 95% Cr‐Is lying away from the null value of 1. However, these comparisons are based only on indirect data with small sample sizes. The only direct evidence on mistletoe (viscum) was from a comparison with bleomycin made in a single study (OR 0.19, 95% Cr‐I 0.02 to 1.62; participants = 17). Mistletoe (viscum) was estimated to have a high rank (rank 2/21) but with a very wide Cr‐I (1 to 16) reflecting uncertainty within the network as to its true rank. The NMA also provides some evidence that TMP may be more effective (i.e. result in fewer pleurodesis failures) than interferon, IPC – not daily drainage, mitoxantrone and placebo. TMP similarly ranked highly on average, but with a wide Cr‐I reflecting considerable uncertainty (ranked joint second with mistletoe (viscum), 95% Cr‐I 1 to 11). The evidence for TMP is based on two studies, recruiting a combined total of 123 participants. We considered both studies at high risk of bias and therefore we did not include them in the sensitivity analysis of studies at low risk of bias. The NMA results are consistent with the pair‐wise meta‐analysis results in providing some evidence that a daily IPC drainage regimen (ranked joint 11th of 21 interventions, 95% Cr‐I 4 to 18) has increased chance of pleurodesis success compared with IPCs without daily drainage (ranked 18th, 95% Cr‐I 13 to 21). Talc administration combined with IPC ranked joint 12th but the very wide Cr‐I demonstrates uncertainty of its true rank (95% Cr‐I 3 to 20). Placebo administration was associated with the highest likelihood of pleurodesis failure, with an estimated rank lowest of 21 interventions (95% Cr‐I 15 to 21). We had a moderate level of certainty that placebo is associated with more pleurodesis failures than talc slurry (OR 15.90, 95% Cr‐I 3.76 to 79.90) with evidence downgraded one level for imprecision due to the wide Cr‐I of this estimate. The ORs and 95% Cr‐Is comparing placebo with TMP, talc poudrage, mepacrine, talc slurry, C parvum and iodine were all far away from 1, providing evidence that placebo is less effective at achieving a pleurodesis. Other potentially efficacious agents were mepacrine, iodine and C parvum, with estimated ranks of 5th (95% Cr‐I 1 to 13) for mepacrine and joint 7th (95% Cr‐I 2 to 14) for iodine and C parvum. Heterogeneity within the network meta‐analysisWe estimated the between‐study SD in treatment effect estimates (log ORs) across the whole network to be Tau = 0.70 (95% Cr‐I 0.30 to 1.17), suggesting a high degree of heterogeneity, although the wide Cr‐I indicates a substantial degree of uncertainty around this. We performed several sensitivity analyses to explore potential reasons for this heterogeneity, based on predefined potential clinical effect modifiers (see ). Due to the smaller number of studies in these analyses, many of them contained fewer interventions than the main network. The estimated rank orders were generally similar to those in the main network (; ). The estimated between‐trial heterogeneity across the network remained high for most sensitivity analyses, but was reduced in the NMA restricted to trials at low risk of bias (Tau 0.37, 95% Cr‐I 0.02 to 1.47) and the NMA restricted to trials excluding people with trapped lung (Tau 0.31, 95% Cr‐I 0.01 to 1.19). We note however that the Cr‐Is around these estimates of Tau are very wide, indicating considerable uncertainty about the extent of heterogeneity. More generally, estimates of Tau in all sensitivity analyses were very imprecise. The upper limit of the 95% Cr‐Is for these values was often close to 2. Since we assumed a uniform (0.2) prior distribution for Tau in each analysis, it is likely that the upper limits would increase further still if we assumed a wider prior distribution (; ; ). Results were fairly robust to exclusion of the higher risk of bias studies, although doxycycline and C parvum both ranked higher than in the main NMA, probably due to the removal of two particular studies (; ) (; ). Talc poudrage and talc slurry were associated with the least pleurodesis failures and their Cr‐Is were the same (talc poudrage: rank 2, 95% Cr‐I 1 to 9; talc slurry: rank 4, 95% Cr‐I 1 to 9) with the OR and Cr‐I of talc poudrage versus talc slurry suggesting little difference between the two agents (OR 0.78, 95% Cr‐I 0.16 to 2.08). ). We observed a diverse range of doses used for many of the pleurodesis agents evaluated, which is a potential cause for the unexplained heterogeneity. Unfortunately, it was not feasible to examine the effect of dose on comparative estimates (ORs). Inconsistency within the network meta‐analysisThere was no statistical evidence for global inconsistency in the main network or in any of the subgroup or sensitivity NMAs (see Figure 6). For the primary outcome analysis of pleurodesis failure, the residual deviance was four points lower (indicating slightly better fit) for the 'inconsistency model' relative to the NMA. However, after penalising for the increased complexity of the inconsistency model (101 'effective parameters' required versus 91 for the NMA), the DIC indicated a preference for the NMA model (DIC of 209.3 relative to 214.9 for the inconsistency model). Open in a separate window 6 Inconsistency plot for the main network. Treatment codes: 01: adriamycin; 02:autologous blood; 03:bleomycin; 04:C parvum; 05:doxycycline; 06:interferon; 07:indwelling pleural catheter (IPC) –daily drainage; 08:IPC –not daily drainage; 09:iodine; 10:mepacrine; 11:mistletoe (viscum); 12:mitoxantrone; 13:mustine; 14:placebo; 15:silver nitrate; 16:thoracoscopic mechanical pleurodesis (TMP); 17:talc poudrage; 18:talc slurry; 19:talc via IPC; 20:tetracycline; 21:triethylenethiophosphoramide. Abbreviations: ROR:ratio of odds ratios; 95% CI:95% confidence interval. Heterogeneity variance was set at 0.4929 (reflecting the estimation of Tau from the network). Similarly, there was no statistical evidence for loop‐specific inconsistency within any of the networks. Inconsistency factors (ratio of odds ratios (RORs)) with 95% CIs for the main network can be found in Figure 6. Although none of these CIs exclude the null value of 1, we note that some of the RORs are large, with extremely wide CIs, due to the small volume of evidence per loop. The possibility of true inconsistencies cannot therefore be excluded. The largest ROR (30.4, truncated 95% CI 1 to 1632.0) related to the loop doxycycline – IPC not daily drainage – talc slurry – talc poudrage. We note that the only direct evidence on doxycycline versus talc poudrage was from a small trial of 31 participants, with zero pleurodesis failures in the talc poudrage arm (), which appears to be the driver of this large ROR. The residual deviance contribution plot (Figure 7) indicates that the data points that were fitted 'better' by the inconsistency model relative to the NMA tended to similarly be those with zero cells: in particular, the trial is highlighted again as potentially inconsistent from other evidence using this approach. As the residual deviance is known to be numerically unstable in the presence of zero cells, this does not cause concern (). Open in a separate window 7 Residual deviance contribution plot for the main network meta‐analysis. * indicates 0 events. Additional post‐hoc sensitivity analysisThe post‐hoc sensitivity analysis that only evaluated agents given through an intercostal chest tube included 37 studies of 16 agents (Appendix 7; Appendix 8). There was very little evidence of difference between the agents: Cr‐Is were wide and the estimated rankings for the individual agents were also very imprecise. The estimated degree of heterogeneity was even higher than the main network (Tau 0.87, 95% Cr‐I 0.37 to 1.52). Primary outcomes for the methods not included in the network meta‐analysisPleurodesis techniquesThe results of the pair‐wise comparisons of the interventions not included in the NMA are shown in Table 9. 3Results for pleurodesis failure of the studies evaluating pleurodesis methods which were not included in the network meta‐analysis StudyReason study excluded from networkIntrapleural agent or intervention 1Pleurodesis failure rate for agent 1Intrapleural agent or intervention 2Pleurodesis failure rate for agent 2OR (95% CI) of agent 1 compared with agent 2***Lung cancer‐specific therapyCisplatin and bevacizumab 6/36Cisplatin17/340.20 (0.07 to 0.60)*No pleurodesis failures in the combined groupTetracycline** 3/19Combined tetracycline and bleomycin0/198.27 (0.40 to 172.05)Bleomycin** 2/19Combined tetracycline and bleomycin0/195.57 (0.25 to 124.19)*Lung cancer‐specific therapyOK‐432 8/17Cisplatin 11/170.48 (0.12 to 1.92)OK‐432 8/17OK‐432 and cisplatin 1/1512.44 (1.32 to 117.03)Cisplatin 11/17OK‐432 and cisplatin 1/1525.67 (2.68 to 245.84)Lung cancer‐specific therapyHigh‐dose OK‐432 5/19Low‐dose OK‐432 3/191.90 (0.38 to 9.44)Lung cancer‐specific therapyOK‐432 3/26Mitomycin C 9/270.26 (0.06 to 1.11)Two talc slurry preparationsMixed‐particle talc 3/14Graded talc (particles > 20 µm) 2/141.64 (0.23 to 11.70)Lung cancer‐specific therapyLC9018 and adriamycin 10/38Adriamycin23/380.23 (0.09 to 0.62)Comparison of different doses of iodine1% iodine 1/302% iodine1/301.00 (0.06 to 16.76)MPM specific surgical techniqueTalc pleurodesis (slurry or poudrage) 25/62VATS pleurectomy24/600.88 (0.43 to 1.82)*Comparison of different doses of silver nitrate90 mg silver nitrate0/20150 mg silver nitrate0/20Not estimable90 mg silver nitrate0/20180 mg silver nitrate 2/200.18 (0.01 to 4.01)150 mg silver nitrate0/20180 mg silver nitrate 2/200.19 (0.01 to 4.01)Lung cancer‐specific therapyCisplatin + 45 mg endostatin14/66Cisplatin24/620.43 (0.2 to 0.93)*Lung cancer‐specific therapyOK‐432 8/33Bleomycin 11/350.70 (0.24 to 2.03)OK‐432 8/33Cisplatin and etoposide 10/340.77 (0.26 to 2.27)Bleomycin 11/35Cisplatin and etoposide 10/341.10 (0.39 to 3.07)Lung cancer specific therapyrAd‐p53 and cisplatin 3/17Cisplatin 9/180.21 (0.05 to 1.01)*Three‐arm study. Open in a separate window CI: confidence interval; IPC: indwelling pleural catheter; MPM: malignant pleural mesothelioma; OR: odds ratio; VATS: video‐assisted thoracoscopic surgery. We did not include one study in the NMA as it was a three‐arm trial evaluating different doses of silver nitrate administered via a chest tube (). Only two of 60 participants had a failed pleurodesis, both in the group receiving the highest dose of silver nitrate. We could not include eight studies in the NMA as they evaluated tumour‐specific therapies for people with MPE due to non‐small cell lung cancer (NSCLC) (; ; ; ; ; ; ; ). The results could not be generalised to people with other tumour types and hence we did not consider these interventions to be jointly randomisable. All of these studies randomised only small numbers of participants. However, in five of the direct comparisons, the OR and 95% CI lay far away from the null value of 1, giving evidence against the null hypothesis of no difference (Table 9). randomised people with NSCLC to receive three cycles of either cisplatin plus intrapleural bevacizumab (a humanised monoclonal antibody to vascular endothelial growth factor (VEGF)) or cisplatin alone. More participants in the cisplatin‐alone group had pleurodesis failure than in the combination group (6/36 with cisplatin plus bevacizumab versus 17/34 with cisplatin alone; OR 5.00, 95% CI 1.66 to 15.09; studies = 1; participants = 70; Analysis 22.1). 22.1 Analysis Comparison 22 Cisplatin, Outcome 1 Pleurodesis failure rate. randomised people with NSCLC with MPE to receive up to two doses of either intrapleural LC9018 (lyophilised Lactobacillus casei) plus adriamycin or adriamycin alone. There were more pleurodesis failures in the control group compared to those who received LC9018 (23/38 with adriamycin alone versus 10/38 with LC9018 plus adriamycin; OR 4.29, 95% CI 1.62 to 11.35; studies = 1, participants = 76; Analysis 14.1). 14.1 Analysis Comparison 14 Adriamycin, Outcome 1 Pleurodesis failure rate. conducted a three‐arm trial, comparing intrapleural OK‐432, an inactivated product of Streptococcus pyogenes A3 with antitumour immune‐modulatory effects in lung cancer, with cisplatin and combined therapy (both OK‐432 and cisplatin). People treated with OK‐432 alone had a higher pleurodesis failure rate than those receiving combination treatment (OR 12.44, 95% CI 1.32 to 117.03; studies = 1, participants = 32), but a lower failure rate than those receiving cisplatin alone (OR 0.48, 95% CI 0.12 to 1.92; studies = 1, participants = 34; Analysis 10.1). 10.1 Analysis Comparison 10 OK‐432, Outcome 1 Pleurodesis failure rate. administered intrathoracic cisplatin in combination with intravenous pemetrexed as the control intervention for people with lung adenocarcinoma and compared this with the addition of intrathoracic Endostar. Participants in the intervention arm had a lower pleurodesis failure rate after three cycles of treatment (OR 0.43, 95% Cr‐I 0.20 to 0.93; participants = 128; Analysis 29.1). 29.1 Analysis Comparison 29 Endostatin, Outcome 1 Pleurodesis failure rate. Other methods to optimise pleurodesisWe evaluated several other methods to optimise pleurodesis, but did not include them in the NMA because we did not consider them to be jointly randomisable (see Table 10). Most studies included small numbers of participants and none provided evidence of a difference in pleurodesis failure rates between the treatments being compared (see Table 10). 4Results for pleurodesis failure of the studies evaluating interventions to optimise pleurodesis which were not included in the network meta‐analysis Type of method to optimise pleurodesisStudyIntervention 1Pleurodesis failure rate for intervention 1Intervention 2Pleurodesis failure rate for intervention 2OR (95% CI) of intervention 1 compared with intervention 2*Mode of administrationTetracycline pleurodesis at the end of thoracoscopy2/15Tetracycline pleurodesis through an intercostal cannula5/140.28 (0.04 to 1.76)Chest tube sizeSmall‐bore chest drain2/9Large‐bore chest drain3/90.57 (0.07 to 4.64)**Small‐bore chest drain Open in a separate window CI: confidence interval; NSAID: non‐steroidal anti‐inflammatory drug; OR: odds ratio. Three studies investigated the use of intrapleural fibrinolytics. recruited people with non‐draining MPE to receive either intrapleural urokinase or placebo with coprimary outcome measures of dyspnoea change and time to pleurodesis failure. Seventy‐one participants were randomised. The authors reported no significant difference between groups in time to pleurodesis failure over the 12‐month study period (13/35 failures in participants receiving urokinase compared with 11/34 receiving placebo; OR 1.24, 95% CI 0.46 to 3.34; Analysis 27.1), and no difference between groups in the number of participants achieving a clinically significant decrease in VAS dyspnoea scores. 27.1 Analysis Comparison 27 Urokinase, Outcome 1 Pleurodesis failure rate. randomised 40 participants to receive either streptokinase or saline placebo in people with multiloculated MPE. Pleurodesis outcome data were not presented for 11 participants, but failure occurred in 2/18 participants receiving streptokinase and 5/11 receiving placebo control (P = 0.07). In , the total volume of pleural fluid drained was higher in the streptokinase group than control; however, there was no difference observed between groups in pleurodesis failure rates (streptokinase versus control: OR 0.46, 95% CI 0.11 to 1.90; Analysis 28.1). 28.1 Analysis Comparison 28 Streptokinase, Outcome 1 Pleurodesis failure rate. Two studies compared small‐ and large‐bore chest drains. randomised 21 participants to receive tetracycline via 10‐Fr and 24‐Fr drains (administered at the end of medical thoracoscopy). They observed no difference in pleurodesis failures between groups (small‐bore versus large‐bore pleurodesis failure: OR 0.57, 95% CI 0.07 to 4.64; Analysis 18.1). 18.1 Analysis Comparison 18 Drain size, Outcome 1 Pleurodesis failure rate. The TIME‐1 2×2 factorial study (), compared the effect of small‐ and large‐bore drains and analgesia (NSAIDs versus opiates) on pain and pleurodesis outcomes in 320 people with MPE. Small chest tubes (12 Fr) failed to meet non‐inferiority for pleurodesis efficacy at three months when compared with large (24 Fr) drains, with 15/50 pleurodesis failures in the 12‐Fr group and 12/50 failures in the 24‐Fr group (small versus large bore: OR 1.36, 95% CI 0.56 to 3.30; Analysis 18.1). We did not identify any RCTs examining the role of pleuroperitoneal shunts. Secondary outcomesDue to the diversity of reporting techniques and outcome measures, it was not possible to perform a formal statistical analysis of many of the predefined secondary outcomes. Adverse effects and complicationsMost studies reported data on adverse effects of the interventions, however four studies did not (; ; ; ). reported adverse events but we could not differentiate the participants with pleural effusions from those with ascites or pericardial effusions. Two study authors provided data on adverse events by personal communications (; ). The methods used to describe the adverse effects observed varied widely between studies. One study demonstrated that mixed particle talc is associated with more lung and systemic inflammation, hypoxaemia and acute respiratory distress syndrome (ARDS) than graded talc (with its smallest particles removed) and tetracycline (). Other notable complications included a possible increased risk of cellulitis and pleural infection associated with IPCs. One study comparing IPCs without daily drainage to talc slurry pleurodesis reported more cases of infection in the IPC arm (five cases of pleural infection requiring admission for intravenous antibiotics, plus 2/52 participants who were managed as outpatients with oral antibiotics in the IPC arm, compared to 1/54 participants requiring hospital admission for pleural infection in the talc slurry arm). However, no IPCs were removed as a consequence of infection (). In another study, 2/74 participants developed a pleural infection and 3/74 developed cellulitis in the IPC arm compared with 1/72 participants with pleural infection in the talc slurry arm (). , however, reported no difference in the rate of infection between participants receiving an IPC without daily drainage and those receiving a chest drain and talc slurry pleurodesis, with two infections occurring in each group. One study comparing daily IPC drainage to talc slurry pleurodesis reported only one wound infection in the IPC group (). One study comparing IPCs without daily drainage to doxycycline pleurodesis reported 6/99 participants receiving an IPC had a local cellulitis infection, which responded to oral antibiotics. No participants with an infection required IPC removal (). Neither study comparing daily IPC drainage to IPCs without daily drainage observed a difference in the rate of pleural infection between study arms (; ). We used NMA to compare rates of the most commonly reported adverse effects: fever and pain. Presence of procedure‐related feverPair‐wise (direct) meta‐analysisThe direct evidence regarding fever is shown in . Twenty‐six direct comparisons were each informed by between one and five studies. There was evidence that talc slurry may be associated with more fever than autologous blood (OR 3.92, 95% CI 1.31 to 11.72; studies = 1; participants = 110; Analysis 2.2) and that placebo, tetracycline and triethylenethiophosphoramide were associated with less fever than mepacrine (placebo: OR 0.31, 95% CI 0.12 to 0.79; Analysis 15.2; tetracycline: OR 0.13, 95% CI 0.02 to 0.89; Analysis 4.2; triethylenethiophosphoramide: OR 0.04, 95% CI 0.01 to 0.30; Analysis 13.2). 2.2 Analysis Comparison 2 Talc slurry, Outcome 2 Fever. 4.2 Analysis Comparison 4 Tetracycline, Outcome 2 Fever. 13.2 Analysis Comparison 13 Triethylenethiophosphoramide, Outcome 2 Fever. 15.2 Analysis Comparison 15 Placebo, Outcome 2 Fever. Network meta‐analysisWe performed NMA of fever data from 30 trials of 14 different treatments, including 2004 participants. ORs from the NMA are shown in Table 11 and estimated rankings of the interventions in Figure 8. The summary of findings from the NMA on risk of developing a fever can be seen in Table 2. Open in a separate window 8 Estimated rank (95% credible interval (Cr‐I)) for causing fever (a low rank suggests increased risk of fever). 5Results of network meta‐analysis for causing fever showing odds ratios (95% CI) of the agents in rows compared to the agents in columns Autologous bloodBleomycinC parvumDoxycyclineIPC – not daily drainageIodineMepacrineMitoxantronePlaceboSilver nitrateTalc poudrageTalc slurryTetracyclineBleomycin11.53 (0.70 to 205.20)NA///////////C parvum67.29 (2.44 to 2021)5.82 (0.82 to 41.96)NA//////////Doxycycline4.21 (0.11 to 157)0.37 (0.03 to 3.49)0.063 (0.005 to 0.73)NA/////////IPC – not daily drainage2.01 (0.01 to 401.30)0.17 (0.002 to 15.18)0.03 (0.00 to 2.93)0.48 (0.01 to 23.3)NA////////Iodine3.67 (0.14 to 101.60)0.32 (0.03 to 3.09)0.05 (0.003 to 1.05)0.87 (0.03 to 22.91)1.82 (0.01 to 281.7)NA///////Mepacrine53.76 (1.45 to 2277)4.65 (0.38 to 62.22)0.80 (0.04 to 19.28)12.72 (0.45 to 422.1)26.79 (0.16 to 4813)14.68 (0.52 to 452.2)NA//////Mitoxantrone3.90 (0.05 to 251.30)0.34 (0.01 to 7.14)0.06 (0.001 to 2.12)0.92 (0.02 to 43.82)1.91 (0.01 to 434.1)1.06 (0.02 to 47.81)0.07 (0.002 to 2.53)NA/////Placebo0.46 (0.003 to 46.52)0.04 (0.00 to 1.55)0.01 (0.00 to 0.42)0.12 (0.001 to 8.56)0.23 (0.001 to 73.08)0.13 (0.001 to 9.2)0.01 (0.00 to 0.34)0.12 (0.01 to 2.35)NA////Silver nitrate0.28 (0.006 to 11.75)0.02 (0.001 to 0.47)0.00 (0.00 to 0.13)0.07 (0.002 to 2.85)0.14 (0.001 to 28.98)0.08 (0.002 to 2.27)0.01 (0.00 to 0.22)0.07 (0.00 to 5.58)0.62 (0.01 to 93.78)NA///Talc poudrage4.41 (0.16 to 120.20)0.38 (0.04 to 3.72)0.07 (0.003 to 1.25)1.04 (0.04 to 27.59)2.18 (0.01 to 330.6)1.19 (0.10 to 14.14)0.08 (0.003 to 2.28)1.13 (0.02 to 58.56)9.57 (0.13 to 1083)15.42 (0.52 to 519.40)NA//Talc slurry4.93 (0.34 to 74.37)0.43 (0.08 to 2.22)0.07 (0.01 to 0.88)1.17 (0.07 to 20.57)2.45 (0.02 to 289)1.35 (0.17 to 10.59)0.09 (0.005 to 1.69)1.26 (0.04 to 47.32)10.65 (0.20 to 931)17.33 (1.07 to 336.40)1.12 (0.15 to 9.12)NA/Tetracycline4.37 (0.29 to 69.73)0.38 (0.09 to 1.62)0.07 (0.01 to 0.60)1.04 (0.08 to 15.55)2.16 (0.02 to 234.9)1.19 (0.10 to 15.28)0.08 (0.01 to 1.08)1.12 (0.04 to 37.43)9.45 (0.20 to 734.3)15.26 (0.88 to 331.70)0.1 (0.08 to 13.05)0.89 (0.13 to 5.81)NATriethylenethiophosphoramide2.88 (0.02 to 523.50)0.25 (0.003 to 20.37)0.04 (0.00 to 5.12)0.69 (0.01 to 102.5)1.42 (0.003 to 786.5)0.78 (0.006 to 110.5)0.05 (0.001 to 2.24)0.72 (0.01 to 118.3)5.84 (0.07 to 1361)10.11 (0.06 to 2164)0.65 (0.005 to 94.31)0.58 (0.01 to 61.79)0.66 (0.01 to 58.19)Results that are significant at the conventional level of P ≤ 0.05 are in bold. Open in a separate window CI: confidence interval; IPC: indwelling pleural catheter; NA: not applicable. Most estimates had very wide Cr‐Is, indicating a large degree of imprecision. Silver nitrate and placebo appeared to be associated with the least fever (estimated rank joint 2nd of 14 interventions (silver nitrate: 95% Cr‐I 1 to 7; placebo: 95% Cr‐I 1 to 11)) (talc slurry versus silver nitrate: OR 17.33, 95% CI 1.07 to 336.40; talc slurry versus placebo: OR 10.65, 95% CI 0.2 to 931). The interventions associated with the most fever appeared to be C parvum and mepacrine, with estimated ranks of joint 13th (C parvum: 95% Cr‐I 10 to 14; mepacrine: 95% Cr‐I 8 to 14) (talc slurry versus C parvum: OR 0.07, 95% CI 0.01 to 0.88; talc slurry versus mepacrine: OR 0.09, 95% CI 0.01 to 1.69). There was no statistical evidence for a difference in the risk of fever, relative to talc slurry, of talc poudrage (OR 0.89, 95% Cr‐I 0.11 to 6.67)), bleomycin (OR 2.33, 95% Cr‐I 0.45 to 12.50)), IPC – not daily drainage (OR 0.41, 95% Cr‐I 0.00 to 50.00) and doxycycline (OR 0.85, 95% Cr‐I 0.05 to 14.29). We tentatively suggest that these interventions may be comparable to talc slurry, but we have a low level of certainty in this conclusion: we downgraded evidence for imprecision due to the wide Cr‐Is of all network estimates. We also downgraded evidence for indirectness, due to differences in adverse event reporting of procedure‐related fever, using different temperature thresholds and time frames for which a fever may be considered attributable to the intervention. The between‐study SD (Tau) for the fever NMA was 1.67 (95% Cr‐I 1.08 to 1.98), indicating a very high degree of statistical heterogeneity. We note that the upper limit of the prior distribution was set to 2. Comparison of DIC values for the NMA model versus the inconsistency model suggested comparable model fit after penalising for complexity (DIC 121.5 for the NMA model versus 121.2 for the inconsistency model). However, we noted a reduction in the SD when moving from the NMA to inconsistency model, which does indicate the possibility of inconsistency within the network. Comparison of residual deviance contributions of individual data points highlighted three studies as potentially inconsistent from the rest of the evidence, two of which included zero counts in the 2×2 outcome data (i.e. either all or no participants in one trial arm experienced fever, which leads to computational instability in residual deviance calculations) (Figure 9). The inconsistency factor method provided no evidence of loop inconsistency (). Open in a separate window 9 Residual deviance contribution plot for the fever network meta‐analysis. * indicates 0 events. Other findingsFor those studies that were not included in the NMA but provided data on fever, the majority revealed no difference between the interventions (; ; ; ). Two studies evaluating OK‐432 revealed more fever in this group compared to the control groups (; ; ) (Analysis 10.2). The mixed talc group had more fever than the graded talc group (OR 15.92, 95% CI 1.81 to 140.16; participants = 46; studies = 1; Analysis 20.2; ). The group who received cisplatin alone had less fever than those who also received rAd‐p53 (OR 0.09, 95% CI 0.02 to 0.51; studies = 1, participants = 35; Analysis 22.2; ). 10.2 Analysis Comparison 10 OK‐432, Outcome 2 Fever. 20.2 Analysis Comparison 20 Other, Outcome 2 Fever. 22.2 Analysis Comparison 22 Cisplatin, Outcome 2 Fever. Presence of procedure‐related painWe only included studies reporting dichotomous outcomes (presence or absence of pain post procedure) in the pair‐wise and NMA. Pair‐wise (direct) meta‐analysisThe direct evidence regarding pain is shown in . There was evidence that tetracycline pleurodesis may cause pain more frequently than autologous blood (OR 69.00, 95% CI 7.61 to 625; studies = 1), mustine (OR 33.87, 95% CI 1.80 to 636; studies = 1) and silver nitrate (OR 55.08, 95% CI 3.02 to 1003; studies = 1) (Analysis 4.3). One study provided evidence that talc slurry may cause pain more frequently than autologous blood (OR 3.57, 95% CI 1.19 to 10.74; participants = 110; Analysis 2.3). 2.3 Analysis Comparison 2 Talc slurry, Outcome 3 Pain. 4.3 Analysis Comparison 4 Tetracycline, Outcome 3 Pain. Network meta‐analysisWe included 31 studies and 14 treatments (including 2753 participants) in the NMA regarding pain (; ). The summary of findings from the NMA of risk of developing procedure‐related pain can be seen in Table 3. There was evidence to suggest that five agents, including bleomycin (OR 19.46, 95% Cr‐I 3.47 to 138.70), doxycycline (OR 22.87, 95% Cr‐I 2.99 to 223.60), talc poudrage (OR 8.64, 95% Cr‐I 1.45 to 96.71) and talc slurry (OR 6.77, 95% Cr‐I 1.40 to 39.01) may be associated with a higher number of participants having pain post procedure than autologous blood (estimated rank 1, 95% Cr‐I 1 to 4). There was no statistical evidence for a difference in risk of procedure‐related pain, relative to talc slurry, of bleomycin (OR 2.85, 95% Cr‐I 0.78 to 11.53), IPC – not daily drainage (OR 1.30, 95% Cr‐I 0.29 to 5.87), doxycycline (OR 3.35, 95% Cr‐I 0.64 to 19.72) or talc poudrage (OR 1.26, 95% Cr‐I 0.45 to 6.04). We tentatively suggest that these interventions may have a comparable frequency of procedure‐related pain to talc slurry, but we have a low level of certainty in this conclusion. Estimates had very wide CIs; therefore, we downgraded by one level in all comparisons for imprecision. We also downgraded evidence for indirectness for all comparisons. The time point at which pain was reported, threshold for reporting and mode of assessment was often unstated by studies (as occurrence of pain was reported as an adverse event) and therefore we felt this was likely to differ between studies. In addition, we downgraded evidence one level for inconsistency in the talc poudrage to talc slurry comparison (I2 = 69%). The between‐study SD (Tau) for the network was 0.69 (95% Cr‐I 0.11 to 1.51), indicating considerable heterogeneity. The DIC indicated comparable fit between the NMA and inconsistency models, with a difference in DIC of 4.8 points (marginally in favour of the inconsistency model, but not reaching the predefined cut‐off of 5 points' difference for global inconsistency). There was a slight reduction in estimated Tau when moving to the inconsistency model, which is however suggestive of possible global inconsistency (). Inspection of the contributions of individual data points to the mean residual deviance showed that the slightly better fit of the inconsistency model was driven by trials in which either all or no participants in one trial arm experienced pain post procedure (i.e. presence of a zero count in the 2×2 outcome data) (Figure 10). Open in a separate window 10 Residual deviance contribution plot for the pain network meta‐analysis. * indicates 0 events. Other findingsSeven studies reported results from pain scales rather than dichotomous outcome data and , therefore, we could not include these in the pair‐wise analysis or NMA (; ; ; ; ; ; ). reported that "pain scores were significantly higher in the mepacrine group (p = < 0.001)" compared to the mitoxantrone group as measured by the WHO analgesic ladder (no raw figures provided) (). In , VAS pain scores demonstrated that participants in the mechanical pleurodesis group had less pain than the talc slurry group at 12 hours' postpleurodesis; however, there was no difference between groups at 48 hours. The other six studies did not provide evidence of a difference in pain between the interventions studied. Eight studies that we did not include in the network (as we did not consider interventions to be jointly randomisable) revealed no difference between interventions (; ; ; ; ; ; ; ). Two studies that evaluated interventions to optimise pleurodesis reported pain outcomes according to drain size. reported fewer participants experienced pain at the time of drain insertion in those with small‐bore drains (10 Fr) compared with large‐bore drains (24 Fr) (OR 0.08, 95% CI 0.01 to 0.75; Analysis 18.2) and that smaller (10‐Fr) drains were better tolerated. Placement of large‐bore (24‐Fr) chest tubes was associated with more pain in the TIME‐1 study, but the study authors reported this was not clinically significant (). There was no difference in pain scores between participants receiving NSAIDs and opiates, although participants in the NSAID group did require more rescue analgesia (). 18.2 Analysis Comparison 18 Drain size, Outcome 2 Pain. One study reported that more participants experienced pain in the OK‐432 group than control (Analysis 10.3; ). 10.3 Analysis Comparison 10 OK‐432, Outcome 3 Pain. Patient‐reported control of breathlessnessTwenty studies reported breathlessness outcomes, using a variety of scoring systems: Medical Research Council (MRC) Dyspnoea Scale (); VAS score (; ; ; ; ; ; ; ; ); 'dyspnoea index' (); BORG score and Guyatt Chronic Respiratory Questionnaire (CRQ) (); Modified Borg Score (); EORTC Core Quality of Life Questionnaire (QLQ‐C30)/Lung Cancer Module (EORTC QLQ‐LC13) questionnaires (; ), functional class (; ; ), scale 0 to 10 (); and patient satisfaction questionnaire with breathlessness rating (). Pair‐wise (direct) meta‐analysisResults from meta‐analysis of patient‐reported control of breathlessness are presented in Table 4. We performed direct meta‐analysis of data from two studies which used a 100‐mm VAS breathlessness scale in participants undergoing talc slurry pleurodesis and IPC insertion without daily drainage. used a scale with no breathlessness at 0 mm and maximum possible breathlessness at 100 mm. We inverted the results reported by , since they used a scale where 0 mm represented "worst imaginable breathlessness" and 100 mm no breathlessness. The minimum clinically important difference using a 100‐mm VAS breathlessness scale in MPE was 19 mm (95% CI 14 to 24) (). We had low certainty in the evidence from our results that IPC without daily drainage may offer comparable breathlessness improvement when compared to talc slurry (MD –6.12 mm, 95% CI –16.32 to 4.08) from a fixed‐effect meta‐analysis. We downgraded evidence for serious study limitations due to lack of blinding (which was not possible due to the nature of the interventions). We also downgraded for indirectness due to the different time points at which VAS data with total numbers of participants was reported by studies (: 42 days; : 180 days). One study used a 100‐mm VAS breathlessness scale (0 mm representing absence of breathlessness and 100 mm most severe symptoms) to compare talc poudrage with talc slurry pleurodesis (). The authors reported no significant difference in VAS dyspnoea scores between intervention arms at all time points (absolute difference in mean VAS score from baseline of talc poudrage versus talc slurry: 0.8, 95% CI –4.6 to 6.2; P = 0.78). Data from this study demonstrated an MD of 4 mm (95% CI –6.26 to 14.26) between talc poudrage and talc slurry. We had a moderate level of certainty in the evidence and downgraded for serious study limitations only, due to lack of blinding of participants and clinicians (which was not possible due to the nature of the interventions). Network meta‐analysisThere were insufficient comparable data to perform an NMA. Other findingsTwo studies compared dyspnoea scores for participants with daily IPC drainage and IPCs without daily drainage. In the AMPLE‐2 study, authors reported that there was no significant difference between VAS breathlessness scores over the first 60 days postintervention (ratio of geometric means 1.32, 95% CI 0.88 to 1.97; P = 0.18; ). In the ASAP study, the proportion of participants with relief of breathlessness at two weeks was 0.65 in the aggressive (daily) drainage arm and 0.40 in the standard (alternate day drainage), with between‐group differences maintained at 12 weeks' postintervention (). compared IPC without daily drainage and doxycycline pleurodesis, demonstrating an improvement in breathlessness in all groups and time points compared to baseline. The only between‐group difference identified was change in Borg score on exertion at 30 days, which appeared to favour IPC (mean 2.2 (SD 2.4) in IPC group versus mean 1.0 (SD 2.4) in doxycycline group; P = 0.05). One study comparing talc slurry pleurodesis with IPC – not daily drainage found that participants from both groups reported less breathlessness at six weeks and the improvement was similar in both treatment arms (mean Modified Borg Score improvement: 2.2 in talc slurry group versus 1.6 in IPC group; P = 0.44), although there was substantial data attrition due to 35/94 participants dying within six weeks (). demonstrated that participants with an IPC drained on a daily basis had significantly better dyspnoea scores at 30 days than those in the talc slurry group (8.5 with IPC drained daily versus 6.1 with talc slurry; P = 0.047). Participants receiving talc through their IPC had less breathlessness at day 56 than those with an IPC alone in the IPC Plus study (mean VAS score difference –7.9 points, 95% CI –15.5 to –0.3 in IPC plus talc group; P = 0.04). However, mean VAS dyspnoea scores over the 70‐day trial period did not differ between the treatment arms (–3.6 points, 95% CI –8.5 to 1.3; P = 0.15) (). Urokinase for multi‐loculated malignant effusions had no significant impact on breathlessness when compared to placebo (adjusted MD from baseline between groups 23.8 mm, 95% CI 212 to 4.4; P = 0.36; ). found more participants receiving doxycycline had severe dyspnoea at two months compared to those receiving bleomycin (5/20 (24%) with doxycycline versus 1/21 (5%) with bleomycin; P = 0.01). noted that participants receiving mitoxantrone had a larger reduction in breathlessness than the mepacrine‐treated participants (absolute values not reported; P ≤ 0.001). did not provide the absolute figures but reported "statistically significant" improvements in dyspnoea one week after treatment at "the final judgement" in the LC9018 group. observed lower dyspnoea scores for participants receiving bleomycin than those receiving iodine at one‐month postintervention, although no figures were included in the paper. observed improved QLQ‐C30 dyspnoea scores in the TMP group compared to talc slurry. In the remaining studies reporting dyspnoea, there were no differences between the study arms in terms of the degree of improvement of dyspnoea (; ; ; ; ). Participants' quality of life and symptom controlTwenty‐four of 80 studies reported quality of life or assessed a symptom score other than dyspnoea. We did not perform pair‐wise (direct) meta‐analysis or NMA of quality of life scores as there was insufficient comparable data. The methods used were Karnofsky Performance Score (KPS) (; ; ; ; ; ), QLQ‐C30 questionnaire (; ; ; ; ; ), SF36 scale (; ; ), WHOQOL‐BREF scale (; Terra 2015), EQ‐5D (; ; ; ; ), VAS Score (; ), Guyatt CRQ (), a symptom questionnaire (), and numerical pain scale (; ; ). Five studies evaluating IPCs reported quality of life data. One study found no difference in the number of participants experiencing 'general malaise' between those randomised to IPC without daily drainage and talc slurry pleurodesis (). Neither study comparing IPC (without daily drainage) to talc slurry observed a difference in quality of life between treatment arms (; ). KPS (MD 8.5, 95% CI –6.2 to 23.3; P = 0.24) and 36‐item Short Form (SF‐36) (MD –12.6, 95% CI –29.3 to 4.1) scores were similar in participants with daily IPC drainage versus IPC without daily drainage at 12 weeks in the ASAP trial (). Participants were asked to complete a 'social functioning score' as a component of the SF‐36 survey in . There were similar improvements across quality of life measures in participants with both daily and alternate day IPC drainage regimens. Participants in the daily IPC drainage group had a bigger improvement in EQ‐5D‐5L scores over the six‐month AMPLE‐2 study period, compared with those in the symptom‐guided drainage group, representing a better quality of life (estimated difference in means 0.112, 95% CI 0.0198 to 0.204; P = 0.0174; ). However, the authors reported no between‐group differences in the VAS quality of life scores (ratio of geometric means 1.220, 95% CI 0.871 to 1.709; P = 0.25; ). There was no difference in Guyatt CRQ scores between participants randomised to IPC (without daily drainage) and doxycycline pleurodesis (). reported that participants who received talc via IPC had higher quality of life scores (with higher scores indicating a better quality of life) than those who received placebo at all time points. Differences in QLQ‐C30 scores reached significance at day 28 (difference 9.2 points, 95% CI 1.1 to 17.4; P = 0.03) and EQ‐5D‐5L at day 42 (difference 0.12 points, 95% CI 0.01 to 0.22; P = 0.03) (). Most studies reported no difference in quality of life measures between the treatment groups (; ; ; ; ; ; ; ; ). reported a "larger reduction" in tiredness in the mitoxantrone group compared to the mepacrine group (absolute figures not provided; P ≤ 0.001). noted less fatigue in the talc poudrage group than the talc slurry group (absolute figures not provided; P = 0.016). Those participants who received LC9018 "demonstrated a significant improvement of PS (performance status) at 1 week" than those who did not (absolute figures not provided; P ≤ 0.05) (). found that more participants who received combination treatment with cisplatin plus Ad‐p53 had a performance score "improvement rate that was significantly higher" at six weeks than those receiving cisplatin alone (11/17 (65%) with cisplatin plus Ad‐p53 versus 6/18 (33%) with cisplatin alone; P = < 0.05). The participants who underwent a video‐assisted thoracoscopic partial pleurectomy had "significantly better" EQ‐5D scores at six months than the talc group in the MesoVATS study (MD 0.08, 95% CI 0.003 to 0.16); P = 0.042), but no difference in their QLQ‐C30 scores (). did not provide data by treatment group. reported 30 participants (83%) receiving bevacizumab and cisplatin had an "improved quality of life" (measured by KPS) as opposed to 15 (50%) in the cisplatin group. observed an "improvement of quality of life" in both the TMP and talc slurry groups, but with pre‐ and post‐treatment QLQ‐C30 scores demonstrating higher global health scores and less fatigue in the TMP group compared to talc slurry. No studies reported on the potential patient burden of community IPC drainages and impact this may have on quality of life. Relative costs of the comparative techniquesSeven of 80 trials reported the relative costs of the interventions. Rapid pleurodesis was cheaper than standard care in Yildirim 2005 (USD 245 (SD 71.5) with rapid pleurodesis versus USD 860 (SD 496) with standard care). Talc slurry was cheaper than bleomycin in three studies: Ong 2000 evaluated the cost per dose (USD 1 per dose with talc slurry versus USD 309 per dose with bleomycin); Haddad 2004 calculated the complete cost for the entire procedure (USD 488 (SD 212.5) with talc slurry versus USD 796 (SD 207.3) with bleomycin) and Zimmer 1997 calculated the cost of each treatment (USD 12.36 with talc slurry versus USD 955.83 with bleomycin). Talc poudrage was also cheaper than bleomycin in Diacon 2000 (CHF 3893 (Swiss Francs) (USD 4206) with talc poudrage versus CHF 4169 (USD 4504) with bleomycin). The total cost of VATS pleurectomy was more than talc pleurodesis (GBP 14,252 (USD 21,682) with VATS pleurectomy versus GBP 10,436 (USD 15,876) with talc pleurectomy) (Rintoul 2014). Dresler 2005 reported no difference between the cost of talc slurry and poudrage (no figures quoted). A costing study performed alongside the TIME‐2 study found IPCs to be a cost‐effective choice when compared to talc slurry and most economical in participants with limited survival. "Substantial uncertainty" about the longer‐term cost‐effectiveness of IPCs was acknowledged due to limitations including sample size of the study population (which was not powered to detect cost‐effectiveness differences) and variables such as nursing time required for IPC drainage and life‐expectancy (). At 12 weeks' postintervention, nine (69%) participants undergoing daily IPC drainage and seven (58%) participants with alternate‐day IPC drainage in the ASAP trial considered that catheter supplies posed no financial burden. Ten (77%) participants in the 'aggressive drainage' arm and six (50%) participants in the standard care arm had costs completely covered by insurance (). Overall mortalityForty‐five studies provided participant mortality data (number of study participants who had died). Pair‐wise (direct) meta‐analysisThe direct evidence regarding mortality is shown in . Only one direct comparison found evidence of a difference between treatment arms; in the comparison between interferon and bleomycin those receiving interferon had a higher rate of mortality (OR 2.16, 95% CI 1.15 to 4.07; participants = 160; Analysis 12.4). 12.4 Analysis Comparison 12 Interferon (IFN), Outcome 4 Mortality. Network meta‐analysisWe incorporated 31 trials of 15 treatments, including 2816 participants, into an NMA analysing mortality (Appendix 14; Appendix 15). Results from the NMA are summarised in Table 5. Rankings within the network were imprecise, with wide CIs; for this reason, we downgraded certainty in the evidence by one level in all comparisons. We also downgraded for indirectness, due to the different time points at which studies reported mortality data. Tetracycline may be associated with higher mortality rates than six agents including bleomycin (OR 2.58, 95% Cr‐I 1.09 to 6.76), talc poudrage (OR 3.06, 95% Cr‐I 1.05 to 9.76) and talc via IPC (OR 7.74, 95% Cr‐I 1.33 to 50.51). We tentatively suggest that bleomycin (OR 1.03, 95% Cr‐I 0.43 to 2.50) and IPC – not daily drainage (OR 0.80, 95% Cr‐I 0.42 to 1.61) may be comparable to talc slurry but have a low level of certainty in this conclusion. We are uncertain whether talc poudrage may be comparable to talc slurry (OR 0.87, 95% Cr‐I 0.51 to 1.49; very‐low certainty). In addition to downgrading for imprecision and indirectness, we also downgraded the evidence for this comparison for inconsistency (I2 = 40%). We are uncertain whether doxycycline may be comparable to talc slurry (OR 0.71, 95% Cr‐I 0.15 to 3.23); very‐low certainty) and downgraded evidence for serious study limitations in addition to imprecision and indirectness. The degree of heterogeneity was low (Tau 0.22, 95% Cr‐I 0.01 to 0.73). There was no evidence of global inconsistency in this network: the DIC was 5 points lower (indicating better fit after penalising for complexity) for the NMA model than for the inconsistency model, and the estimate of between‐study heterogeneity (Tau) was very similar under both models. The residual deviance under each of the two models was almost identical (53.8 NMA versus 54.1 inconsistency model): therefore, we did not present plots of residual deviance contributions for this outcome, as these are uninformative. Similarly, there was no evidence of loop inconsistency (). Other findingsMost studies that were not included in the network showed no differences in mortality (Clementsen 1998; Crnjac 2004; Goodman 2006; Ishida 2006; Mager 2002; Maskell 2004; ; Rintoul 2014; Terra 2015; Villanueva 1994; Yildirim 2005; Yoshida 2007; Zhao 2009). Median survivalThirty studies reported median survival (days) for the treatment groups. Two studies found a survival difference between the treatment arms. found a median survival of 232 days with LC9018 versus 125 days with control (participants = 95; P = 0.008). observed an increase in time to death in the urokinase group (median survival: 69 days with urokinase versus 48 days with placebo; P = 0.026). reported a longer median survival in participants receiving high‐dose OK‐432 than low‐dose OK‐432, but did not report the spread or whether this difference was significant (33.6 days with high dose versus 22.6 days with low dose; participants = 38). Evans 1993 found survival was longer after thoracoscopic tetracycline pleurodesis than bedside administration (total participants = 34; P = 0.03; raw data only available as a survival curve). Duration of inpatient stayTwenty‐eight of 80 studies reported data for duration of inpatient stay. Total length of stayMany studies reported no difference between interventions (; ; ; ; ; ; ; ; ; ; ; ; ; ). and reported a shorter length of stay when chest drains were removed earlier following sclerosant administration compared to standard care (: mean: 2.33 days (SD 0.62) with shorter versus 8.33 days (SD 4.85) with standard; P ≤ 0.001; participants = 27; : median: 4 days (interquartile range (IQR) 4 to 8) with shorter versus 8 (IQR 6 to 9) with standard; P ≤ 0.01; participants = 41). , which evaluated a rapid drainage strategy prior to sclerosant administration, also showed this group had a shorter length of stay than the standard care group (mean: 2.2 days with rapid versus 9.0 days with standard; P ≤ 0.001; participants = 79). The talc group had a shorter length of stay than the VATS partial pleurectomy group in the MesoVATS study (median: 3 days (IQR 2 to 5) with talc versus 7 days (IQR 5 to 11) with VATS; P ≤ 0.001; participants = 196) (). Participants undergoing TMP had a shorter hospital stay than those receiving talc slurry in (mean: 5.5 days (SD 2.5) with TMP versus 7.5 (SD 3.3) with talc slurry; P = 0.001; participants = 87). Although the mean duration of thoracic drainage was shorter for participants undergoing TMP in , there was no difference in the total length of hospital stay. reported that participants receiving an IPC (without daily drainage) spent fewer days in hospital from procedure to death or 12 months compared to those receiving talc slurry (10 days (IQR 3 to 17) with IPC (without daily drainage) versus 12 days (IQR 7 to 21) with talc slurry; P = 0.03; participants = 146). Over the 12‐month TIME‐2 study, participants receiving an IPC (without daily drainage) spent a median of 1 day (IQR 0 to 3 days) in hospital for drainage or drainage‐related complications compared to a median of 4.5 days (IQR 2.5 to 7.5) in the talc slurry pleurodesis group (P ≤ 0.001) (). Talc administration via IPC and daily IPC drainage did not result in a difference in the number of days spent in hospital when compared to IPC without daily drainage (; ). Time from intervention to dischargereported that participants randomised to receive an IPC had a reduced hospital admission time from randomisation to discharge compared to those receiving doxycycline pleurodesis (median: 1 day with IPC versus 6.5 with doxycycline; P ≤ 0.001; participants = 144). This was mirrored by who reported a median hospitalisation period of 4 days versus 0 days (P ≤ 0.0001) favouring participants in the IPC without daily drainage arm compared to those receiving talc slurry pleurodesis. reported a reduced length of initial hospital admission for IPC insertion (median stay: 1 day (IQR 1‐2 days) with IPC insertion versus 3 days (IQR 3‐4 days) with talc pleurodesis; P ≤ 0.001). In the TIME‐2 study, time from randomisation to discharge was a median of 0 days (IQR 0 to 1) in the IPC (without daily drainage) group and 4 days (IQR 2 to 6) in the talc pleurodesis group (difference: 3.5 days fewer, 95% CI –4.8 to –1.5; P ≤ 0.01) (). Participants receiving urokinase for non‐draining MPE had a shorter length of hospital stay from randomisation to discharge compared to those receiving placebo (mean 6.2 days (SD 2.7) with urokinase versus 8.7 days (SD 6.5) with placebo; P = 0.049) (). Participants randomised to autologous blood pleurodesis had a shorter duration of postpleurodesis hospital stay than those receiving talc slurry (mean: 2.8 days (SD 0.9) with autologous blood pleurodesis versus 3.6 days (SD 1.8) with talc slurry; P = 0.04) (), and tetracycline (2.6 (SD 1.2) with autologous blood pleurodesis versus 4.3 days (SD 2.4) with tetracycline; P = 0.03) (). found participants receiving iodine had a shorter postprocedural length of stay than those undergoing talc poudrage (mean: 4.5 days (SD 1.1) with iodine versus 5.7 (SD 2) with talc poudrage; P = 0.02; participants = 42). Patient acceptabilityThree trials reported patient acceptability of the interventions (; ; ). Participants recruited to the ASAP trial showed an overall high level of satisfaction with IPCs when asked to complete a patient satisfaction questionnaire. At 12 weeks' postintervention, 12 participants (92%) in the 'aggressive' daily drainage study arm and 11 participants (92%) in the standard (not daily drainage) arm felt they would choose an IPC again as a treatment for pleural effusion‐related breathlessness. When asked at 12 weeks' postintervention, nine (69%) participants in the daily drainage group and five (42%) participants in the standard care group reported it was 'extremely easy' to drain the catheter at home (). No studies reported on the potential patient burden of community IPC drainages and the impact this may have on quality of life. Demmy 2012 did not provide raw data by treatment group. reported no difference between talc slurry and talc poudrage in terms of participants' perception of convenience (no raw data provided). The only trial evaluating mistletoe (viscum) reported that 2/13 participants in the mistletoe arm withdrew their consent for ongoing study participation after experiencing allergic reactions to the first dose. The outcomes for these participants were not available and hence the trial deemed them non‐evaluable (). Need for repeat invasive pleural interventionWe considered that the risk of requiring a repeat invasive pleural procedure for symptomatic re‐accumulation of pleural fluid is an important factor when selecting an initial management strategy for MPE. Pleural fluid re‐accumulation, due to failure of the initial pleurodesis, is frequently associated with increasing breathlessness. Undergoing an additional procedure commonly incurs more time in hospital and re‐exposure to the risk of procedure‐related complications. Direct (pair‐wise) meta‐analysisWe performed pair‐wise meta‐analyses comparing talc poudrage, bleomycin and IPCs without daily drainage to talc slurry, in terms of need for repeat invasive pleural intervention. Results are summarised in Table 6. We had a moderate level of certainty that participants receiving talc poudrage probably have a comparable risk of requiring repeat invasive pleural intervention than those receiving talc slurry (OR 0.96, 95% Cr‐I 0.59 to 1.56; studies = 2; participants = 380; ; ). We downgraded certainty in the evidence by one level for indirectness, due to differences between study protocols ( administered 4 g of graded talc by 12‐Fr to 14‐Fr drains in the talc slurry arm and by 16‐Fr to 24‐Fr drains in the talc poudrage arm, whereas administered 5 g of 'non‐calibrated' talc via 28‐Fr drains). Participants receiving an IPC (without daily drainage) are probably less likely to require repeat invasive pleural intervention than participants receiving talc slurry pleurodesis (OR 0.25, 95% Cr‐I 0.13 to 0.48; studies = 3; participants = 343; moderate certainty; ; ; ). We downgraded evidence by one level for indirectness, as participants with trapped lung were excluded by one study (), but included by and . We made note of study limitations due to lack of blinding (which was not possible due to the nature of the study interventions) in the talc poudrage to talc slurry and IPC without daily drainage to talc slurry comparisons, but did not downgrade evidence as requirement for repeat intervention was guided by symptoms and radiology, with involvement of a second blinded clinician in one study () prior to repeat intervention in participants with less than one‐third opacification of the hemithorax. Data were also available from one study comparing bleomycin to talc slurry, but the result was very imprecise (OR for repeat procedure 4.33, 95% Cr‐I 0.16 to 114.58; participants = 33; very‐low certainty; ). We downgraded evidence by one level for serious study limitations, as data comparing bleomycin to talc slurry were available from only one study, at high risk of bias in three domains. We downgraded evidence by two levels due to gross concerns of imprecision due to the small number of participants (33) and very wide CIs. There was no direct evidence comparing doxycycline or placebo to talc slurry. From these results, we estimated that 20/100 participants (95% CI 16 to 24) will require a repeat invasive procedure with talc slurry, 19/100 (95% CI 11 to 30) with talc poudrage, 6/100 (95% CI 3 to 11) with IPC without daily drainage and 52/100 (95% CI 4 to 97) with bleomycin. Network meta‐analysisWe performed a post‐hoc NMA for requirement for ipsilateral repeat invasive pleural intervention. However, there were no meaningful results. There was only one evidence loop in the entire network and the indirect evidence was computationally unstable due to the presence of a zero cell count. DiscussionThis is the first update of the review published in Issue 5, 2016 (), which replaced the original review published in 2004 (). Summary of main resultsThe management of MPE has long been subject to debate and research. This systematic review of the current literature attempts to combine all the available randomised evidence regarding the wide variety of interventions for the condition. Since the last iteration of this review in 2016, a number of robust, large randomised trials have been published evaluating some key, clinically important questions in this area. These have provided us with a wealth of new data, including more important patient‐reported outcomes and better insights into the role for IPCs in MPE management. Our primary NMA evaluating pleurodesis failure indicated that talc poudrage may have fewer pleurodesis failures than talc slurry (OR 0.50, 95% Cr‐I 0.21 to 1.02; moderate‐certainty evidence). However, direct evidence from four statistically homogeneous trials (I2 = 0%) estimated an OR closer to the null value of 1 (OR 0.81, 95% CI 0.61 to 1.08; Analysis 3.1), indicating that the two interventions may have comparable efficacy. A sensitivity NMA restricted to studies at low risk of bias provided a similar effect estimate, with a wide Cr‐I (OR 0.78, 95% Cr‐I 0.16 to 2.08). Estimated ranks of talc poudrage and talc slurry were third (95% Cr‐I 1 to 6) and sixth (95% Cr‐I 3 to 10) of 21 interventions from the primary NMA and second (95% Cr‐I 1 to 9) and fourth (95% Cr‐I 1 to 9) of 18 interventions from the sensitivity analysis restricted to trials at low risk of bias. 3.1 Analysis Comparison 3 Talc poudrage, Outcome 1 Pleurodesis failure rate. A large number of trials estimated pleurodesis failure rates with talc slurry (907 participants randomised to this intervention across 19 studies): talc slurry was therefore used as the comparator intervention in the 'Summary of findings' tables (Table 1;Table 2; Table 3; Table 4; Table 5; Table 6). Although other interventions, such as mistletoe (viscum) and TMP, appeared to rank highly within the primary NMA, these interventions were only evaluated by very small studies (63 participants randomised to TMP and 10 to mistletoe (viscum) in total), all with an overall high risk of bias. Hence, estimates of the relative efficacy or rank of these interventions are very imprecise (wide Cr‐Is) and we excluded both of these agents from the low risk of bias sensitivity analysis. Given the very small number of participants randomised to these interventions, it is not possible to draw conclusions about their use in routine clinical practice. Our results indicate that IPCs without daily drainage (rank 18th, 95% Cr‐I 13 to 21) of 21 interventions in the main network and rank 15th (95% Cr‐I 9 to 18) of 18 interventions in the sensitivity analysis excluding studies at high risk of bias) are less likely to effect a definitive pleurodesis allowing IPC removal than several other interventions, including talc poudrage and talc slurry (moderate certainty). However, pleurodesis efficacy may be increased with daily IPC drainage or by administration of talc slurry via the IPC. Importantly, direct meta‐analysis demonstrated that participants with an IPC (without daily drainage) were less likely to require repeat invasive pleural intervention than participants treated with talc slurry pleurodesis (OR 0.25, 95% CI 0.13 to 0.48; studies = 3, participants = 343; moderate‐certainty evidence). This is a potentially important finding for patients, since requirement of a repeat invasive pleural intervention may be a more relevant and meaningful outcome than obtaining a definitive pleurodesis. We considered this an important factor with regard to patient acceptability of the available interventions. The networks evaluating fever and pain found only uncertain evidence of minimal differences between agents, with no evidence for differences between the most commonly used interventions reported in the 'Summary of findings' tables. Five studies provided data on infection rates in participants receiving IPCs compared to chemical pleurodesis (; ; ; ; ). Data from three studies suggest participants receiving an IPC may have a higher risk of developing cellulitis or pleural infection. Notably, no IPCs were removed as a consequence of infection (; ; ). There were insufficient comparable data to perform an NMA of breathlessness outcomes. However, the evidence suggests no difference in postintervention VAS breathlessness scores of participants receiving an IPC (without daily drainage) compared to talc slurry pleurodesis, based on a direct meta‐analysis of data from two studies (MD in change in 0‐mm to 100‐mm VAS score –6.12 mm, 95% CI –16.32 to 4.08; low‐certainty evidence) (minimum clinically important difference for dyspnoea in MPE using the VAS breathlessness scale 19 mm, 95% CI 14 to 24; ). Direct comparison from one study demonstrated likely comparable outcomes for breathlessness control between talc poudrage and talc slurry (MD 4.00 mm, 95% CI –6.26 to 14.26; moderate‐certainty evidence; ). There was also insufficient comparable data to perform an NMA of quality of life outcomes. Most studies reported no difference between interventions on quality of life outcomes. Only seven studies reported the relative costs of interventions. Three studies found talc slurry to be cheaper than bleomycin. A costing study performed alongside the TIME‐2 trial found IPCs to be a cost‐effective choice when compared to talc slurry and most economical in participants with limited survival, but noted further research is needed about the longer‐term cost‐effectiveness of IPCs (). The NMA evaluating mortality found only uncertain evidence of minimal differences between agents, with no evidence for differences between the most commonly used interventions reported in the 'Summary of findings' tables. Twenty‐eight of 30 studies reporting median survival (days) found no difference between interventions. Participants receiving an IPC spent fewer days in hospital over the course of their remaining life, or until 12 months, in two studies (; ). Data also demonstrates that participants undergoing an IPC insertion had a faster time to hospital discharge than those admitted for a chemical pleurodesis (; ; ; ). Overall completeness and applicability of evidenceThis is the largest systematic review of the evidence surrounding interventions in MPE in the published literature. We used robust search strategies to identify all the available randomised evidence and diligently contacted the study authors regarding missing data where possible. However, despite attempting to contact the study authors, we were unable to obtain additional information regarding 40 records during the full‐text screening process (36/207 records identified from searches in 2016, included within the 135 listed as 'not eligible' and a further 4/156 records identified in 2019 updated searches, included within the 124 'not relevant' records) in order to confirm whether eligibility criteria for inclusion in the review were met. We only included RCTs within this review. As per the protocol, we excluded studies which were not randomised (at high risk of bias for sequence generation, allocation concealment, or both). It is possible that publication bias may therefore affect the validity of the results. The small number of studies for each pair‐wise comparison (maximum of five), meant funnel plots would not be informative (). As the interventions could not be logically ordered, we also decided a comparison‐adjusted funnel plot for the network was not valid (). Several studies included in this review had very small numbers of participants, which raises the possibility of small‐study effects, which may have resulted in an overestimation of treatment efficacy. Only 13/80 included studies had outcome data for more than 100 participants (; ; ; ; ; ; ; ; ; ; ; ; ). However, a comparison between pair‐wise meta‐analysis results from random‐effects versus fixed‐effect models (which gives relatively more weight to larger studies, hence reducing the impact of small studies) found no meaningful differences. When evaluating different pleurodesis agents, we elected to combine different doses of each agent from the available studies for the purposes of comparison. This was necessary due to variation in the doses between studies, which would have made the network more sparse and unconnected. This is a limitation of our review, since differential treatment effects according to doses could have been missed. This is one possible explanation for the high levels of heterogeneity observed in our meta‐analyses, which we were unable to investigate further due to the complexity of the data. One included study was designed to compare different doses of silver nitrate and this revealed no difference in terms of pleurodesis efficacy or adverse effects (). Many of the included studies did not assess patient quality of life, symptom control, acceptability of the intervention to the patient, duration of inpatient stay and costs. Of those that did, we were limited by the diversity of outcome measurement systems used and inconsistent reporting of data and it was therefore not possible to perform an NMA for these outcomes. Although pair‐wise and NMA of the risk of having procedure‐related pain was possible using data from studies that reported the presence or absence of pain, we were unable to incorporate data from studies which used a scoring system to grade severity of pain (continuous outcome data), due to the range of different scales used. Although such outcomes were secondary objectives of our review, they are important factors when selecting a management strategy and hence the paucity of data on these important patient‐reported outcome measures limits the applicability of the evidence from this review to everyday clinical practice. It is also important to consider the global availability of some of these agents when considering the clinical applicability of our findings. Agents such as tetracycline and C parvum are not widely available, precluding their routine use. Other sclerosants included in this review are unlicensed for use as a pleurodesis agent. Our data regarding the adverse effects of these treatments are limited. As we have selected only RCTs for inclusion in this review, there is the potential that rare but important adverse effects were missed using our methodology. There are reports of adverse effects of pleurodesis agents resulting from absorption of the agent into the systemic circulation. For example, systemic absorption of mixed particle size talc is thought to be linked to rare but occasionally life‐threatening acute respiratory distress syndrome, a risk that is minimised by the use of graded (large‐particle) talc (), now standard practice in Europe and increasingly available worldwide. Mepacrine gained popularity in Scandinavia as a pleurodesis agent, although rare psychotic episodes and seizures, thought to be related to systemic absorption if administered at high doses, limited its use (). We only managed to synthesise the data on the main adverse effects and so we cannot reliably infer the full adverse effect profiles of these treatments from this review. An appreciation of the adverse effect profile of these interventions is vital when weighing up the risks and benefits of the procedures, particularly as many of the patients in this population have a limited life‐expectancy and hence minimising discomfort during their remaining time is imperative. The definition of pleurodesis efficacy varied between studies, with many relying on radiology alone, which is increasingly considered inadequate without considering symptom recurrence. Achieving a pleurodesis may not represent the best strategy for all. Patients may have a personal preference regarding the best treatment strategy for themselves. Therefore, factors such as breathlessness control and risk of repeat invasive pleural intervention are also important to discuss when selecting the best treatment strategy. Many patients would rather avoid hospital admission and elect for an outpatient pathway, which may make the use of an IPC more appealing than a chemical pleurodesis. Quality of the evidenceThe overall certainty of the evidence ranged from moderate to very low (Table 1; Table 2; Table 3; Table 4; Table 5; Table 6). The risk of bias in several included studies is substantial and we downgraded evidence for study limitations in the pleurodesis failure rate network, patient‐reported breathlessness control meta‐analysis, mortality NMA and meta‐analysis of risk of requiring a repeat invasive pleural intervention. The vast majority of studies were unblinded, which in part reflects the nature of the interventions but also the symptom‐based nature of the endpoints measured, precluding blinding of the outcome reporting as well. Documentation of the methods used for sequence generation and allocation concealment were frequently omitted and it was often not possible to obtain this information retrospectively. However, in a sensitivity analysis including only studies at low risk of bias (defined as a maximum of one high‐risk domain in the risk of bias assessment), the relative rankings of interventions were similar. The heterogeneity estimate (Tau) was substantially reduced in this sensitivity analysis (from 0.70 to 0.37), indicating that bias may have been a contributor to the high level of heterogeneity in the primary analysis. Given the inevitable death of patients in this palliative population, true ITT analysis was often not performed, resulting in the potential for attrition bias. These missing data were handled differently by the various included studies. Some studies included participants on the basis of their 'last observation carried forward' (i.e. their last outcome prior to death) and others excluded these participants from the analysis completely. No studies used other imputation methods to account for these missing data. We downgraded evidence for indirectness due to variation in definitions of pleurodesis failure, inconsistencies in the doses of sclerosant used and the different approaches towards inclusion or exclusion of participants with trapped lung. There was also variation in how participant attrition was handled and the time point at which pleurodesis failure was assessed. We did state how this would be handled a priori, using hierarchies of preferences; however, these factors may have impacted on the results of the final NMA. Additionally, we downgraded evidence due to imprecision; many ranks and effect estimates had wide Cr‐Is. This was particularly evident in the NMAs of risk of procedure‐related fever and pain, and risk of mortality, where all relative effect estimates had wide Cr‐Is. We had very high concerns of imprecision in the bleomycin to talc slurry comparison in the risk of repeat pleural intervention meta‐analysis and evidence was downgraded by two levels. We downgraded evidence by one level for inconsistency for the IPC without daily drainage to talc slurry comparison for pleurodesis failure rate (I2 = 61%) and for the talc poudrage to talc slurry comparison within the pain (I2 = 69%) and mortality (I2 = 40%) outcomes. There was a substantial degree of both statistical and clinical heterogeneity in each network of comparisons. Aside from the analyses restricted to studies at lower risk of bias and trials excluding trapped lung (which did appear to reduce the degree of heterogeneity) the other sensitivity analyses, selected on the basis of factors hypothesised to be clinical effect modifiers, did not appear to explain the high level of heterogeneity. This signifies the complexity of this condition and the treatments, which results in substantial clinical heterogeneity. Possible explanations include different effects of varying tumour subtypes, early lung entrapment which is not clinically detectable, varying drug doses and subtle technique‐related procedural factors, such as adequacy of pleural fluid drainage prior to instillation of the sclerosant. Potential biases in the review processThis review is based on the available published evidence and not on individual patient data, which would give a more accurate estimation of treatment effect and a clearer understanding of the heterogeneity (Deeks 2011). However, as we have included studies published as long ago as 1977, individual patient information was therefore not available and patient‐level meta‐analysis would not be possible without excluding the majority of the available evidence. In order to allow inclusion of as many eligible studies as possible, we combined data obtained using different definitions of pleurodesis failure and timings in the same analysis. We predefined the methodology for this in the protocol using hierarchies of preferences. We performed sensitivity analyses to ensure the results were robust. A potential source of bias in our primary outcome measure, pleurodesis failure, is the inevitable participant attrition due to mortality reported in many studies. If there had been real differences in mortality (and therefore dropout) across the interventions, this could bias the estimates of relative pleurodesis failure rates. However, analysis of the data on mortality and median survival times showed only a possible association between tetracycline and increased mortality rates and no differences in the vast majority of comparisons. It should also be noted that the initial screening of titles and abstracts up to 2016 was performed by just one review author. From 2016 to 2020, this was done by two review authors. Agreements and disagreements with other studies or reviewsSeveral other systematic reviews have been published in this area (; ; ; ; ; ). All have presented only direct comparisons, rather than also incorporating indirect comparisons of alternative agents using NMA methods. We consider that NMA is much more informative, as the diversity of the control groups used when comparing one agent with 'all others' means that important relative treatment effects may be either over‐ or underestimated. We used robust inclusion and exclusion criteria to identify eligible studies, which resulted in some studies included in other systematic reviews in this field being excluded from this one. These studies have been recorded in the section of this review, with justifications given for their exclusion. The main reasons were failure to use a truly random process to assign treatment groups and the inclusion of ascites or pericardial fluid accumulation, which could not be differentiated in the results section. Previously published meta‐analyses have suggested that talc is the most effective agent (associated with the fewest pleurodesis failures) and is best delivered thoracoscopically, however, found both talc poudrage and talc slurry offered similar rates of pleurodesis efficacy, in keeping with our results. In a systematic review of quality of life following intervention for MPE, also acknowledged limitations due to heterogeneity in study design and varied measurement tools. While thoracoscopic talc poudrage, talc slurry and IPCs improved short‐term health‐related quality of life, no consensus was formed on the overall best treatment approach, with particular respect to long‐term outcomes. Our review has demonstrated that IPCs are associated with reduced rates of invasive ipsilateral re‐intervention and reduced procedure‐related length of hospital stay, mirrored by . Authors' conclusionsImplications for practiceFor clinicians and for people with malignant pleural effusionsThis systematic review suggests that of the commonly available pleurodesis techniques, talc poudrage and talc slurry both rank highly and are more effective at achieving a pleurodesis than sclerosants such as bleomycin (rank 11th, 95% credible interval (Cr‐I) 7 to 15) and doxycycline (rank 12th, 95% Cr‐I 5 to 18). Although indwelling pleural catheters (IPCs) are probably associated with higher pleurodesis failure rates than many of the other interventions described, this is likely to be improved by daily catheter drainage or instillation of talc slurry via the IPC. Moreover, pair‐wise meta‐analysis suggests that the use of IPCs results in less need for further invasive pleural interventions than talc slurry, which may be an important advantage for some patients. Talc poudrage was associated with a similar risk of requiring further invasive pleural procedures when compared to talc slurry (odds ratio (OR) 0.96, 95% Cr‐I 0.59 to 1.56). Where breathlessness outcomes were reported, symptom relief for participants with IPCs may be comparable to talc slurry. For those undergoing talc poudrage pleurodesis, breathlessness relief was probably comparable to talc slurry pleurodesis. In four studies, IPCs were associated with a reduced length of hospital stay (; ; ; ), a clinically relevant outcome for a patient group where anticipated survival is often short. Where pleurodesis success is not the primary outcome of interest, such as for those with trapped lung or previous pleurodesis failure, or for patients who wish to minimise repeated invasive procedures or avoid a hospital admission, IPCs may be a favourable choice. We have noted comparable improvements in postintervention quality of life outcomes in participants with IPCs (with or without daily drainage), talc slurry, talc poudrage and doxycycline pleurodesis (; ; ; ; ; ). The study, which is currently recruiting in the UK, with health‐related quality of life as its primary outcome in participants undergoing IPC with talc via IPC and talc slurry pleurodesis, will further inform practice. This review was not designed to evaluate rarer but potentially clinically important adverse effects. However, graded (large particle talc) has less systemic absorption than mixed particle size talc and should therefore be used to reduce the rare but important risk of acute respiratory distress syndrome (). Concerns regarding the dose‐dependent systemic absorption of intrapleural mepacrine, and the subsequent risk of transient psychotic episodes and seizures, have not been identified in the randomised trials of these agents, but are likely to limit its routine use (). Non‐steroidal anti‐inflammatory drug (NSAID) use has not been shown to adversely affect pleurodesis outcomes (). Data from three studies suggest participants receiving an IPC may have a higher risk of cellulitis and pleural infection (; ; ). Therefore, appropriate information regarding IPC care and symptoms of infection should be given. Worldwide, talc is reported to be the most commonly used pleurodesis agent (; ; ), and consequently it is likely to have the best appreciated adverse effect profile. Therefore, if graded talc is available, this would appear to be an effective choice for bedside pleurodesis, supported by the largest body of evidence. For policy makersWe have identified that many of the available treatment options have their own advantages and disadvantages, in terms of their effectiveness at inducing a pleurodesis, their adverse event profile and the chance a patient will need a subsequent invasive pleural intervention. Therefore, it is important that a range of treatment strategies are accessible and available to patients depending on their clinical situation and their personal preference. For example, there should be adequate provision of both IPC and an inpatient pleurodesis to allow patients and clinicians to decide on an optimal treatment pathway for that individual. For funders of the interventionThere are insufficient data regarding the relative costs of many of the interventions described in this review to provide robust conclusions regarding this. In the short term, IPCs have been found to be a cost‐effective choice but the longer‐term cost implications have not been formally established. Implications for researchGeneral implicationsThere is a paucity of data regarding patient preference. Although people with an IPC are likely to spend less time in hospital, we found no data relating to considerations such as lifestyle restrictions imposed by drainage regimens, limitation on social and functional activities, and consequent impact on wellbeing. An improved understanding of the key outcomes which are important to people with malignant pleural effusion (MPE) would be beneficial. Carer burden is another significant consideration, particularly in regions where community healthcare services do not provide IPC drainage. The health economic implications of the available interventions are additional important factors that warrant further research. Limited data suggest that IPCs are a cost‐effective choice in people with limited survival (), but substantial uncertainty around this estimate remains, particularly in respect to long‐term outcomes. The cost of community nursing and environmental implications associated with single‐use drainage equipment may make IPCs a less favourable choice in some settings. There is a lack of robust randomised evidence for surgical interventions in the MPE population. Our review has highlighted that pleurodesis success from thoracoscopic mechanical pleurodesis may yield results similar to talc poudrage, but further high‐quality evidence is required to delineate the role of this. The study, comparing talc slurry via IPC with video‐assisted thoracoscopic surgery (VATS) mechanical abrasion or talc poudrage may provide further clarity. There is limited evidence regarding the most effective management of people with trapped lung. Case series suggest trapped lung affects 10% to 20% of people with MPE and the rapid recurrence of fluid after pleural interventions and the loss of elasticity of the visceral pleura often results in severe symptoms of recurrent breathlessness and pain during fluid aspirations (; ; ). Often these patients are excluded from MPE trials given the lack of efficacy of pleurodesis in this subgroup and hence there is a dearth of evidence on how best to manage them. Future randomised controlled trials (RCTs) to delineate the optimal management strategy specific to this population would be beneficial. Further understanding of how the disease course of mesothelioma may differ from metastatic pleural disease may influence future treatment choices when considering the management of MPE. The pilot study, which is currently recruiting in the UK, may lead to a phase III study comparing the efficacy of IPC versus VATS partial pleurectomy/decortication for participants with malignant pleural mesothelioma with pleural effusion and trapped lung. As our understanding of the pathology of MPE develops and our knowledge of the available management options expands, a universal approach to all patients with malignant effusions is likely to underestimate the complexity of this condition and a hunt for the 'best' pleurodesis technique to over‐simplify its challenges. Different strategies are already known to have unique advantages and disadvantages and may therefore be suited to different cohorts of patients. We have demonstrated the heterogeneity of this patient population. It is only by gaining an understanding of the priorities of patients themselves and the real‐life implications of the various treatment options that we will be able to select the most appropriate management strategy for an individual. Further patient‐centred qualitative research, as well as study of the methods to optimise current strategies ( trial) and combine techniques to amalgamate the benefits of the varying modalities, are exciting potential areas of ongoing and future research. DesignUnderstanding the factors contributing to the high risk of bias in a large number of the previous studies in this field is crucial when designing future clinical trials in MPE. Attempting to minimise these risks by careful trial design has the potential to improve our evidence base and ensure robust, valid conclusions are drawn from the available evidence. Measurement (endpoints)An important limitation of this review is the heterogeneous reporting of patient‐centred outcome measures across trials, which precluded network meta‐analyses of these clinically important outcomes. This has important implications for future research. Selection of appropriate, clinically relevant, standardised outcome measures is essential to aid robust, unbiased analysis of trial data and facilitate future systematic reviews (). Specific to this review, an international agreement on the definition of pleurodesis success, the timing at which it should be assessed and development of MPE‐specific, validated patient‐reported outcome measurement tools would be hugely beneficial when combining data from future RCTs, along with a consensus about how to handle the inevitable patient attrition due to death. What's newDateEventDescription10 February 2020New search has been performedThis review has been updated with the results of a new search in June 2019.10 February 2020New citation required and conclusions have changedThe conclusions have changed due to the inclusion of 18 new studies (2079 participants). We have more data to be more certain of the effects of talc slurry, talc poudrage and indwelling pleural catheters. HistoryProtocol first published: Issue 5, 2013 DateEventDescription9 April 2019AmendedComma deleted in ongoing study reference (OPUS Trial).2 April 2019AmendedPublished Notes text amended.11 January 2018Review declared as stableSee Published notes.21 August 2014AmendedUpdated the authors' Declaration of Interest statements. AcknowledgementsCochrane Review Group funding acknowledgement: this project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, the NIHR, the NHS or the Department of Health and Social Care. The authors and editors are grateful to the following peer reviewers for their time and comments: Dr Stephen Wilson (East Lancashire Hospitals NHS Trust, UK); Dr Robert Killeen MD (Hematology & Oncology, Hospice & Palliative Medicine, USA); and consumer reviewers Ahmed Hussein Saleh Ibrahim and Abhijna Vithal Yergolkar. AppendicesAppendix 1. Search strategiesCENTRAL (the Cochrane library) #1 MeSH descriptor: [Pleural Effusion] explode all trees #2 (pleura* near/5 (effusion* or fluid*)):ti,ab,kw (Word variations have been searched) #3 #1 or #2 #4 MeSH descriptor: [Neoplasms] explode all trees #5 (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*):ti,ab,kw (Word variations have been searched) #6 #4 or #5 #7 #3 and #6 MEDLINE (Ovid) 1 exp Pleural Effusion/ 2 (pleura* adj5 (effusion* or fluid*)).mp. 3 or/1‐2 4 exp Neoplasms/ 5 (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*).mp. 6 or/4‐5 7 randomized controlled trial.pt. 8 controlled clinical trial.pt. 9 randomized.ab. 10 placebo.ab. 11 clinical trials as topic.sh. 12 randomly.ab. 13 trial.ti. 14 7 or 8 or 9 or 10 or 11 or 12 or 13 15 3 and 6 and 14 Embase (Ovid) 1 exp Pleural Effusion/ 2 (pleura* adj5 (effusion* or fluid*)).mp. 3 or/1‐2 4 exp neoplasm/ 5 (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*).mp. 6 or/4‐5 7 random$.tw. 8 factorial$.tw. 9 crossover$.tw. 10 cross over$.tw. 11 cross‐over$.tw. 12 placebo$.tw. 13 (doubl$ adj blind$).tw. 14 (singl$ adj blind$).tw. 15 assign$.tw. 16 allocat$.tw. 17 volunteer$.tw. 18 Crossover Procedure/ 19 double‐blind procedure.tw. 20 Randomized Controlled Trial/ 21 Single Blind Procedure/ 22 or/7‐21 23 (animal/ or nonhuman/) not human/ 24 22 not 23 25 3 and 6 and 24 Web of Science (ISI) SSCI & SCI #11 #10 AND #2 #10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 #9 Topic=(((("random* allocat*") or ("random* assign*")))) #8 Topic=(((crossover))) #7 Topic=(((("tripl* blind*") or ("tripl* mask*")))) #6 Topic=(((("trebl* blind*") or ("trebl* mask*")))) #5 Topic=(((("doubl* blind*") or ("doubl* mask*")))) #4 Topic=(((("singl* blind*") or ("singl* mask*")))) #3 Topic=(((("clin* trial*")))) #2 Topic=((pleura* near/5 (effusion* or fluid*))) AND Topic=((cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*)) #1 Topic=((pleura* near/5 (effusion* or fluid*))) CINAHL (EBSCO) S25 S18 AND S21 AND S24 S24 S22 OR S23 S23 (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*) S22 (MH "Neoplasms+") S21 S19 OR S20 S20 (pleura* N5 (effusion* or fluid*)) S19 (MH "Pleural Effusion+") S18 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 S17 (allocat* random*) S16 (MH "Quantitative Studies") S15 (MH "Placebos") S14 placebo* S13 (random* allocat*) S12 (MH "Random Assignment") S11 (Randomi?ed control* trial*) S10 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or (singl* mask* ) S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 S8 (allocat* random*) S7 (MH "Quantitative Studies") S6 (MH "Placebos") S5 placebo* S4 (random* allocat*) S3 (MH "Random Assignment") S2 (Randomi?ed control* trial*) S1 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or (singl* mask* ) Appendix 2. Distribution of study population characteristics across all the included studies and within each pair‐wise comparisonPotential effect modifiersTotal n (%)Bleomycin vs C parvum n (%)Bleomycin vs doxycycline n (%)Bleomycin vs iodine n (%)Bleomycin vs talc poudrage n (%)Bleomycin vs talc slurry n (%)Bleomycin vs tetracycline n (%)IPC daily drainage vs IPC –not daily drainage n (%)IPC –not daily drainage vs talc slurry n (%)Mustine vs tetracycline n (%)Talc poudrage vs talc slurry n (%)Talc slurry vs iodine n (%)Talc slurry vs TMP n (%)Number of studies—79222255222422Cell types includedAll58 (73)1 (50)2 (100)2 (100)1 (50)5 (100)5 (100)2 (100)2 (100)2 (100)4 (100)2 (100)0Only breast8 (10)0001 (50)00000002 (100)Only lung8 (10)000000000000Other5 (6)1 (50)00000000000Trapped lungExcluded 37 (47)002 (100)1 (50)3 (60)1 (20)1 (50)1 (50)03 (75)2 (100)1 (50)Included42 (53)2 (100)2 (100)01 (50)2 (40)4 (80)1 (50)1 (50)2 (100)1 (25)01 (50)Drain sizeUnknown31 (39)1 (50)1 (50)1 (50)1 (50)1 (20)4 (80)NANA02 (50)02 (100)Small (< 20‐Fr)14 (18)1 (50)1 (50)01 (50)1 (20)0NANA1 (50)000Large (≥ 20‐Fr)21 (27)001 (50)03 (60)1 (20)NANA1 (50)2 (50)2 (100)0Study comparing large with small drains4 (5)000000NANA0000How was pleurodesis definedClinicoradiological definition58 (73)2 (100)1 (50)01 (50)4 (80)4 (80)2 (100)2 (100)2 (100)2 (50)2 (100)1 (50)Radiological recurrence only22 (28)01 (50)2 (100)1 (50)1 (20)1 (20)0002 (50)01 (50)Time point pleurodesis defined2–4 months31 (39)1 (50)1 (50)01 (50)1 (20)2 (40)2 (100)02 (100)2 (50)01 (50)> 4–7 months3 (4)001 (50)0000001 (25)1 (50)0> 11–12 months4 (5)00000002 (100)0001 (50)< 2 months34 (42)1 (50)1 (50)1 (50)02 (40)3 (60)0001 (25)1 (50)0Not stated7 (9)0001 (50)2 (40)0000000*If the study reported multiple time points, the one referred to here was that used in our primary analysis (according to our hierarchy of preferences (see )) Appendix 3. Sensitivity analysis of the direct meta‐analysis results for pleurodesis failure using the fixed‐effect model showing odds ratios (95% CI) of the rows compared to the columns AdriamycinAutologous bloodBleomycinC parvumDoxycyclineIFNIPC – daily drainageIPC – not daily drainageIodineMepacrineMitoxantroneMustinePlaceboSilver nitrateTMPTalc poudrageTalc slurryTalc via IPCTetracyclineAutologous bloodNANANANANANANANANANANANANANANANA/NA/BleomycinNANANA///NANA///NANANANA//NA/C parvumNANA0.72 (0.32 to 1.61); n = 2; Chi2 = 17; I2 = 94%NA/NANANANANANA/NANANANANANA/DoxycyclineNANA0.66 (0.24 to 1.83); Chi2 = 0.22; I2 = 0%1.91 (0.43 to 8.48); n = 1NANANA/NANANANANANANA/NANANAIFNNANA3.25 (1.54 to 6.89); n = 1NANANANANANANANANANANANANANANANAIPC –daily drainageNANANANANANANA/NANANANANANANANA/NANAIPC –not daily drainageNANANANA4.28 (1.59 to 11.54); n = 1NA3.26 (1.80 to 5.88); n = 2; Chi2 = 0.55; I2 = 0%NANANANANANANANANA//NAIodineNANA0.63 (0.25 to 1.59); n = 2; Chi2 = 1.33; I2 = 25%NANANANANANANANANANANANA//NANAMepacrineNANA0.16 (0.03 to 0.89); n = 1NANANANANANANA/NA/NANANA/NA/Mistletoe (viscum)NANA0.19 (0.02 to 1.62); n = 1NANANANANANANANANANANANANANANANAMitoxantroneNANA3.18 (1.17 to 8.65); n = 1NANANANANANA7.61 (0.35 to 163.82); n = 1NANA/NANANANANANAMustine2.71 (0.1 to 74.98); n = 1NANA10.80 (1.64 to 70.93); n = 1NANANANANANANANANANANA/NANA/PlaceboNANANANANANANANANA14.4 (1.37 to 150.81); n = 11.33 (0.56 to 3.17); n = 1NANANANANA/NA/Silver nitrateNANANANANANANANANANANANANANANANA/NA/TMPNANANANANANANANANANANANANANANANA/NANATalc poudrageNANA0.1 (0.02 to 0.48); n = 2; Chi2 = 0.01; I2 = 0%NA0.02 (0.00 to 0.47); n = 1NANANA0.57 (0.08 to 3.80); n = 1NANA0.13 (0.02 to 0.71); n = 1NANANANA/NA/Talc slurryNA0.69 (0.24 to 1.95); n = 10.82 (0.41 to 1.65); n = 5; Chi2 = 4.53; I2 = 12%NANANA0.30 (0.08 to 1.14); n = 10.18 (0.10 to 0.31); n = 2; Chi2 = 2.58; I2 = 61%0.87 (0.25 to 3.04); n = 2; Chi2 = 0.70; I2 = 0%0.48 (0.14 to 1.60); n = 1NANA0.07 (0.00 to 1.51); n = 15.82 (0.21 to 158.82); n = 12.28 (0.83 to 6.23); n = 2; Chi2 = 0; I2 = 0%1.24 (0.92 to 1.65); n = 4; Chi2 = 0.89; I2 = 0%NANA/Talc via IPCNANANANANANANA0.36 (0.18 to 0.73); n = 1NANANANANANANANANANANATetracycline0.90 (0.05 to 16.59); n = 10.71 (0.14 to 3.60); n = 12.00 (1.07 to 3.73); n = 5; Chi2 = 1.23; I2 = 0%3.18 (0.52 to 19.64); n = 1NANANANANA1.60 (0.12 to 20.99); n = 1NA0.37 (0.10 to 1.35); n = 2; Chi2 = 0; I2 = 0%0.30 (0.05 to 1.94); n = 10.60 (0.15 to 2.47); n = 1NA12.10 (1.32 to 111.30); n = 10.78 (0.19 to 3.13); n = 1NANATriethylenethiophosphoramideNANANANANANANANANA4.95 (1.02 to 24.10); n = 1NANA0.34 (0.03 to 3.69); n = 1NANANANANANAIFN: interferon; IPC: indwelling pleural catheter; n: the number of studies included in the pair‐wise comparison; NA: no direct pair‐wise comparison available; TMP: thoracoscopic mechanical pleurodesis Appendix 4. Overview of the network meta‐analysis results for pleurodesis failure in the secondary endpoints and sensitivity analysesNumber of pleurodesis methods evaluatedNumber of trials included in networkTau (95% CI)Global inconsistencyLoop‐specific inconsistency identified?Consistency modelInconsistency modelMean Res DevpDDICSDMean Res DevpDDICSDWhole network21550.70 (0.30 to 1.17)11891.3209.30.7113.9101214.90.8NoFever14301.67 (1.08 to 1.98)65.256.2121.51.6764.556.7121.21.24NoMortality15310.22 (0.01 to 0.73)53.845.098.80.2254.249.9104.00.25NoPain14310.69 (0.11 to 1.51)67.251.0118.20.6960.053.4113.40.53NoOnly data collected at 1 month16300.71 (0.07 to 1.51)63.753116.80.7163.256.9120.10.4NoOnly data collected at 3 months9100.54 (0.03 to 1.83)19.91938.80.5419.719.238.80.55NoOnly data collected at 6 months790.44 (0.02 to 1.75)16.916.233.10.4417.316.934.20.53NoTrials excluding people with trapped lung13230.31 (0.01 to 1.19)47.337.284.50.3145.541.486.90.45NoTrials using a clinicoradiological definition of pleurodesis19370.89 (0.42 to 1.54)78.566.8145.30.897871.3149.41.09NoTrials using large‐bore chest tubes12190.73 (0.04 to 1.84)42.433.575.90.7339.335.174.40.83NoTrials with a lower risk of bias (scoring 'high' risk of bias in maximum 1 domain)18270.37 (0.02 to 1.47)56.946.2103.20.3754.151.2105.30.59NoTrials delivering agents by chest tube16370.87 (0.37 to 1.52)78.763.61420.8776.669.51461.19NoCI: confidence interval; DIC: deviance information criterion; Mean Res Dev: mean residual deviance; pD: probability of direction; SD: standard deviation Appendix 5. Estimated rank (95% Cr‐I) for pleurodesis efficacy in the sensitivity analysis only evaluating those trials with a lower risk of bias (lower rank confers higher risk of pleurodesis failure)Pleurodesis methodEstimated rank (95% Cr‐I)Talc poudrage2 (1 to 9)Talc slurry4 (1 to 9)C parvum4 (1 to 12)Mepacrine6 (1 to 13)Iodine6 (1 to 16)Doxycycline7 (1 to 14)Adriamycin7 (1 to 18)Autologous blood8 (2 to 15)Tetracycline9 (4 to 14)IPC – daily drainage9 (2 to 15)Silver nitrate9 (1 to 17)Talc via IPC10 (2 to 17)Bleomycin12 (6 to 16)Mustine14 (6 to 18)Triethylenethiophosphoramide14 (4 to 18)IPC – not daily drainage15 (9 to 18)Mitoxantrone17 (12 to 18)Placebo17 (12 to 18)Cr‐I: credible interval; IPC: indwelling pleural catheter Appendix 6. Estimated rank (95% Cr‐I) for the subgroup analysis evaluating the network of agents given via a chest tube (IPC and talc poudrage studies excluded)Pleurodesis agentEstimated rank (95% Cr‐I)Mistletoe1 (1 to 12)C parvum4 (1 to 11)Mepacrine4 (1 to 11)Talc slurry5 (2 to 10)Iodine6 (1 to 12)Doxycycline6 (1 to 13)Adriamycin7 (1 to 16)Bleomycin8 (5 to 12)Silver nitrate8 (1 to 15)Autologous blood9 (2 to 15)Tetracycline10 (5 to 13)Triethylenethiophosphoramide12 (2 to 16)IFN13 (4 to 16)Mustine13 (5 to 16)Mitoxantrone14 (9 to 16)Placebo15 (11 to 16)Cr‐I: credible interval; IFN: interferon Appendix 7. Results of the sensitivity analysis only evaluating those studies with a lower risk of bias. Table of odds ratios (95% Cr‐I) from network meta‐analysis (agents in the rows compared to those in the columns) AdriamycinAutologous bloodBleomycinC parvumDoxycyclineIPC – daily drainageIPC – not daily drainageIodineMepacrineMitoxantroneMustinePlaceboSilver nitrateTalc poudrageTalc slurryTalc via IPCTetracyclineAutologous blood1.19 (0.02 to 93.9)////////////////Bleomycin2.22 (0.05 to 182.3)1.92 (0.35 to 11.75)///////////////C parvum0.53 (0.01 to 40.43)0.45 (0.05 to 3.39)0.24 (0.03 to 1.6)//////////////Doxycycline1.03 (0.02 to 88.63)0.89 (0.1 to 6.19)0.46 (0.05 to 2.79)1.93 (0.32 to 11.97)/////////////IPC –daily drainage1.39 (0.02 to 130.3)1.21 (0.13 to 8.99)0.63 (0.07 to 4.23)2.61 (0.28 to 23.54)1.35 (0.23 to 8.18)////////////IPC –not daily drainage4.8 (0.09 to 396.5)4.17 (0.6 to 24.27)2.17 (0.32 to 11.31)9.03 (1.32 to 65.19)4.64 (1.21 to 20.97)3.44 (1.24 to 10.76)///////////Iodine0.86 (0.01 to 102)0.74 (0.06 to 9.08)0.39 (0.06 to 2.12)1.62 (0.12 to 25.95)0.83 (0.07 to 13.69)0.6 (0.05 to 10.89)0.18 (0.02 to 2.41)//////////Mepacrine0.84 (0.02 to 65.69)0.73 (0.1 to 3.93)0.38 (0.06 to 1.71)1.57 (0.19 to 12.5)0.82 (0.1 to 6.23)0.6 (0.07 to 4.91)0.17 (0.03 to 1.02)0.99 (0.07 to 9.67)/////////Mitoxantrone7.95 (0.17 to 771.1)6.92 (1.03 to 55.22)3.59 (0.98 to 14.58)15.23 (1.95 to 158.8)7.8 (1.05 to 86.25)5.68 (0.71 to 74.35)1.66 (0.26 to 15.45)9.33 (1.10 to 92.31)9.49 (2.06 to 71.96)////////Mustine3.67 (0.09 to 242.7)3.18 (0.37 to 26.7)1.66 (0.2 to 12.24)6.94 (1.22 to 47.12)3.6 (0.42 to 35.78)2.67 (0.25 to 33.31)0.77 (0.09 to 7.21)4.32 (0.27 to 62.01)4.44 (0.54 to 42.76)0.46 (0.05 to 3.92)///////Placebo9.9 (0.2 to 846.1)8.57 (1.2 to 61.69)4.47 (0.87 to 20.47)18.8 (2.39 to 170.9)9.63 (1.21 to 96.37)7.0 (0.8 to 81.68)2.04 (0.29 to 17.39)11.55 (1.07 to 118.7)11.63 (2.55 to 74.49)1.24 (0.31 to 4.15)2.67 (0.32 to 24.4)//////Silver nitrate1.44 (0.02 to 112.5)1.23 (0.1 to 10.64)0.64 (0.05 to 5.17)2.71 (0.21 to 26.91)1.42 (0.1 to 15.34)1.0 (0.07 to 12.43)0.3 (0.02 to 2.84)1.68 (0.07 to 23.96)1.73 (0.16 to 16.04)0.18 (0.01 to 1.65)0.39 (0.03 to 3.6)0.15 (0.01 to 1.28)/////Talc poudrage0.43 (0.01 to 32.56)0.37 (0.04 to 1.81)0.19 (0.02 to 0.82)0.8 (0.08 to 6.18)0.42 (0.04 to 2.89)0.31 (0.03 to 2.12)0.09 (0.01 to 0.44)0.5 (0.03 to 4.58)0.51 (0.07 to 2.79)0.05 (0.005 to 0.29)0.11 (0.009 to 0.95)0.04 (0.004 to 0.26)0.3 (0.03 to 3.21)////Talc slurry0.58 (0.01 to 43.55)0.49 (0.12 to 1.85)0.26 (0.06 to 0.93)1.07 (0.17 to 7.11)0.55 (0.11 to 3.31)0.4 (0.08 to 2.43)0.12 (0.03 to 0.46)0.66 (0.07 to 5.83)0.68 (0.18 to 3.01)0.07 (0.01 to 0.34)0.15 (0.02 to 1.11)0.06 (0.01 to 0.3)0.4 (0.05 to 3.98)1.29 (0.47 to 6.64)///Talc via IPC1.73 (0.02 to 184.8)1.5 (0.13 to 14.11)0.78 (0.07 to 6.62)3.23 (0.3 to 36.3)1.66 (0.24 to 13.33)1.23 (0.22 to 7.85)0.36 (0.08 to 1.51)2.03 (0.1 to 32.3)2.06 (0.22 to 23.2)0.22 (0.02 to 2.18)0.47 (0.03 to 6.06)0.18 (0.01 to 1.92)1.19 (0.09 to 23.75)3.96 (0.49 to 52.51)3.05 (0.41 to 20.77)//Tetracycline1.49 (0.04 to 90.75)1.28 (0.26 to 5.7)0.67 (0.14 to 2.54)2.8 (0.58 to 14.46)1.44 (0.24 to 9.61)1.06 (0.15 to 8.71)0.31 (0.06 to 1.78)1.75 (0.17 to 15.38)1.78 (0.39 to 9.31)0.19 (0.03 to 0.86)0.4 (0.08 to 1.81)0.15 (0.03 to 0.68)1.04 (0.19 to 7.42)3.46 (0.71 to 26.49)2.61 (0.66 to 10.57)0.86 (0.09 to 8.34)/Triethylenethiophosphoramide4.1 (0.05 to 451.1)3.58 (0.26 to 41.75)1.86 (0.15 to 17.95)7.76 (0.51 to 118.6)4.02 (0.27 to 61.94)2.94 (0.19 to 48.22)0.85 (0.07 to 10.85)4.85 (0.22 to 83.07)4.9 (0.74 to 36.17)0.52 (0.04 to 4.67)1.12 (0.07 to 17.03)0.43 (0.04 to 3.46)2.89 (0.18 to 57.68)9.77 (0.88 to 144.5)7.28 (0.72 to 68.87)2.4 (0.13 to 43.45)2.78 (0.25 to 27.95)Results that are significant at the conventional level of P < 0.05 are in bold Appendix 8. Results of the sensitivity analysis only evaluating agents given via chest tube. Table of odds ratios (95% Cr‐I) from network meta‐analysis (the agents in the rows compared to the agents in the columns) for pleurodesis success AdriamycinAutologous bloodBleomycinC parvumDoxycyclineIFNIodineMepacrineMistletoe (viscum)MitoxantroneMustinePlaceboSilver nitrateTalc slurryTetracyclineAutologous blood1.52 (0.02 to 136.90)NA/////////////Bleomycin1.22 (0.02 to 82.63)0.80 (0.13 to 4.81)NA////////////C parvum0.62 (0.01 to 46.29)0.41 (0.05 to 3.31)0.52 (0.14 to 1.75)NA///////////Doxycycline0.86 (0.01 to 76.37)0.57 (0.05 to 6.10)0.72 (0.13 to 3.56)1.38 (0.23 to 8.17)NA//////////IFN4.03 (0.04 to 443.40)2.65 (0.18 to 40.87)3.33 (0.43 to 25.84)6.45 (0.61 to 74.77)4.66 (0.36 to 68.95)NA/////////Iodine0.80 (0.01 to 64.26)0.53 (0.06 to 4.28)0.66 (0.17 to 2.42)1.28 (0.22 to 7.88)0.92 (0.12 to 7.88)0.20 (0.02 to 2.18)NA////////Mepacrine0.55 (0.01 to 43.69)0.37 (0.04 to 2.96)0.46 (0.10 to 1.80)0.89 (0.14 to 5.54)0.64 (0.07 to 5.65)0.14 (0.01 to 1.55)0.70 (0.10 to 4.28)NA///////Mistletoe (viscum)0.18 (0.00 to 30.85)0.12 (0.00 to 3.75)0.15 (0.01 to 2.73)0.29 (0.01 to 7.09)0.21 (0.01 to 6.20)0.05 (0.00 to 1.55)0.23 (0.01 to 5.58)0.33 (0.01 to 8.72)NA//////Mitoxantrone6.52 (0.08 to 615.00)4.25 (0.43 to 49.93)5.30 (1.11 to 30.71)10.33 (1.49 to 91.82)7.44 (0.82 to 91.14)1.58 (0.13 to 24.39)8.06 (1.11 to 72.15)11.54 (1.94 to 95.99)35.67 (1.34 to 1301)NA/////Mustine4.18 (0.06 to 324.30)2.76 (0.23 to 34.54)3.45 (0.52 to 24.35)6.72 (1.01 to 50.82)4.85 (0.45 to 60.37)1.04 (0.06 to 17.35)5.26 (0.55 to 54.66)7.57 (0.80 to 82.36)23.10 (0.71 to 929.90)0.65 (0.05 to 7.32)NA////Placebo10.25 (0.13 to 943.80)6.64 (0.72 to 74.51)8.32 (1.72 to 48.89)16.22 (2.35 to 140.30)11.68 (1.27 to 139.60)2.49 (0.20 to 38.28)12.63 (1.76 to 111.10)18.15 (3.28 to 135.80)56.06 (2.05 to 2060)1.57 (0.30 to 8.24)2.40 (0.22 to 29.19)NA///Silver nitrate1.21 (0.01 to 122.10)0.81 (0.05 to 11.30)1.01 (0.09 to 9.14)1.97 (0.14 to 22.51)1.42 (0.08 to 21.46)0.31 (0.01 to 5.68)1.54 (0.10 to 18.64)2.22 (0.15 to 27.79)6.76 (0.14 to 300.90)0.19 (0.01 to 2.57)0.29 (0.01 to 4.31)0.12 (0.01 to 1.58)NA//Talc slurry0.77 (0.01 to 54.75)0.51 (0.09 to 2.78)0.64 (0.25 to 1.60)1.24 (0.28 to 5.79)0.90 (0.14 to 6.14)0.19 (0.02 to 1.77)0.97 (0.25 to 3.78)1.39 (0.34 to 6.26)4.25 (0.20 to 110.90)0.12 (0.02 to 0.66)0.19 (0.02 to 1.39)0.08 (0.01 to 0.40)0.64 (0.07 to 7.41)NA/Tetracycline1.58 (0.03 to 98.83)1.04 (0.17 to 5.93)1.30 (0.52 to 3.12)2.52 (0.66 to 9.98)1.82 (0.30 to 11.75)0.39 (0.04 to 3.49)1.97 (0.42 to 9.10)2.83 (0.65 to 13.53)8.64 (0.40 to 223.90)0.24 (0.04 to 1.30)0.38 (0.06 to 2.16)0.16 (0.03 to 0.78)1.28 (0.16 to 12.58)2.03 (0.66 to 6.22)NATriethylenethiophosphoramide2.99 (0.02 to 418.10)1.97 (0.09 to 42.32)2.47 (0.18 to 33.93)4.81 (0.28 to 86.73)3.47 (0.16 to 79.33)0.74 (0.03 to 20.29)3.75 (0.21 to 67.61)5.38 (0.53 to 61.45)16.58 (0.33 to 967.70)0.47 (0.02 to 7.31)0.71 (0.03 to 16.62)0.30 (0.02 to 3.74)2.45 (0.09 to 83.81)3.86 (0.28 to 55.37)1.91 (0.14 to 27.69)Results that are significant at the conventional level of P < 0.05 are in bold Appendix 9. Direct pair‐wise evidence for fever, expressed as odds ratios (95% CI) for the rows compared to the columns, using random‐effects meta‐analysis Autologous bloodBleomycinC parvumDoxycyclineIPC – not daily drainageIodineMepacrineMitoxantroneMustinePlaceboSilver NitrateTalc poudrageTalc slurryTetracyclineBleomycinNANA//NA///NANANA///C parvumNA2.30 (0.9 to 5.92); n = 2; Tau2 = 0; I2 = 0%NA/NANANANA/NANANANA/DoxycyclineNA0.37 (0.01 to 12.35); n = 2;Tau2 = 5.18; I2 = 80%0.14 (0.03 to 0.54); n = 1NA/NANANANANANANANANAInterferonNA0.00 (0.00 to 0.11); n = 1NANANANANANANANANANANANAIPC –not daily drainageNANANA0.44 (0.07 to 2.8); n = 1NANANANANANANANANANAIodineNA1.00 (0.13 to 7.6); n = 1NANANANANANANANANA//NAMepacrineNA1.91 (0.52 to 7.01); n = 1NANANANANANANA/NANANA/MitoxantroneNA0.90 (0.30 to 2.71); n = 1NANANANANANANA/NANANANAMustineNANA0.23 (0.01 to 6.25); n = 1NANANANANANANANANANANAPlaceboNANANANANANA0.31 (0.12 to 0.79); n = 10.02 (0.0 to 0.35); n = 1NANANANANANASilver nitrateNANANANANANANANANANANANA//Talc poudrageNA1.15 (0.14 to 9.38); n = 1NANANA4.22 (0.43 to 41.45); n = 1NANANANANANA/NATalc slurry3.92 (1.31 to 11.72); n = 10.95 (0.36 to 2.51); n = 3: Tau2 = 0; I2 = 0%NANANA1.07 (0.32 to 3.59); n = 2; Tau2 = 0; I2 = 0%NANANANA0.70 (0.15 to 3.24); n = 11.65 (0.42 to 6.48); n = 2; Tau2 = 0.54; I2 = 31%NA/Tetracycline4.53 (0.83 to 24.65); n = 10.49 (0.16 to 1.5); n = 5; Tau2 = 0.63; I2 = 39%0.00 (0.00 to 0.06); n = 1NANANA0.13 (0.02 to 0.89); n = 1NANANA327.86 (16.05 to 6697.61); n = 1NA0.92 (0.23 to 3.63); n = 1NATriethylenethiophosphoramideNANANANANANA0.04 (0.01 to 0.30); n = 1NANA3.52 (0.15 to 81.92); n = 1NANANANA* indicates that the comparison included a three‐arm study Appendix 10. Table of the relative chance of pain from direct pair‐wise evidence using random‐effects model (odds ratios (95% Cr‐I) (rows compared to columns) Autologous bloodBleomycinC parvumDoxycyclineIPC – daily drainageIPC – not daily drainageIodineMepacrineMitoxantroneMustinePlaceboSilver nitrateTalc poudrageTalc slurryTetracyclineBleomycinNANA//NANA///NANANA///C parvumNA1.42 (0.54 to 3.75); n = 2; Tau2 = 0; I2 = 0%NA/NANANANANANANANANANA/DoxycyclineNA1.19 (0.37 to 3.80); n = 2; Tau2 = 0.3; I2 = 42%0.10 (0.01 to 0.96); n = 1NANA/NANANANANANANANANAIFNNA0.03 (0.00 to 0.53); n = 1NANANANANANANANANANANANANAIPC –daily drainageNANANANANA/NANANANANANANA/NAIPC –not daily drainageNANANA0.06 (0.00 to 1.24); n = 11.36 (0.78 to 2.37); n = 2; Tau2 = 0; I2 = 0%NANANANANANANANANANAIodineNA1.00 (0.13 to 7.60); n = 1NANANANANANANANANANA//NAMepacrineNA2.15 (0.52 to 9.00); n = 1NANANANANANANANA14.53 (0.71 to 298); n = 1NANANA/MitoxantroneNA2.08 (0.64 to 6.76); n = 1NANANANANANANANANANANANANATalc poudrageNA3.62 (0.14 to 95.78); n = 1NANANANA9.97 (0.50 to 198); n = 1NANANANANANA/NATalc slurry3.57 (1.19 to 10.74); n = 10.60 (0.15 to 2.46); n = 3; Tau2 = 0; I2 = 0%NANA0.31 (0.01 to 7.95); n = 10.62 (0.19 to 1.95); n = 2; Tau2 = 0%; I2 = 0%2.00 (0.55 to 7.30); n = 1NANANANANANANA/Talc via IPCNANANANANA0.71 (0.23 to 2.15); n = 1NANANANANANANANANATetracycline69.00 (7.61 to 625); n = 11.65 (0.79 to3.43); n = 4; Tau2 = 0.19; I2 = 34%0.41 (0.12 to 1.45); n = 1NANANANA0.18 (0.03 to 1.23); n = 1NA33.87 (1.80 to 636); n = 1NA55.08 (3.02 to 1003); n = 1NA3.28 (0.73 to 14.68); n = 1NATriethylenethiophosphoramideNANANANANANANA0.48 (0.10 to 2.30); n = 1NANA7.43 (0.35 to 156); n = 1NANANANA* indicates that the comparison included a three‐arm study Appendix 11. Table of the relative chances of pain from network meta‐analysis (expressed as odds ratios (95% Cr‐I) (rows compared to the columns) Autologous bloodBleomycinC parvumDoxycyclineIPC – daily drainageIPC – not daily drainageIodineMepacrineMitoxantroneTalc poudrageTalc slurryTalc via IPCTetracyclineBleomycin19.46 (3.47 to 138.70)NA///////////C parvum57.61 (8.11 to 559.60)2.94 (0.97 to 10.09)NA//////////Doxycycline22.87 (2.99 to 223.60)1.17 (0.35 to 4.12)0.40 (0.09 to 1.71)NA/////////IPC – daily drainage7.17 (0.70 to 95.49)0.37 (0.04 to 3.29)0.13 (0.01 to 1.33)0.32 (0.03 to 3.21)NA////////IPC – not daily drainage8.93 (1.08 to 86.34)0.46 (0.07 to 2.84)0.15 (0.02 to 1.20)0.39 (0.05 to 2.84)1.25 (0.32 to 4.08)NA///////Iodine3.39 (0.40 to 33.84)0.18 (0.03 to 0.99)0.06 (0.01 to 0.44)0.15 (0.02 to 1.16)0.47 (0.04 to 4.96)0.38 (0.05 to 3.21)NA//////Mepacrine82.89 (8.40 to 1105.00)4.21 (0.81 to 24.85)1.43 (0.19 to 10.81)3.63 (0.46 to 30.27)11.55 (0.77 to 181.00)9.35 (0.83 to 121.60)24.32 (2.29 to 303.60)NA/////Mitoxantrone42.78 (3.08 to 742.30)2.18 (0.29 to 17.20)0.74 (0.07 to 7.51)1.87 (0.17 to 20.19)5.97 (0.30 to 116.70)4.82 (0.32 to 81.23)12.62 (0.87 to 194.60)0.52 (0.04 to 7.07)NA////Talc poudrage8.64 (1.45 to 96.71)0.45 (0.09 to 3.00)0.15 (0.02 to 1.29)0.38 (0.06 to 3.41)1.21 (0.16 to 13.50)0.98 (0.17 to 8.81)2.55 (0.52 to 20.24)0.11 (0.01 to 1.29)0.20 (0.02 to 3.57)NA///Talc slurry6.77 (1.40 to 39.01)0.35 (0.09 to 1.28)0.12 (0.02 to 0.60)0.30 (0.05 to 1.56)0.95 (0.14 to 5.77)0.77 (0.17 to 3.39)2.00 (0.42 to 9.70)0.08 (0.01 to 0.63)0.16 (0.01 to 1.73)0.80 (0.17 to 2.20)NA//Talc via IPC6.16 (0.34 to 126.00)0.32 (0.02 to 4.60)0.11 (0.01 to 1.80)0.27 (0.01 to 4.32)0.86 (0.07 to 8.49)0.69 (0.09 to 5.02)1.82 (0.10 to 32.86)0.07 (0.00 to 1.66)0.14 (0.00 to 4.11)0.71 (0.03 to 9.01)0.91 (0.07 to 10.82)NA/Tetracycline29.74 (5.70 to 207.90)1.54 (0.65 to 3.75)0.52 (0.14 to 1.81)1.31 (0.30 to 5.61)4.17 (0.45 to 38.50)3.37 (0.51 to 24.51)8.81 (1.42 to 61.82)0.36 (0.06 to 1.97)0.70 (0.08 to 6.40)3.44 (0.48 to 17.66)4.39 (1.14 to 19.03)4.86 (0.32 to 82.62)NATriethylenethiophosphoramide38.85 (1.53 to 1235.00)1.97 (0.12 to 35.27) 0.67 (0.03 to 13.86)1.69 (0.08 to 38.16)5.37 (0.15 to 192.70)4.35 (0.16 to 136.80)11.37 (0.41 to 336.60)0.47 (0.05 to 4.47)0.90 (0.03 to 30.84)4.39 (0.14 to 104.20)5.66 (0.27 to 135.60)6.28 (0.13 to 340.60)1.29 (0.07 to 22.94)Results that are significant at the conventional level of P ≤ 0.05 are in bold Appendix 12. Estimated rank (95% Cr‐I) for causing pain (a low rank suggesting more pain)Pleurodesis agentEstimated rank (95% Cr‐I)Autologous blood1 (1 to 4)Iodine2 (1 to 8)Talc via IPC4 (1 to 13)Talc slurry5 (2 to 8)IPC –daily drainage5 (2 to 12)IPC –not daily drainage6 (2 to 12)Talc poudrage6 (2 to 12)Bleomycin8 (4 to 11)Doxycycline9 (4 to 13)Tetracycline10 (6 to 13)Mitoxantrone11 (3 to 14)Triethylenethiophosphoramide11 (2 to 14)C parvum12 (8 to 14)Mepacrine13 (8 to 14)Cr‐I: credible interval; IPC: indwelling pleural catheter Appendix 13. Table of the relative chance of mortality from direct evidence using random‐effects model (odds ratios (95% Cr‐I) (rows compared to columns) Autologous bloodBleomycinC parvumDoxycyclineIFNIPC – daily drainageIPC – not daily drainageIodineMepacrineMitoxantroneMustineTalc poudrageTalc slurryBleomycinNANA///NANANANA/NA//C parvumNA1.66 (0.51 to 5.38); n = 1NANANANANANANANA/NANADoxycyclineNA0.69 (0.26 to 1.87); n = 1NANANANANANANANANANANAIFNNA2.16 (1.15 to 4.07); n = 1NANANANANANANANANANANAIPC –daily drainageNANANANANANA/NANANANANA/IPC –not daily drainageNANANANANA1.29 (0.72 to 2.32); n = 2; Tau2 = 0; I2 = 0%NANANANANANA/IodineNANANANANANANANANANANA//MepacrineNANANANANANANANANA/NANA/MitoxantroneNA0.47 (0.21 to 1.05); n = 1NANANANANANA0.61 (0.09 to 4.37); n = 1NANANANAMustineNANA2.40 (0.38 to 15.32); n = 1NANANANANANANANA/NATalc poudrageNA1.22 (0.29 to 5.13); n = 1NANANANANA2.64 (0.58 to 12.09); n = 1NANA0.42 (0.09 to 1.96); n = 1NA/Talc slurry1.38 (0.30 to 6.47); n = 11.12 (0.36 to 3.46); n = 2; Tau2 = 0; I2 = 0%NANANA0.59 (0.19 to 1.79); n = 11.43 (0.91 to 2.23); n = 3; Tau2 = 0, I2 = 0%2.71 (0.10 to 70.65); n = 11.88 (0.70 to 5.02); n = 1NANA1.10 (0.69 to 1.75); n = 3; Tau2 = 0.07, I2 = 40%NATalc via IPCNANANANANANA0.44 (0.17 to 1.15); n = 1NANANANANANATetracyclineNot estimable1.60 (0.69 to 3.69); n = 2; Tau2 = 0%; I2 = 0%3.00 (0.28 to 31.99); n = 1NANANANANANANANA0.19 (0.03 to 1.10); n = 1NA* indicates that the comparison included a three‐arm study Appendix 14. Table of the relative chances of mortality from network meta‐analysis (expressed as odds ratios (95% Cr‐I) (rows compared to columns) Autologous bloodBleomycinC parvumDoxycyclineIFNIPC – daily drainageIPC – not daily drainageIodineMepacrineMitoxantroneMustineTalc poudrageTalc slurry Appendix 15. Estimated rank (95% Cr‐I) for mortality (low rank suggesting higher mortality)Pleurodesis agentEstimated rank (95% Cr‐I)Talc via IPC2 (1 to 11)Iodine2 (1 to 11)Mitoxantrone3 (1 to 10)Mepacrine5 (1 to 12)Doxycycline6 (1 to 14)Autologous blood6 (1 to 15)IPC –not daily drainage7 (3 to 12)IPC –daily drainage7 (3 to 13)Talc Poudrage8 (4 to 12)Talc Slurry9 (6 to 13)Bleomycin10 (4 to 13)C parvum11 (3 to 15)IFN13 (7 to 15)Tetracycline14 (10 to 15)Mustine14 (6 to 15)Cr‐I: credible interval; IFN: interferon; IPC: indwelling pleural catheter NotesNew search for studies and content updated (conclusions changed) Data and analysesComparison 1Bleomycin Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate22 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Bleomycin vs iodine299Odds Ratio (M‐H, Random, 95% CI)1.54 [0.51, 4.64]1.2 Bleomycin vs talc slurry5199Odds Ratio (M‐H, Random, 95% CI)1.22 [0.55, 2.70]1.3 Bleomycin vs tetracycline5220Odds Ratio (M‐H, Random, 95% CI)0.50 [0.27, 0.93]1.4 Bleomycin vs talc poudrage257Odds Ratio (M‐H, Random, 95% CI)9.70 [2.10, 44.78]1.5 Bleomycin vs C parvum278Odds Ratio (M‐H, Random, 95% CI)1.81 [0.02, 189.25]1.6 Bleomycin vs doxycycline2122Odds Ratio (M‐H, Random, 95% CI)1.50 [0.54, 4.20]1.7 Bleomycin vs interferon (IFN)1160Odds Ratio (M‐H, Random, 95% CI)0.31 [0.15, 0.65]1.8 Bleomycin vs mitoxantrone185Odds Ratio (M‐H, Random, 95% CI)0.31 [0.12, 0.86]1.9 Bleomycin vs mepacrine136Odds Ratio (M‐H, Random, 95% CI)6.40 [1.12, 36.44]1.10 Bleomycin vs combined tetracycline and bleomycin138Odds Ratio (M‐H, Random, 95% CI)5.57 [0.25, 124.19]1.11 Bleomycin vs cisplatin and etoposide169Odds Ratio (M‐H, Random, 95% CI)1.1 [0.39, 3.07]1.12 Bleomycin vs OK‐432168Odds Ratio (M‐H, Random, 95% CI)1.43 [0.49, 4.17]1.13 Bleomycin vs viscum117Odds Ratio (M‐H, Random, 95% CI)5.33 [0.62, 45.99]2 Fever17 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Bleomycin vs talc slurry399Odds Ratio (M‐H, Random, 95% CI)0.90 [0.31, 2.56]2.2 Bleomycin vs talc poudrage132Odds Ratio (M‐H, Random, 95% CI)0.87 [0.11, 7.05]2.3 Bleomycin vs tetracycline5250Odds Ratio (M‐H, Random, 95% CI)2.05 [0.67, 6.34]2.4 Tetracycline vs C parvum280Odds Ratio (M‐H, Random, 95% CI)0.43 [0.17, 1.12]2.5 Bleomycin vs IFN1160Odds Ratio (M‐H, Random, 95% CI)151.35 [9.08, 2522.62]2.6 Bleomycin vs mitoxantrone196Odds Ratio (M‐H, Random, 95% CI)1.11 [0.37, 3.36]2.7 Bleomycin vs mepacrine140Odds Ratio (M‐H, Random, 95% CI)0.52 [0.14, 1.92]2.8 Bleomycin vs doxycycline2148Odds Ratio (M‐H, Random, 95% CI)2.69 [0.08, 89.51]2.9 Bleomycin vs combined tetracycline and bleomycin140Odds Ratio (M‐H, Random, 95% CI)0.47 [0.04, 5.69]2.10 Bleomycin vs OK432167Odds Ratio (M‐H, Random, 95% CI)0.7 [0.23, 2.13]2.11 Bleomycin vs cisplatin and etoposide169Odds Ratio (M‐H, Random, 95% CI)2.22 [0.82, 6.01]2.12 Bleomycin vs iodine160Odds Ratio (M‐H, Random, 95% CI)1.0 [0.13, 7.60]3 Pain15 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Bleomycin vs talc slurry273Odds Ratio (M‐H, Random, 95% CI)1.66 [0.41, 6.80]3.2 Bleomycin vs tetracycline4220Odds Ratio (M‐H, Random, 95% CI)0.61 [0.29, 1.27]3.3 Bleomycin vs talc poudrage132Odds Ratio (M‐H, Random, 95% CI)0.28 [0.01, 7.31]3.4 Bleomycin vs C parvum271Odds Ratio (M‐H, Random, 95% CI)0.70 [0.27, 1.85]3.5 Bleomycin vs IFN1160Odds Ratio (M‐H, Random, 95% CI)32.34 [1.89, 552.23]3.6 Bleomycin vs mitoxantrone196Odds Ratio (M‐H, Random, 95% CI)0.48 [0.15, 1.56]3.7 Bleomycin vs mepacrine140Odds Ratio (M‐H, Random, 95% CI)0.46 [0.11, 1.94]3.8 Bleomycin vs doxycycline2148Odds Ratio (M‐H, Random, 95% CI)0.84 [0.26, 2.70]3.9 Bleomycin vs OK‐432167Odds Ratio (M‐H, Random, 95% CI)0.40 [0.14, 1.12]3.10 Bleomycin vs cisplatin and etoposide169Odds Ratio (M‐H, Random, 95% CI)0.83 [0.32, 2.16]3.11 Bleomycin vs iodine160Odds Ratio (M‐H, Random, 95% CI)1.0 [0.13, 7.60]4 Mortality11 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Bleomycin vs combined tetracycline and bleomycin140Odds Ratio (M‐H, Random, 95% CI)1.0 [0.06, 17.18]4.2 Bleomycin vs talc slurry2116Odds Ratio (M‐H, Random, 95% CI)0.89 [0.29, 2.75]4.3 Bleomycin vs tetracycline2125Odds Ratio (M‐H, Random, 95% CI)0.63 [0.27, 1.44]4.4 Bleomycin vs talc poudrage132Odds Ratio (M‐H, Random, 95% CI)0.82 [0.20, 3.43]4.5 Bleomycin vs C parvum155Odds Ratio (M‐H, Random, 95% CI)0.60 [0.19, 1.94]4.6 Bleomycin vs IFN1160Odds Ratio (M‐H, Random, 95% CI)0.46 [0.25, 0.87]4.7 Bleomycin vs mitoxantrone196Odds Ratio (M‐H, Random, 95% CI)2.15 [0.95, 4.86]4.8 Bleomycin vs OK‐432168Odds Ratio (M‐H, Random, 95% CI)2.66 [0.98, 7.23]4.9 Bleomycin vs doxycycline2122Odds Ratio (M‐H, Random, 95% CI)1.44 [0.53, 3.90]4.10 Bleomycin vs cisplatin and etoposide169Odds Ratio (M‐H, Random, 95% CI)2.22 [0.82, 6.01]5 Repeat pleural intervention133Odds Ratio (M‐H, Fixed, 95% CI)4.33 [0.16, 114.58]5.1 Bleomycin vs talc slurry133Odds Ratio (M‐H, Fixed, 95% CI)4.33 [0.16, 114.58] Open in a separate window 1.2 Analysis Comparison 1 Bleomycin, Outcome 2 Fever. 1.3 Analysis Comparison 1 Bleomycin, Outcome 3 Pain. 1.4 Analysis Comparison 1 Bleomycin, Outcome 4 Mortality. 1.5 Analysis Comparison 1 Bleomycin, Outcome 5 Repeat pleural intervention. Comparison 2Talc slurry Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate20 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Talc slurry vs talc poudrage4919Odds Ratio (M‐H, Random, 95% CI)1.24 [0.92, 1.65]1.2 Talc slurry vs bleomycin5199Odds Ratio (M‐H, Random, 95% CI)0.82 [0.37, 1.82]1.3 Talc slurry vs indwelling pleural catheter (IPC) – not daily drainage2249Odds Ratio (M‐H, Random, 95% CI)0.18 [0.07, 0.45]1.4 Talc slurry vs mepacrine189Odds Ratio (M‐H, Random, 95% CI)0.48 [0.14, 1.60]1.5 Talc slurry vs placebo121Odds Ratio (M‐H, Random, 95% CI)0.07 [0.00, 1.51]1.6 Talc slurry vs iodine275Odds Ratio (M‐H, Random, 95% CI)0.85 [0.24, 3.08]1.7 Talc slurry vs tetracycline132Odds Ratio (M‐H, Random, 95% CI)1.29 [0.32, 5.17]1.8 Talc slurry vs silver nitrate125Odds Ratio (M‐H, Random, 95% CI)5.82 [0.21, 158.82]1.9 Talc slurry vs thoracoscopic mechanical pleurodesis (TMP)2123Odds Ratio (M‐H, Random, 95% CI)2.28 [0.83, 6.23]1.10 Talc slurry vs autologous blood1110Odds Ratio (M‐H, Random, 95% CI)0.69 [0.24, 1.95]1.11 Talc slurry vs IPC – daily drainage155Odds Ratio (M‐H, Random, 95% CI)0.30 [0.08, 1.14]2 Fever9 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Talc slurry vs talc poudrage2479Odds Ratio (M‐H, Random, 95% CI)1.65 [0.42, 6.48]2.2 Talc slurry vs bleomycin398Odds Ratio (M‐H, Random, 95% CI)0.95 [0.36, 2.51]2.3 Talc slurry vs tetracycline134Odds Ratio (M‐H, Random, 95% CI)1.09 [0.28, 4.32]2.4 Talc slurry vs iodine275Odds Ratio (M‐H, Random, 95% CI)1.07 [0.32, 3.59]2.5 Talc slurry vs silver nitrate160Odds Ratio (M‐H, Random, 95% CI)0.7 [0.15, 3.24]2.6 Talc slurry vs autologous blood1110Odds Ratio (M‐H, Random, 95% CI)3.92 [1.31, 11.72]3 Pain12 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Talc slurry vs bleomycin399Odds Ratio (M‐H, Random, 95% CI)0.60 [0.15, 2.46]3.2 Talc slurry vs talc poudrage2812Odds Ratio (M‐H, Random, 95% CI)1.27 [0.41, 3.96]3.3 Talc slurry vs tetracycline134Odds Ratio (M‐H, Random, 95% CI)0.30 [0.07, 1.36]3.4 Talc slurry vs iodine275Odds Ratio (M‐H, Random, 95% CI)2.0 [0.55, 7.30]3.5 Talc slurry vs IPC – not daily drainage2232Odds Ratio (M‐H, Random, 95% CI)0.62 [0.19, 1.95]3.6 Talc slurry vs placebo131Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]3.7 Talc slurry vs autologous blood1110Odds Ratio (M‐H, Random, 95% CI)3.57 [1.19, 10.74]3.8 Talc slurry vs IPC – daily drainage157Odds Ratio (M‐H, Random, 95% CI)0.31 [0.01, 7.95]4 Breathlessness3344Mean Difference (IV, Fixed, 95% CI)1.09 [‐6.14, 8.32]4.1 Talc slurry vs IPC (not daily drainage)2160Mean Difference (IV, Fixed, 95% CI)6.12 [‐4.08, 16.32]4.2 Talc slurry vs talc poudrage1184Mean Difference (IV, Fixed, 95% CI)‐4.0 [‐14.26, 6.26]5 Mortality14 Odds Ratio (M‐H, Random, 95% CI)Subtotals only5.1 Talc slurry vs talc poudrage3725Odds Ratio (M‐H, Random, 95% CI)1.10 [0.69, 1.75]5.2 Talc slurry vs bleomycin2116Odds Ratio (M‐H, Random, 95% CI)1.12 [0.36, 3.46]5.3 Talc slurry vs iodine275Odds Ratio (M‐H, Random, 95% CI)2.71 [0.10, 70.65]5.4 Talc slurry vs IPC – not daily drainage3344Odds Ratio (M‐H, Random, 95% CI)1.43 [0.91, 2.23]5.5 Talc slurry vs mepacrine189Odds Ratio (M‐H, Random, 95% CI)1.88 [0.70, 5.02]5.6 Talc slurry vs TMP187Odds Ratio (M‐H, Random, 95% CI)10.64 [0.55, 203.85]5.7 Talc slurry vs autologous blood1117Odds Ratio (M‐H, Random, 95% CI)1.38 [0.30, 6.47]5.8 Talc slurry vs IPC – daily drainage157Odds Ratio (M‐H, Random, 95% CI)0.59 [0.19, 1.79]6 Repeat pleural intervention6756Odds Ratio (M‐H, Random, 95% CI)1.95 [0.90, 4.20]6.1 Talc slurry vs IPC – not daily drainage3343Odds Ratio (M‐H, Random, 95% CI)3.91 [1.98, 7.72]6.2 Talc slurry vs talc poudrage2380Odds Ratio (M‐H, Random, 95% CI)1.05 [0.64, 1.71]6.3 Talc slurry vs bleomycin133Odds Ratio (M‐H, Random, 95% CI)0.23 [0.01, 6.10] Open in a separate window 2.4 Analysis Comparison 2 Talc slurry, Outcome 4 Breathlessness. 2.5 Analysis Comparison 2 Talc slurry, Outcome 5 Mortality. 2.6 Analysis Comparison 2 Talc slurry, Outcome 6 Repeat pleural intervention. Comparison 3Talc poudrage Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate10 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Talc poudrage vs talc slurry4919Odds Ratio (M‐H, Random, 95% CI)0.81 [0.61, 1.08]1.2 Talc poudrage vs bleomycin257Odds Ratio (M‐H, Random, 95% CI)0.10 [0.02, 0.48]1.3 Talc poudrage vs tetracycline133Odds Ratio (M‐H, Random, 95% CI)0.08 [0.01, 0.76]1.4 Talc poudrage vs iodine142Odds Ratio (M‐H, Random, 95% CI)0.57 [0.08, 3.80]1.5 Talc poudrage vs mustine137Odds Ratio (M‐H, Random, 95% CI)0.13 [0.02, 0.71]1.6 Talc poudrage vs doxycycline131Odds Ratio (M‐H, Random, 95% CI)0.02 [0.00, 0.47]2 Fever4 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Talc poudrage vs talc slurry2479Odds Ratio (M‐H, Random, 95% CI)0.60 [0.15, 2.37]2.2 Talc poudrage vs bleomycin132Odds Ratio (M‐H, Random, 95% CI)1.15 [0.14, 9.38]2.3 Talc poudrage vs iodine142Odds Ratio (M‐H, Random, 95% CI)4.22 [0.43, 41.45]3 Pain4 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Talc poudrage vs talc slurry2812Odds Ratio (M‐H, Random, 95% CI)0.79 [0.25, 2.45]3.2 Talc poudrage vs bleomycin132Odds Ratio (M‐H, Random, 95% CI)3.62 [0.14, 95.78]3.3 Talc poudrage vs iodine142Odds Ratio (M‐H, Random, 95% CI)9.97 [0.50, 198.04]4 Breathlessness1184Mean Difference (IV, Random, 95% CI)4.0 [‐6.26, 14.26]4.1 Talc poudrage vs talc slurry1184Mean Difference (IV, Random, 95% CI)4.0 [‐6.26, 14.26]5 Mortality7 Odds Ratio (M‐H, Random, 95% CI)Subtotals only5.1 Talc poudrage vs talc slurry3725Odds Ratio (M‐H, Random, 95% CI)0.91 [0.57, 1.46]5.2 Talc poudrage vs bleomycin132Odds Ratio (M‐H, Random, 95% CI)1.22 [0.29, 5.13]5.3 Talc poudrage vs tetracycline141Odds Ratio (M‐H, Random, 95% CI)5.25 [0.91, 30.22]5.4 Talc poudrage vs iodine142Odds Ratio (M‐H, Random, 95% CI)2.64 [0.58, 12.09]5.5 Talc poudrage vs mustine146Odds Ratio (M‐H, Random, 95% CI)0.43 [0.09, 1.96]6 Repeat pleural intervention2380Odds Ratio (M‐H, Fixed, 95% CI)0.96 [0.59, 1.56]6.1 Talc poudrage vs talc slurry2380Odds Ratio (M‐H, Fixed, 95% CI)0.96 [0.59, 1.56] Open in a separate window 3.2 Analysis Comparison 3 Talc poudrage, Outcome 2 Fever. 3.3 Analysis Comparison 3 Talc poudrage, Outcome 3 Pain. 3.4 Analysis Comparison 3 Talc poudrage, Outcome 4 Breathlessness. 3.5 Analysis Comparison 3 Talc poudrage, Outcome 5 Mortality. 3.6 Analysis Comparison 3 Talc poudrage, Outcome 6 Repeat pleural intervention. Comparison 4Tetracycline Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate14 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Tetracycline vs C parvum132Odds Ratio (M‐H, Random, 95% CI)3.18 [0.52, 19.64]1.2 Tetracycline vs talc slurry132Odds Ratio (M‐H, Random, 95% CI)0.78 [0.19, 3.13]1.3 Tetracycline vs adriamycin121Odds Ratio (M‐H, Random, 95% CI)0.9 [0.05, 16.59]1.4 Tetracyclines vs placebo120Odds Ratio (M‐H, Random, 95% CI)0.3 [0.05, 1.94]1.5 Tetracycline vs talc poudrage133Odds Ratio (M‐H, Random, 95% CI)12.1 [1.32, 111.30]1.6 Tetracycline vs mustine259Odds Ratio (M‐H, Random, 95% CI)0.37 [0.10, 1.35]1.7 Tetracycline vs combined tetracycline and bleomycin138Odds Ratio (M‐H, Random, 95% CI)8.27 [0.40, 172.05]1.8 Tetracycline vs bleomycin5220Odds Ratio (M‐H, Random, 95% CI)2.00 [1.07, 3.75]1.9 Tetracycline vs mepacrine121Odds Ratio (M‐H, Random, 95% CI)1.6 [0.12, 20.99]1.10 Tetracycline vs autologous blood148Odds Ratio (M‐H, Random, 95% CI)0.71 [0.14, 3.60]1.11 Tetracycline vs silver nitrate150Odds Ratio (M‐H, Random, 95% CI)0.60 [0.15, 2.47]1.12 Tetracycline poudrage vs tetracycline slurry129Odds Ratio (M‐H, Random, 95% CI)0.28 [0.04, 1.76]2 Fever11 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Tetracycline vs talc slurry134Odds Ratio (M‐H, Random, 95% CI)0.92 [0.23, 3.63]2.2 Tetracycline vs bleomycin5250Odds Ratio (M‐H, Random, 95% CI)0.49 [0.16, 1.50]2.3 Tetracycline vs C parvum136Odds Ratio (M‐H, Random, 95% CI)0.00 [0.00, 0.06]2.4 Tetracycline vs mepacrine122Odds Ratio (M‐H, Random, 95% CI)0.13 [0.02, 0.89]2.5 Tetracycline vs combination tetracycline and bleomycin140Odds Ratio (M‐H, Random, 95% CI)0.47 [0.04, 5.69]2.6 Tetracycline vs placebo122Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]2.7 Tetracycline vs mustine140Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]2.8 Tetracycline vs autologous blood148Odds Ratio (M‐H, Random, 95% CI)4.53 [0.83, 24.65]2.9 Tetracycline vs silver nitrate150Odds Ratio (M‐H, Random, 95% CI)327.86 [16.05, 6697.61]3 Pain10 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Tetracycline vs talc slurry134Odds Ratio (M‐H, Random, 95% CI)3.28 [0.73, 14.68]3.2 Tetracycline vs bleomycin4220Odds Ratio (M‐H, Random, 95% CI)1.65 [0.79, 3.43]3.3 Tetracycline vs C parvum141Odds Ratio (M‐H, Random, 95% CI)0.41 [0.12, 1.45]3.4 Tetracycline vs mustine140Odds Ratio (M‐H, Random, 95% CI)33.87 [1.80, 636.88]3.5 Tetracycline vs mepacrine122Odds Ratio (M‐H, Random, 95% CI)0.18 [0.03, 1.23]3.6 Tetracycline vs placebo122Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]3.7 Tetracycline vs autologous blood148Odds Ratio (M‐H, Random, 95% CI)69.00 [7.61, 625.86]3.8 Tetracycline vs silver nitrate150Odds Ratio (M‐H, Random, 95% CI)55.08 [3.02, 1003.70]4 Mortality6300Odds Ratio (M‐H, Random, 95% CI)0.99 [0.30, 3.26]4.1 Tetracycline vs talc poudrage141Odds Ratio (M‐H, Random, 95% CI)0.19 [0.03, 1.10]4.2 Tetracycline vs bleomycin2125Odds Ratio (M‐H, Random, 95% CI)1.60 [0.69, 3.69]4.3 Tetracycline vs C parvum136Odds Ratio (M‐H, Random, 95% CI)3.00 [0.28, 31.99]4.4 Tetracycline vs silver nitrate150Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]4.5 Tetracycline vs autologous blood148Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0] Open in a separate window 4.4 Analysis Comparison 4 Tetracycline, Outcome 4 Mortality. Comparison 5C parvum Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate5 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 C parvum vs bleomycin278Odds Ratio (M‐H, Random, 95% CI)0.55 [0.01, 57.48]1.2 C parvum vs tetracycline132Odds Ratio (M‐H, Random, 95% CI)0.31 [0.05, 1.94]1.3 C parvum vs doxycycline135Odds Ratio (M‐H, Random, 95% CI)0.52 [0.12, 2.33]1.4 C parvum vs mustine118Odds Ratio (M‐H, Random, 95% CI)0.33 [0.04, 2.52]2 Fever5 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 C parvum vs bleomycin280Odds Ratio (M‐H, Random, 95% CI)2.30 [0.90, 5.92]2.2 C parvum vs tetracycline136Odds Ratio (M‐H, Random, 95% CI)288.00 [16.62, 4991.05]2.3 C parvum vs mustine121Odds Ratio (M‐H, Random, 95% CI)4.41 [0.16, 121.68]2.4 C parvum vs doxycycline141Odds Ratio (M‐H, Random, 95% CI)7.37 [1.84, 29.55]3 Pain4153Odds Ratio (M‐H, Random, 95% CI)2.51 [1.10, 5.75]3.1 C parvum vs bleomycin271Odds Ratio (M‐H, Random, 95% CI)1.42 [0.54, 3.75]3.2 C parvum vs tetracycline141Odds Ratio (M‐H, Random, 95% CI)2.44 [0.69, 8.66]3.3 C parvum vs doxycycline141Odds Ratio (M‐H, Random, 95% CI)7.37 [1.84, 29.55]4 Mortality3 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 C parvum vs bleomycin155Odds Ratio (M‐H, Random, 95% CI)1.66 [0.51, 5.38]4.2 C parvum vs tetracycline136Odds Ratio (M‐H, Random, 95% CI)0.33 [0.03, 3.55]4.3 C parvum vs mustine121Odds Ratio (M‐H, Random, 95% CI)0.42 [0.07, 2.66] Open in a separate window 5.2 Analysis Comparison 5 C parvum, Outcome 2 Fever. 5.3 Analysis Comparison 5 C parvum, Outcome 3 Pain. 5.4 Analysis Comparison 5 C parvum, Outcome 4 Mortality. Comparison 6Indwelling pleural catheter (IPC) – not daily drainage Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate6 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 IPC – not daily drainage vs talc slurry2249Odds Ratio (M‐H, Random, 95% CI)5.46 [2.20, 13.55]1.2 IPC – not daily drainage vs talc via IPC1139Odds Ratio (M‐H, Random, 95% CI)2.76 [1.36, 5.60]1.3 IPC – not daily drainage vs IPC – daily drainage2236Odds Ratio (M‐H, Random, 95% CI)3.23 [1.79, 5.85]1.4 IPC – not daily drainage vs doxycycline1119Odds Ratio (M‐H, Random, 95% CI)4.28 [1.59, 11.54]2 Fever1119Odds Ratio (M‐H, Fixed, 95% CI)0.44 [0.07, 2.80]3 Pain6 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 IPC – not daily drainage vs talc slurry2232Odds Ratio (M‐H, Random, 95% CI)1.63 [0.51, 5.15]3.2 IPC – not daily drainage vs talc via IPC1154Odds Ratio (M‐H, Random, 95% CI)1.41 [0.47, 4.28]3.3 IPC – not daily drainage vs IPC – daily drainage2236Odds Ratio (M‐H, Random, 95% CI)1.36 [0.78, 2.37]3.4 IPC – not daily drainage vs doxycycline1119Odds Ratio (M‐H, Random, 95% CI)0.06 [0.00, 1.24]4 Breathlessness2160Mean Difference (IV, Fixed, 95% CI)‐6.12 [‐16.32, 4.08]4.1 IPC – not daily drainage vs talc slurry2160Mean Difference (IV, Fixed, 95% CI)‐6.12 [‐16.32, 4.08]5 Mortality6734Odds Ratio (M‐H, Random, 95% CI)0.99 [0.66, 1.49]5.1 IPC – not daily drainage vs talc slurry3344Odds Ratio (M‐H, Random, 95% CI)0.70 [0.45, 1.09]5.2 IPC – not daily drainage vs talc via IPC1154Odds Ratio (M‐H, Random, 95% CI)2.29 [0.87, 6.04]5.3 IPC – not daily drainage vs IPC – daily drainage2236Odds Ratio (M‐H, Random, 95% CI)1.29 [0.72, 2.32]6 Repeat pleural procedure3343Odds Ratio (M‐H, Fixed, 95% CI)0.25 [0.13, 0.48] Open in a separate window 6.2 Analysis Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 2 Fever. 6.3 Analysis Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 3 Pain. 6.4 Analysis Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 4 Breathlessness. 6.5 Analysis Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 5 Mortality. 6.6 Analysis Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 6 Repeat pleural procedure. Comparison 7Iodine Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate5 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Iodine vs talc poudrage142Odds Ratio (M‐H, Random, 95% CI)1.76 [0.26, 11.83]1.2 Iodine vs talc slurry275Odds Ratio (M‐H, Random, 95% CI)1.17 [0.32, 4.25]1.3 Iodine vs bleomycin299Odds Ratio (M‐H, Random, 95% CI)0.65 [0.22, 1.96]2 Fever4 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Iodine vs talc slurry275Odds Ratio (M‐H, Random, 95% CI)0.93 [0.28, 3.13]2.2 Iodine vs talc poudrage142Odds Ratio (M‐H, Random, 95% CI)0.24 [0.02, 2.33]2.3 Iodine vs bleomycin160Odds Ratio (M‐H, Random, 95% CI)1.0 [0.13, 7.60]3 Pain4 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Iodine vs talc slurry275Odds Ratio (M‐H, Random, 95% CI)0.5 [0.14, 1.83]3.2 Iodine vs talc poudrage142Odds Ratio (M‐H, Random, 95% CI)0.10 [0.01, 1.99]3.3 Iodine vs bleomycin160Odds Ratio (M‐H, Random, 95% CI)1.0 [0.13, 7.60]4 Mortality2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Iodine vs talc poudrage142Odds Ratio (M‐H, Random, 95% CI)0.38 [0.08, 1.73]4.2 Iodine vs talc slurry139Odds Ratio (M‐H, Random, 95% CI)0.37 [0.01, 9.64] Open in a separate window 7.1 Analysis Comparison 7 Iodine, Outcome 1 Pleurodesis failure rate. 7.2 Analysis Comparison 7 Iodine, Outcome 2 Fever. 7.3 Analysis Comparison 7 Iodine, Outcome 3 Pain. 7.4 Analysis Comparison 7 Iodine, Outcome 4 Mortality. Comparison 8Doxycycline Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate5 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Doxycycline vs talc poudrage131Odds Ratio (M‐H, Random, 95% CI)42.69 [2.13, 856.61]1.2 Doxycycline vs bleomycin2122Odds Ratio (M‐H, Random, 95% CI)0.67 [0.24, 1.86]1.3 Doxycycline vs C parvum135Odds Ratio (M‐H, Random, 95% CI)1.91 [0.43, 8.48]1.4 Doxycycline vs IPC – not daily drainage1119Odds Ratio (M‐H, Random, 95% CI)0.23 [0.09, 0.63]2 Fever4308Odds Ratio (M‐H, Random, 95% CI)0.48 [0.09, 2.59]2.1 Doxycycline vs bleomycin2148Odds Ratio (M‐H, Random, 95% CI)0.37 [0.01, 12.35]2.2 Doxycycline vs C parvum141Odds Ratio (M‐H, Random, 95% CI)0.14 [0.03, 0.54]2.3 Doxycycline vs IPC – not daily drainage1119Odds Ratio (M‐H, Random, 95% CI)2.26 [0.36, 14.23]3 Pain4 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Doxycycline vs bleomycin2148Odds Ratio (M‐H, Random, 95% CI)1.19 [0.37, 3.80]3.2 Doxycycline vs C parvum141Odds Ratio (M‐H, Random, 95% CI)0.10 [0.01, 0.96]3.3 Doxycycline vs IPC – not daily drainage1119Odds Ratio (M‐H, Random, 95% CI)17.26 [0.80, 370.79]4 Mortality1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Doxycycline vs bleomycin180Odds Ratio (M‐H, Random, 95% CI)0.69 [0.26, 1.87] Open in a separate window 8.2 Analysis Comparison 8 Doxycycline, Outcome 2 Fever. 8.3 Analysis Comparison 8 Doxycycline, Outcome 3 Pain. 8.4 Analysis Comparison 8 Doxycycline, Outcome 4 Mortality. Comparison 9Duration of drainage after pleurodesis administration Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate3 Odds Ratio (M‐H, Fixed, 95% CI)Subtotals only2 Mortality3 Odds Ratio (M‐H, Random, 95% CI)Subtotals only Open in a separate window 9.1 Analysis Comparison 9 Duration of drainage after pleurodesis administration, Outcome 1 Pleurodesis failure rate. 9.2 Analysis Comparison 9 Duration of drainage after pleurodesis administration, Outcome 2 Mortality. Comparison 10OK‐432 Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate4 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 OK‐432 and mitomycin C153Odds Ratio (M‐H, Random, 95% CI)0.26 [0.06, 1.11]1.2 OK‐432 vs cisplatin and etoposide167Odds Ratio (M‐H, Random, 95% CI)0.77 [0.26, 2.27]1.3 OK‐432 and cisplatin134Odds Ratio (M‐H, Random, 95% CI)0.48 [0.12, 1.92]1.4 High dose vs low dose138Odds Ratio (M‐H, Random, 95% CI)1.90 [0.38, 9.44]1.5 OK‐432 vs bleomycin168Odds Ratio (M‐H, Random, 95% CI)0.70 [0.24, 2.03]1.6 OK‐432 vs OK‐432 and cisplatin132Odds Ratio (M‐H, Random, 95% CI)12.44 [1.32, 117.03]2 Fever3 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 OK‐432 vs cisplatin134Odds Ratio (M‐H, Random, 95% CI)256.00 [14.70, 4457.27]2.2 OK‐432 vs OK‐432 and cisplatin132Odds Ratio (M‐H, Random, 95% CI)14.00 [1.46, 134.25]2.3 OK‐432 vs mitomycin C153Odds Ratio (M‐H, Random, 95% CI)26.67 [5.91, 120.42]2.4 OK‐432 vs bleomycin167Odds Ratio (M‐H, Random, 95% CI)1.43 [0.47, 4.35]2.5 OK‐432 vs cisplatin and etoposide166Odds Ratio (M‐H, Random, 95% CI)3.17 [1.08, 9.30]3 Pain3 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 OK‐432 vs cisplatin134Odds Ratio (M‐H, Random, 95% CI)6.67 [1.15, 38.60]3.2 OK‐432 vs OK‐432 and cisplatin132Odds Ratio (M‐H, Random, 95% CI)1.33 [0.33, 5.43]3.3 OK‐432 vs mitomycin C153Odds Ratio (M‐H, Random, 95% CI)1.04 [0.14, 8.00]3.4 OK‐432 vs bleomycin167Odds Ratio (M‐H, Random, 95% CI)2.53 [0.89, 7.15]3.5 OK‐432 vs cisplatin and etoposide166Odds Ratio (M‐H, Random, 95% CI)2.1 [0.73, 6.01]4 Mortality2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 OK‐432 vs cisplatin134Odds Ratio (M‐H, Random, 95% CI)1.31 [0.31, 5.53]4.2 OK‐432 vs combined OK‐432 and cisplatin132Odds Ratio (M‐H, Random, 95% CI)2.18 [0.44, 10.91]4.3 OK‐432 vs bleomycin168Odds Ratio (M‐H, Random, 95% CI)0.38 [0.14, 1.03]4.4 OK‐432 vs cisplatin and etoposide167Odds Ratio (M‐H, Random, 95% CI)0.84 [0.32, 2.18] Open in a separate window 10.4 Analysis Comparison 10 OK‐432, Outcome 4 Mortality. Comparison 11Mepacrine Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate5 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Mepacrine vs talc slurry189Odds Ratio (M‐H, Random, 95% CI)2.08 [0.62, 6.96]1.2 Mepacrine vs bleomycin136Odds Ratio (M‐H, Random, 95% CI)0.16 [0.03, 0.89]1.3 Mepacrine vs tetracycline121Odds Ratio (M‐H, Random, 95% CI)0.63 [0.05, 8.20]1.4 Mepacrine vs placebo123Odds Ratio (M‐H, Random, 95% CI)0.07 [0.01, 0.73]1.5 Mepacrine vs mitoxantrone126Odds Ratio (M‐H, Random, 95% CI)7.61 [0.35, 163.82]1.6 Mepacrine vs triethylene...129Odds Ratio (M‐H, Random, 95% CI)0.20 [0.04, 0.98]2 Fever3 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Mepacrine vs bleomycin140Odds Ratio (M‐H, Random, 95% CI)1.91 [0.52, 7.01]2.2 Mepacrine vs tetracycline122Odds Ratio (M‐H, Random, 95% CI)8.00 [1.13, 56.79]2.3 Mepacrine vs placebo123Odds Ratio (M‐H, Random, 95% CI)62.43 [2.85, 1365.52]2.4 Mepacrine vs triethylene...129Odds Ratio (M‐H, Random, 95% CI)23.83 [3.35, 169.39]3 Pain3114Odds Ratio (M‐H, Random, 95% CI)4.56 [1.66, 12.52]3.1 Mepacrine vs bleomycin140Odds Ratio (M‐H, Random, 95% CI)2.15 [0.52, 9.00]3.2 Mepacrine vs tetracycline122Odds Ratio (M‐H, Random, 95% CI)5.6 [0.81, 38.51]3.3 Mepacrine vs placebo123Odds Ratio (M‐H, Random, 95% CI)14.53 [0.71, 298.21]3.4 Mepacrine vs triethylenethiophosphoramide129Odds Ratio (M‐H, Random, 95% CI)23.71 [1.19, 474.06]4 Mortality2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Mepacrine vs talc slurry189Odds Ratio (M‐H, Random, 95% CI)0.53 [0.20, 1.43]4.2 Mepacrine vs mitoxantrone128Odds Ratio (M‐H, Random, 95% CI)1.64 [0.23, 11.70] Open in a separate window 11.1 Analysis Comparison 11 Mepacrine, Outcome 1 Pleurodesis failure rate. 11.2 Analysis Comparison 11 Mepacrine, Outcome 2 Fever. 11.3 Analysis Comparison 11 Mepacrine, Outcome 3 Pain. 11.4 Analysis Comparison 11 Mepacrine, Outcome 4 Mortality. Comparison 12Interferon (IFN) Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 IFN vs bleomycin1160Odds Ratio (M‐H, Random, 95% CI)3.25 [1.54, 6.89]2 Fever1160Odds Ratio (M‐H, Random, 95% CI)0.01 [0.00, 0.11]3 Pain1160Odds Ratio (M‐H, Random, 95% CI)0.03 [0.00, 0.53]3.1 IFN vs bleomycin1160Odds Ratio (M‐H, Random, 95% CI)0.03 [0.00, 0.53]4 Mortality1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 IFN vs bleomycin1160Odds Ratio (M‐H, Random, 95% CI)2.16 [1.15, 4.07] Open in a separate window 12.2 Analysis Comparison 12 Interferon (IFN), Outcome 2 Fever. 12.3 Analysis Comparison 12 Interferon (IFN), Outcome 3 Pain. Comparison 13Triethylenethiophosphoramide Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Triethylene... vs placebo124Odds Ratio (M‐H, Random, 95% CI)0.34 [0.03, 3.69]1.2 Triethylene... vs mepacrine129Odds Ratio (M‐H, Random, 95% CI)4.95 [1.02, 24.10]2 Fever153Odds Ratio (M‐H, Random, 95% CI)0.32 [0.00, 26.74]2.1 Triethylene... vs placebo124Odds Ratio (M‐H, Random, 95% CI)3.52 [0.15, 81.92]2.2 Triethylene... vs mepacrine129Odds Ratio (M‐H, Random, 95% CI)0.04 [0.01, 0.30]3 Pain153Odds Ratio (M‐H, Random, 95% CI)1.39 [0.10, 20.15]3.1 Triethylene... vs mepacrine129Odds Ratio (M‐H, Random, 95% CI)0.48 [0.10, 2.30]3.2 Triethylene... vs placebo124Odds Ratio (M‐H, Random, 95% CI)7.43 [0.35, 156.28] Open in a separate window 13.3 Analysis Comparison 13 Triethylenethiophosphoramide, Outcome 3 Pain. Comparison 14Adriamycin Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Adriamycin vs mustine120Odds Ratio (M‐H, Random, 95% CI)0.37 [0.01, 10.18]1.2 Adriamycin vs tetracycline121Odds Ratio (M‐H, Random, 95% CI)1.11 [0.06, 20.49]1.3 Adriamycin vs LC9018 and adriamycin176Odds Ratio (M‐H, Random, 95% CI)4.29 [1.62, 11.35]2 Fever1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3 Pain1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only Open in a separate window 14.2 Analysis Comparison 14 Adriamycin, Outcome 2 Fever. 14.3 Analysis Comparison 14 Adriamycin, Outcome 3 Pain. Comparison 15Placebo Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate6 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Placebo vs mepacrine123Odds Ratio (M‐H, Random, 95% CI)14.40 [1.37, 150.81]1.2 Placebo vs mitoxantrone195Odds Ratio (M‐H, Random, 95% CI)1.33 [0.56, 3.17]1.3 Placebo vs triethylene...124Odds Ratio (M‐H, Random, 95% CI)2.91 [0.27, 31.21]1.4 Placebo vs talc slurry121Odds Ratio (M‐H, Random, 95% CI)13.93 [0.66, 293.99]1.5 Placebo vs tetracycline120Odds Ratio (M‐H, Random, 95% CI)3.33 [0.51, 21.58]1.6 Placebo vs urokinase169Odds Ratio (M‐H, Random, 95% CI)0.81 [0.30, 2.19]1.7 Placebo vs streptokinase140Odds Ratio (M‐H, Random, 95% CI)3.00 [0.51, 17.74]2 Fever2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Placebo vs mepacrine195Odds Ratio (M‐H, Random, 95% CI)0.31 [0.12, 0.79]2.2 Placebo vs mitoxantrone123Odds Ratio (M‐H, Random, 95% CI)0.02 [0.00, 0.35]2.3 Placebo vs triethylene...124Odds Ratio (M‐H, Random, 95% CI)0.28 [0.01, 6.62]3 Pain3100Odds Ratio (M‐H, Random, 95% CI)0.10 [0.01, 0.82]3.1 Placebo vs talc slurry131Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]3.2 Placebo vs tetracycline122Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]3.3 Placebo vs mepacrine123Odds Ratio (M‐H, Random, 95% CI)0.07 [0.00, 1.41]3.4 Placebo vs triethylene...124Odds Ratio (M‐H, Random, 95% CI)0.13 [0.01, 2.83]4 Mortality171Odds Ratio (M‐H, Fixed, 95% CI)12.40 [0.66, 233.22] Open in a separate window 15.1 Analysis Comparison 15 Placebo, Outcome 1 Pleurodesis failure rate. 15.3 Analysis Comparison 15 Placebo, Outcome 3 Pain. 15.4 Analysis Comparison 15 Placebo, Outcome 4 Mortality. Comparison 16Mustine Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate4 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Mustine vs tetracycline259Odds Ratio (M‐H, Random, 95% CI)2.72 [0.74, 9.98]1.2 Mustine vs talc poudrage137Odds Ratio (M‐H, Random, 95% CI)8.00 [1.40, 45.76]1.3 Mustine vs C parvum131Odds Ratio (M‐H, Random, 95% CI)10.8 [1.64, 70.93]1.4 Mustine vs adriamycin120Odds Ratio (M‐H, Random, 95% CI)2.71 [0.10, 74.98]2 Fever2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Mustine vs tetracycline140Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]2.2 Mustine vs C parvum121Odds Ratio (M‐H, Random, 95% CI)0.23 [0.01, 6.25]3 Pain1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4 Mortality2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Mustine vs talc poudrage146Odds Ratio (M‐H, Random, 95% CI)2.35 [0.51, 10.86]4.2 Mustine vs C parvum121Odds Ratio (M‐H, Random, 95% CI)2.4 [0.38, 15.32] Open in a separate window 16.2 Analysis Comparison 16 Mustine, Outcome 2 Fever. 16.3 Analysis Comparison 16 Mustine, Outcome 3 Pain. 16.4 Analysis Comparison 16 Mustine, Outcome 4 Mortality. Comparison 17Mitoxantrone Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate3 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Mitoxantrone vs placebo195Odds Ratio (M‐H, Random, 95% CI)0.75 [0.32, 1.79]1.2 Mitoxantrone vs mepacrine126Odds Ratio (M‐H, Random, 95% CI)7.61 [0.35, 163.82]1.3 Mitoxantrone vs bleomycin185Odds Ratio (M‐H, Random, 95% CI)3.18 [1.17, 8.65]2 Pain196Odds Ratio (M‐H, Random, 95% CI)2.08 [0.64, 6.76]3 Fever2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Mitoxantrone vs bleomycin196Odds Ratio (M‐H, Random, 95% CI)0.90 [0.30, 2.71]3.2 Mitoxantrone vs placebo195Odds Ratio (M‐H, Random, 95% CI)3.28 [1.26, 8.49]4 Mortality2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Mitoxantrone vs bleomycin196Odds Ratio (M‐H, Random, 95% CI)0.47 [0.21, 1.05]4.2 Mitoxantrone vs mepacrine128Odds Ratio (M‐H, Random, 95% CI)0.61 [0.09, 4.37] Open in a separate window 17.2 Analysis Comparison 17 Mitoxantrone, Outcome 2 Pain. 17.3 Analysis Comparison 17 Mitoxantrone, Outcome 3 Fever. 17.4 Analysis Comparison 17 Mitoxantrone, Outcome 4 Mortality. Comparison 18Drain size Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate2118Odds Ratio (M‐H, Random, 95% CI)1.19 [0.53, 2.69]2 Pain1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3 Mortality2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only Open in a separate window 18.3 Analysis Comparison 18 Drain size, Outcome 3 Mortality. Comparison 19Thoracoscopic mechanical pleurodesis (TMP) Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate2123Odds Ratio (M‐H, Random, 95% CI)0.44 [0.16, 1.20]2 Mortality1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only Open in a separate window 19.1 Analysis Comparison 19 Thoracoscopic mechanical pleurodesis (TMP), Outcome 1 Pleurodesis failure rate. 19.2 Analysis Comparison 19 Thoracoscopic mechanical pleurodesis (TMP), Outcome 2 Mortality. Comparison 20Other Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate4464Odds Ratio (M‐H, Random, 95% CI)1.16 [0.76, 1.78]1.1 Rotation vs no rotation120Odds Ratio (M‐H, Random, 95% CI)2.25 [0.17, 29.77]1.2 Mixed particle talc vs graded talc128Odds Ratio (M‐H, Random, 95% CI)1.64 [0.23, 11.70]1.3 Talc pleurodesis vs video‐assisted thoracoscopic surgery (VATS) parietal pleurectomy1122Odds Ratio (M‐H, Random, 95% CI)1.01 [0.49, 2.09]1.4 Non‐steroidal anti‐inflammatory drugs (NSAIDs) vs opiates for analgesia1294Odds Ratio (M‐H, Random, 95% CI)1.19 [0.68, 2.08]2 Fever1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Mixed particle talc vs graded talc146Odds Ratio (M‐H, Random, 95% CI)15.92 [1.81, 140.16]3 Pain2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Streptokinase vs control147Odds Ratio (M‐H, Random, 95% CI)3.00 [0.12, 77.47]3.2 NSAID vs opiate (in requiring rescue analgesia)1320Odds Ratio (M‐H, Random, 95% CI)1.73 [1.08, 2.78]4 Mortality3 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Mixed particle talc vs graded talc143Odds Ratio (M‐H, Random, 95% CI)0.88 [0.25, 3.07]4.2 Talc pleurodesis vs VATS partial pleurectomy1175Odds Ratio (M‐H, Random, 95% CI)0.92 [0.45, 1.90]4.3 NSAIDs vs opiates for analgesia1320Odds Ratio (M‐H, Random, 95% CI)1.36 [0.87, 2.12] Open in a separate window 20.1 Analysis Comparison 20 Other, Outcome 1 Pleurodesis failure rate. 20.3 Analysis Comparison 20 Other, Outcome 3 Pain. 20.4 Analysis Comparison 20 Other, Outcome 4 Mortality. Comparison 21Silver nitrate Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Silver nitrate vs talc slurry125Odds Ratio (M‐H, Random, 95% CI)0.17 [0.01, 4.68]1.2 Silver nitrate vs tetracycline150Odds Ratio (M‐H, Random, 95% CI)1.66 [0.41, 6.78]2 Fever2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Silver nitrate vs talc slurry160Odds Ratio (M‐H, Random, 95% CI)1.43 [0.31, 6.61]2.2 Silver nitrate vs tetracycline150Odds Ratio (M‐H, Random, 95% CI)0.00 [0.00, 0.06]3 Pain150Odds Ratio (M‐H, Fixed, 95% CI)0.02 [0.00, 0.33]3.1 Silver nitrate vs tetracycline150Odds Ratio (M‐H, Fixed, 95% CI)0.02 [0.00, 0.33]4 Mortality150Odds Ratio (M‐H, Fixed, 95% CI)0.0 [0.0, 0.0] Open in a separate window 21.1 Analysis Comparison 21 Silver nitrate, Outcome 1 Pleurodesis failure rate. 21.2 Analysis Comparison 21 Silver nitrate, Outcome 2 Fever. 21.3 Analysis Comparison 21 Silver nitrate, Outcome 3 Pain. 21.4 Analysis Comparison 21 Silver nitrate, Outcome 4 Mortality. Comparison 22Cisplatin Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate4 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Cisplatin vs cisplatin and bevacizumab170Odds Ratio (M‐H, Random, 95% CI)5.00 [1.66, 15.09]1.2 Cisplatin vs OK‐432134Odds Ratio (M‐H, Random, 95% CI)2.06 [0.52, 8.17]1.3 Cisplatin vs OK‐432 and cisplatin132Odds Ratio (M‐H, Random, 95% CI)25.67 [2.68, 245.84]1.4 Cisplatin vs rAd‐p53 and cisplatin135Odds Ratio (M‐H, Random, 95% CI)4.67 [0.99, 22.03]1.5 Cisplatin vs cisplatin and endostatin1128Odds Ratio (M‐H, Random, 95% CI)2.35 [1.07, 5.12]2 Fever2 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Cisplatin vs OK‐432134Odds Ratio (M‐H, Random, 95% CI)0.00 [0.00, 0.07]2.2 Cisplatin vs OK‐432 and cisplatin132Odds Ratio (M‐H, Random, 95% CI)0.05 [0.01, 0.52]2.3 Cisplatin vs rAd‐p53 and cisplatin135Odds Ratio (M‐H, Random, 95% CI)0.09 [0.02, 0.51]3 Pain1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Cisplatin vs OK‐432134Odds Ratio (M‐H, Random, 95% CI)0.15 [0.03, 0.87]3.2 Cisplatin vs OK‐432 and cisplatin132Odds Ratio (M‐H, Random, 95% CI)0.2 [0.03, 1.21]4 Mortality3 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Cisplatin vs OK‐432134Odds Ratio (M‐H, Random, 95% CI)0.76 [0.18, 3.23]4.2 Cisplatin vs combination OK‐432 and cisplatin132Odds Ratio (M‐H, Random, 95% CI)1.67 [0.32, 8.59]4.3 Cisplatin vs combination rAd‐p53 and cisplatin135Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]4.4 Cisplatin vs combination cisplatin and endostatin1128Odds Ratio (M‐H, Random, 95% CI)1.29 [0.57, 2.93] Open in a separate window 22.3 Analysis Comparison 22 Cisplatin, Outcome 3 Pain. 22.4 Analysis Comparison 22 Cisplatin, Outcome 4 Mortality. Comparison 23Duration of drainage prior to administration of sclerosant Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate179Odds Ratio (M‐H, Random, 95% CI)0.79 [0.22, 2.82] Open in a separate window 23.1 Analysis Comparison 23 Duration of drainage prior to administration of sclerosant, Outcome 1 Pleurodesis failure rate. Comparison 24Dose of silver nitrate Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Silver nitrate 90 mg vs 150 mg140Odds Ratio (M‐H, Random, 95% CI)0.0 [0.0, 0.0]1.2 Silver nitrate 90 mg vs 180 mg140Odds Ratio (M‐H, Random, 95% CI)0.18 [0.01, 4.01]1.3 Silver nitrate 150 mg vs 180 mg140Odds Ratio (M‐H, Random, 95% CI)0.18 [0.01, 4.01]2 Fever1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only2.1 Silver nitrate 90 mg vs 150 mg140Odds Ratio (M‐H, Random, 95% CI)0.63 [0.09, 4.24]2.2 Silver nitrate 90 mg vs 180 mg140Odds Ratio (M‐H, Random, 95% CI)1.0 [0.13, 7.89]2.3 Silver nitrate 150 mg vs 180 mg140Odds Ratio (M‐H, Random, 95% CI)1.59 [0.24, 10.70]3 Pain1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only3.1 Silver nitrate 90 mg vs 150 mg140Odds Ratio (M‐H, Random, 95% CI)1.0 [0.13, 7.89]3.2 Silver nitrate 90 mg vs 180 mg140Odds Ratio (M‐H, Random, 95% CI)1.0 [0.13, 7.89]3.3 Silver nitrate 150 mg vs 180 mg140Odds Ratio (M‐H, Random, 95% CI)1.0 [0.13, 7.89]4 Mortality1 Odds Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Silver nitrate 90 mg vs 150 mg139Odds Ratio (M‐H, Random, 95% CI)3.18 [0.30, 33.58]4.2 Silver nitrate 90 mg vs 180 mg139Odds Ratio (M‐H, Random, 95% CI)7.80 [0.38, 161.87]4.3 Silver nitrate 150 mg vs 180 mg138Odds Ratio (M‐H, Random, 95% CI)3.16 [0.12, 82.64] Open in a separate window 24.1 Analysis Comparison 24 Dose of silver nitrate, Outcome 1 Pleurodesis failure rate. 24.2 Analysis Comparison 24 Dose of silver nitrate, Outcome 2 Fever. 24.3 Analysis Comparison 24 Dose of silver nitrate, Outcome 3 Pain. 24.4 Analysis Comparison 24 Dose of silver nitrate, Outcome 4 Mortality. Comparison 25Talc via indwelling pleural catheter (IPC) Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate1139Odds Ratio (M‐H, Random, 95% CI)0.36 [0.18, 0.73]2 Pain1154Odds Ratio (M‐H, Fixed, 95% CI)0.71 [0.23, 2.15]3 Mortality1154Odds Ratio (M‐H, Fixed, 95% CI)0.44 [0.17, 1.15]3.1 Talc via IPC vs IPC – not daily drainage1154Odds Ratio (M‐H, Fixed, 95% CI)0.44 [0.17, 1.15] Open in a separate window 25.2 Analysis Comparison 25 Talc via indwelling pleural catheter (IPC), Outcome 2 Pain. 25.3 Analysis Comparison 25 Talc via indwelling pleural catheter (IPC), Outcome 3 Mortality. Comparison 26Autologous blood Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate2158Odds Ratio (M‐H, Random, 95% CI)1.44 [0.60, 3.47]1.1 Autologous blood vs talc slurry1110Odds Ratio (M‐H, Random, 95% CI)1.46 [0.51, 4.16]1.2 Autologous blood vs tetracycline148Odds Ratio (M‐H, Random, 95% CI)1.4 [0.28, 7.06]2 Fever2158Odds Ratio (M‐H, Fixed, 95% CI)0.24 [0.10, 0.61]2.1 Autologous blood vs talc slurry1110Odds Ratio (M‐H, Fixed, 95% CI)0.25 [0.09, 0.76]2.2 Autologous blood vs tetracycline148Odds Ratio (M‐H, Fixed, 95% CI)0.22 [0.04, 1.20]3 Pain2158Odds Ratio (M‐H, Fixed, 95% CI)0.13 [0.05, 0.32]3.1 Autologous blood vs talc slurry1110Odds Ratio (M‐H, Fixed, 95% CI)0.28 [0.09, 0.84]3.2 Autologous blood vs tetracycline148Odds Ratio (M‐H, Fixed, 95% CI)0.01 [0.00, 0.13]4 Mortality2165Odds Ratio (M‐H, Fixed, 95% CI)0.72 [0.15, 3.38]4.1 Autologous blood vs talc slurry1117Odds Ratio (M‐H, Fixed, 95% CI)0.72 [0.15, 3.38]4.2 Autologous blood vs tetracycline148Odds Ratio (M‐H, Fixed, 95% CI)0.0 [0.0, 0.0] Open in a separate window 26.1 Analysis Comparison 26 Autologous blood, Outcome 1 Pleurodesis failure rate. 26.2 Analysis Comparison 26 Autologous blood, Outcome 2 Fever. 26.3 Analysis Comparison 26 Autologous blood, Outcome 3 Pain. 26.4 Analysis Comparison 26 Autologous blood, Outcome 4 Mortality. Comparison 27Urokinase Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate169Odds Ratio (M‐H, Fixed, 95% CI)1.24 [0.46, 3.34]2 Mortality171Odds Ratio (M‐H, Fixed, 95% CI)0.08 [0.00, 1.52] Open in a separate window 27.2 Analysis Comparison 27 Urokinase, Outcome 2 Mortality. Comparison 28Streptokinase Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate264Odds Ratio (M‐H, Fixed, 95% CI)0.31 [0.10, 0.93]2 Pain147Odds Ratio (M‐H, Fixed, 95% CI)1.33 [0.26, 6.74] Open in a separate window 28.2 Analysis Comparison 28 Streptokinase, Outcome 2 Pain. Comparison 29Endostatin Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate1128Odds Ratio (M‐H, Fixed, 95% CI)0.43 [0.20, 0.93]2 Mortality1128Odds Ratio (M‐H, Fixed, 95% CI)0.77 [0.34, 1.76] Open in a separate window 29.2 Analysis Comparison 29 Endostatin, Outcome 2 Mortality. Comparison 30Dose of iodine Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate160Odds Ratio (M‐H, Fixed, 95% CI)1.0 [0.06, 16.76] Open in a separate window 30.1 Analysis Comparison 30 Dose of iodine, Outcome 1 Pleurodesis failure rate. Comparison 31Indwelling pleural catheter (IPC) – daily drainage Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate3291Odds Ratio (M‐H, Random, 95% CI)0.59 [0.15, 2.35]1.1 IPC – daily drainage vs talc slurry155Odds Ratio (M‐H, Random, 95% CI)3.31 [0.88, 12.50]1.2 IPC – daily drainage vs IPC not daily drainage2236Odds Ratio (M‐H, Random, 95% CI)0.31 [0.17, 0.56]2 Pain3293Odds Ratio (M‐H, Fixed, 95% CI)0.78 [0.45, 1.34]2.1 IPC – daily drainage vs talc slurry157Odds Ratio (M‐H, Fixed, 95% CI)3.22 [0.13, 82.38]2.2 IPC – daily drainage vs IPC – not daily drainage2236Odds Ratio (M‐H, Fixed, 95% CI)0.74 [0.42, 1.28]3 Mortality3293Odds Ratio (M‐H, Fixed, 95% CI)0.92 [0.55, 1.53]3.1 IPC – daily drainage vs talc slurry157Odds Ratio (M‐H, Fixed, 95% CI)1.70 [0.56, 5.17]3.2 IPC – daily drainage vs IPC – not daily drainage2236Odds Ratio (M‐H, Fixed, 95% CI)0.77 [0.43, 1.38] Open in a separate window 31.1 Analysis Comparison 31 Indwelling pleural catheter (IPC) – daily drainage, Outcome 1 Pleurodesis failure rate. 31.2 Analysis Comparison 31 Indwelling pleural catheter (IPC) – daily drainage, Outcome 2 Pain. 31.3 Analysis Comparison 31 Indwelling pleural catheter (IPC) – daily drainage, Outcome 3 Mortality. Comparison 32Mistletoe (viscum) Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Pleurodesis failure rate117Odds Ratio (M‐H, Random, 95% CI)0.19 [0.02, 1.62] Open in a separate window 32.1 Analysis Comparison 32 Mistletoe (viscum), Outcome 1 Pleurodesis failure rate. Characteristics of studiesCharacteristics of included studies [ordered by study ID]MethodsSingle‐centre RCT comparing the efficacy of cosmetic talc with iodopovidone for pleurodesis (India).ParticipantsInclusion criteria: recurrent symptomatic pleural effusion with improvement of breathlessness with thoracentesis; or primary or secondary pneumothorax. MethodsSingle‐centre RCT of povidone‐iodine and bleomycin pleurodesis for MPE (Iran).ParticipantsInclusion criteria: biopsy or cytologically confirmed MPE (all tumour types); recurrent and symptomatic effusion; CXR confirming lung expansion of 90% after thoracentesis; KPS > 70. MethodsSingle‐centre RCT comparing efficacy and safety of iodopovidone and bleomycin for pleurodesis in MPE (Iran).ParticipantsInclusion criteria: MPE with positive cytology who were candidates for pleurodesis. Methods2‐centre RCT of intrapleural quinacrine (mepacrine) vs tetracycline via tube thoracostomy for MPE (USA).ParticipantsInclusion criteria: documented cancer with pleural effusion; pleural fluid cytology or pleural biopsy confirming malignancy or exudate effusion presumed to be malignant; symptomatic from the effusion or rapidly re‐accumulating effusion > 500 mL. MethodsMulticentre RCT comparing talc slurry pleurodesis via IPC with saline placebo (UK) – IPC Plus.ParticipantsInclusion criteria: symptomatic MPE, IPC chosen for treatment, expected survival > 2 months, ECOG performance status ≤ 2 after fluid removal. MethodsMulticentre (17 sites) RCT comparing talc poudrage with talc slurry pleurodesis (UK) – TAPPS.ParticipantsInclusion criteria: MPE (histocytologically confirmed or unexplained effusion and cancer or pleural changes on cross‐sectional imaging consistent with malignancy), able to tolerate local anaesthetic thoracoscopy under moderate sedation and estimated survival > 3 months. MethodsRCT of mitoxantrone vs mepacrine via an intercostal drain (Sweden – number of centres not specified).ParticipantsCytologically confirmed, symptomatic MPE with an expected survival > 3 months (KPS > 60). Excluded if cytotoxic chemotherapy in the preceding month. MethodsRCT comparing talc slurry pleurodesis with IPC and symptom‐guided drainage.ParticipantsInclusion criteria: histocytologically confirmed MPE or progressive malignancy with pleural effusion after exclusion of an alternative cause. MethodsSingle‐centre RCT of tetracycline pleurodesis using a small percutaneous catheter (CH10), compared to a large‐bore chest tube (CH24) inserted after thoracoscopy (Denmark).ParticipantsSymptomatic, recurrent MPE, confirmed on pleural fluid cytology. Expected survival of > 3 months (all tumour types included). MethodsSingle‐centre RCT comparing TMP with talc slurry (Slovenia).ParticipantsInclusion criteria: breast carcinoma and a resulting morphologically confirmed MPE. MethodsUnblinded, multicentre RCT comparing IPC with talc slurry pleurodesis (UK) – TIME‐2 trial.ParticipantsInclusion criteria: clinically confident diagnosis of MPE requiring pleurodesis. MethodsMulticentre RCT comparing bedside talc pleurodesis and daily tunnelled catheter drainage for management of MPE (USA).ParticipantsInclusion criteria: symptomatic people with histo/cytologically confirmed malignancy and a previously untreated, unilateral pleural effusion requiring management; ECOG Performance Score 0–2. MethodsProspective, single‐centre RCT of thoracoscopic talc poudrage vs bedside bleomycin pleurodesis via a small‐bore chest tube (Switzerland).ParticipantsInclusion criteria: documented MPE (all cell types); complete lung expansion on postdrainage CXR; improvement in symptoms after drainage; expected survival > 1 month; capable of undergoing medical thoracoscopy. MethodsMulticentre RCT comparing talc poudrage with talc slurry pleurodesis in MPE. Both groups received 4–5 g sterile talc intrapleurally (USA).ParticipantsInclusion criteria: history of malignancy (all tumour types), pleural effusion requiring sclerosis, ECOG performance status 0–2, life‐expectancy > 2 months, ability to undergo GA. MethodsSingle‐centre RCT of intrapleural cisplatin ± bevacizumab in MPE due to NSCLC (China).ParticipantsInclusion criteria: advanced NSCLC; large uni‐ or bilateral pleural effusion; positive pleural fluid cytology; no intrapleural therapy in previous month; KPS > 60; aged > 18 years; predicted survival > 3 months; no major organ dysfunction; no previous chemotherapy in previous 6 weeks. Methods3‐arm, single‐centre RCT comparing intrapleural bleomycin, tetracycline and combination treatment for pleurodesis of MPE (Iran).ParticipantsInclusion criteria: histologically or cytologically confirmed, symptomatic MPE (all cell types). MethodsSingle‐centre RCT of medical vs surgical pleurodesis with tetracycline (UK).ParticipantsInclusion criteria: cytology‐confirmed MPE and histological or cytological evidence of metastatic breast cancer. MethodsSingle‐centre RCT of talc poudrage and mustine (via chest tube) in people with breast cancer. All participants underwent VATS procedure under GA (UK).ParticipantsInclusion criteria: histologically confirmed breast cancer and radiologically verified pleural effusion. MethodsSingle‐centre RCT of intrapleural talc and tetracycline in MPE secondary to breast cancer (UK).ParticipantsInclusion criteria: histologically confirmed breast cancer and a symptomatic pleural effusion on radiology. MethodsSingle‐centre, prospective RCT comparing intrapleural administration of mistletoe preparation (viscum fraxini‐2) with bleomycin in people with MPE (Egypt).ParticipantsInclusion criteria: histologically confirmed, recurrent, symptomatic MPE (all cell types); aged > 18 years; ECOG Performance Score ≤ 2; adequate bone marrow, liver and kidney function; written consent; ability to comply with the follow‐up. MethodsSingle‐centre RCT evaluating duration of chest tube drainage after talc slurry pleurodesis (UK).ParticipantsInclusion criteria: confirmed MPE requiring palliation of breathlessness due to the effusion (all cell types). MethodsRCT comparing intrapleural mitoxantrone with normal saline after thoracoscopy in people with MPE (Germany).ParticipantsInclusion criteria: complete resolution of the effusion after thoracoscopy; malignancy on pleural biopsy. MethodsSingle‐centre RCT comparing talc slurry and bleomycin pleurodesis (Brazil).ParticipantsInclusion criteria: documented recurrent symptomatic MPE (with positive cytology or confirmed metastatic disease elsewhere with no other cause found for the effusion); symptomatic relief by therapeutic aspiration; complete lung re‐expansion after therapeutic aspiration. MethodsProspective, single‐centre RCT of bleomycin and talc in MPE secondary to breast cancer (UK).ParticipantsInclusion criteria: breast carcinoma with radiographically confirmed pleural effusion. MethodsMulticentre RCT of pleurodesis using Corynebacterium parvum vs bleomycin (Sweden).ParticipantsInclusion criteria: pleural effusion due to metastases from cytologically or histologically confirmed bronchogenic carcinoma or adenocarcinoma; ≥ 2 previous aspirations of effusion. MethodsSingle‐centre RCT analysing release of growth factors in pleural fluid and blood following talc slurry and mechanical pleurodesis (Slovenia).ParticipantsInclusion criteria: breast carcinoma and cytologically confirmed MPE, lung re‐expanded after thoracic drainage, eligible for surgery, ECOG Performance Score 0–2. MethodsSingle‐centre RCT comparing talc slurry pleurodesis and iodine for treatment of recurrent MPE (Egypt).ParticipantsInclusion criteria: clinical and histopathologically diagnosed recurrent MPE. MethodsSingle‐centre RCT of intrapleural cisplatin vs OK‐432 vs combination (Japan).ParticipantsInclusion criteria: symptomatic, histocytologically confirmed pleural malignancy secondary to NSCLC, ECOG Performance Score 0–3, adequate renal, haematological and cardiac function. MethodsMulticentre phase II trial of OK‐432, evaluating 2 different doses of intrapleural OK‐432 (Japan).ParticipantsInclusion criteria: histological or cytological proof of MPE with NSCLC; no previous therapy for MPE; aged > 20 years; ECOG Performance Score 0–3; life‐expectancy > 12 weeks; adequate organ and bone marrow function; daily chest tube drainage < 200 mL. MethodsSingle‐centre RCT to determine efficacy and safety of autologous blood pleurodesis compared with tetracycline for MPE (Thailand).ParticipantsInclusion criteria: aged > 18 years, symptomatic MPE (histocytologically confirmed), life‐expectancy > 3 months, agreement to receive chemical pleurodesis. MethodsSingle‐centre RCT comparing the efficacy of autologous blood and talc for pleurodesis (Thailand).ParticipantsInclusion criteria: aged > 18 years, recurrent symptomatic MPE (cytologically or histologically confirmed), predicted life‐expectancy > 1 month (ECOG Performance Score 0–2 and without severe comorbidity), who agreed to receive chemical pleurodesis. MethodsSingle‐centre RCT of intrapleural adriamycin, nitrogen mustard and rolitetracycline (Australia).ParticipantsHistocytologically confirmed malignant effusions (pleural or pericardial or peritoneal); no previous intracavitary chemotherapy; no concurrent radiotherapy or systemic treatment. MethodsSingle‐centre RCT comparing intrapleural bleomycin and tetracycline in MPE (USA).ParticipantsInclusion criteria: histologically confirmed malignancy; symptomatic pleural effusion with either > 3 g/dL protein or malignant cells on cytology. MethodsSingle‐centre, prospective RCT of mepacrine vs bleomycin as pleurodesis agent in MPE (Norway).ParticipantsInclusion criteria: MPE; previous treatment with a therapeutic tap; life‐expectancy > 1 month. MethodsSingle‐centre, prospective RCT of talc vs doxycycline in the control of MPE (Poland).ParticipantsInclusion criteria: pleural effusion with clinical suspicion of malignant origin. MethodsRCT (2 recruiting centres) of intrapleural Corynebacterium parvum and tetracycline for pleurodesis of MPE (UK).ParticipantsInclusion criteria: histologically or cytologically confirmed MPE. MethodsSingle‐centre RCT of tetracycline and mechlorethamine (mustine) for pleurodesis of MPEs (Greece).ParticipantsInclusion criteria: documented MPE (all tumour types); respiratory distress was the main problem of participants. MethodsSingle‐centre RCT of OK‐432 and mitomycin C pleurodesis in people with lung cancer with MPE (Taiwan).ParticipantsInclusion criteria: histology/cytology confirmed MPE due to lung cancer; effusion requiring repeated thoracentesis; ECOG performance score 0–3. MethodsRCT of bleomycin, tetracycline and talc for pleurodesis of MPE.ParticipantsInclusion criteria: MPE (either cytology positive or an exudative effusion attributed to a histologically confirmed malignancy elsewhere) (all cell types); life‐expectancy > 2 months. MethodsSingle‐centre RCT evaluating the distribution of talc during a talc slurry pleurodesis – comparing rotation with non‐rotation of participants after instillation of talc slurry (the Netherlands).ParticipantsInclusion criteria: symptomatic MPE confirmed by cytology or histology (all cell types). MethodsSingle‐centre RCT of tetracycline vs bleomycin pleurodesis in MPE (Spain).ParticipantsInclusion criteria: MPE (all cell types) causing respiratory symptoms, confirmed by cytological examination or pleural biopsy and an expected survival ≥ 1 month, with a KPS ≥ 50. MethodsSingle‐centre RCT comparing pleurodesis using mixed particle Talc (> 50% of particles are < 20 μm) vs graded talc (< 50% of particles are < 20 μm) (UK).ParticipantsInclusion criteria: symptomatic pleural effusion, confirmed to be malignant by cytology or pleural biopsy (all cell types). MethodsMulticentre RCT of LC9018 + doxorubicin vs doxorubicin alone in MPE secondary to lung cancer (Japan). MethodsSingle‐centre RCT of mepacrine hydrochloride, triethylenethiophosphoramide and pleurocentesis alone in the treatment of MPE (Denmark).ParticipantsInclusion criteria: unilateral MPE (positive cytology > 200 IU/L lactate dehydrogenase and > 30 g/L protein) (all cell types); 1 previous pleurocentesis of > 500 mL. MethodsRCT of intrapleural Corynebacterium parvum vs mustine in recurrent MPE (UK).ParticipantsRecurrent effusion associated with histologically confirmed malignant disease (all cell types); ≥ 2 previous pleural aspirations; symptoms of dyspnoea, cough or local pain. MethodsMulticentre RCT comparing the effect of intrapleural urokinase on dyspnoea and pleurodesis success in people with non‐draining MPE – TIME 3 (UK).ParticipantsInclusion criteria: adults with MPE (histocytological diagnosis or a recurrent large pleural effusion in the context of histologically confirmed cancer outside the pleural space), with a patent and correctly sited chest tube inserted for dyspnoea relief and significant residual pleural fluid (> 25% opacification of the hemithorax on CXR). A trial modification was made from March 2011 in response to increasing use of USS in the UK to include people with > 15% opacification on CXR or > 2 cm of loculated pleural fluid on USS. MethodsSingle‐centre RCT of thoracoscopic talc poudrage vs povidone‐iodine pleurodesis through an intercostal drain (Egypt).ParticipantsInclusion criteria: MPE as a complication of breast carcinoma. MethodsMulticentre RCT comparing daily vs symptom‐guided IPC drainage and breathlessness scores in people with symptomatic MPE (11 centres in Australia, New Zealand, Hong Kong and Malaysia).ParticipantsInclusion criteria: adults requiring IPC for management of MPE, malignant cells in pleural fluid or pleural biopsy or large exudative effusion without other cause in people with known disseminated extrapleural malignancy. MethodsRCT comparing pleurodesis with 1% and 2% iodopovidone for MPE (Brazil).ParticipantsInclusion criteria: recurrent symptomatic MPE, > 70% lung re‐expansion on CX.R after drainage, Karnofsky Performance Status > 40. MethodsSingle‐centre RCT of talc vs bleomycin in MPE (Belgium).ParticipantsInclusion criteria: hist/cytologically confirmed, symptomatic MPE; KPS ≥ 50; expected survival ≤ 1 year. MethodsSingle‐centre RCT of intrapleural streptokinase in MPE undergoing chest drainage (Turkey).ParticipantsInclusion criteria: definitive diagnosis of MPE with dyspnoea. MethodsSingle‐centre RCT of talc vs bleomycin in MPE (Singapore).ParticipantsInclusion criteria: symptomatic, unilateral MPE confirmed by cytology or pleural biopsy (all cell types). MethodsMulticentre RCT bleomycin vs C parvum in MPE (UK).ParticipantsInclusion criteria: histocytologically confirmed malignancy with effusion (all cell types); life‐expectancy > 30 days. MethodsSingle‐centre, prospective RCT comparing rapid and standard drainage prior to talc slurry pleurodesis (Turkey).ParticipantsInclusion criteria: potentially recurrent histologically or cytologically confirmed MPE, or both (all cell types). Methods2‐centre, prospective RCT of silver nitrate vs talc slurry in MPE (Brazil).ParticipantsInclusion criteria: documented MPE (positive pleural biopsy or cytology – all cell types); KPS > 60; life‐expectancy > 1 month. MethodsProspective RCT of bleomycin vs doxycycline in MPE (USA).ParticipantsInclusion criteria: symptomatic effusion; confirmed or strongly suspected that malignancy is the cause for the effusion. MethodsRCT comparing IPCs and doxycycline pleurodesis for MPE.ParticipantsInclusion criteria: malignancy with moderate pleural effusion and breathlessness relived after thoracentesis. MethodsSingle‐centre RCT comparing the pleurodesis success of doxycycline and bleomycin in MPE (Iran).ParticipantsInclusion criteria: symptomatic, cytologically confirmed MPE. Methods2×2 factorial design multicentre RCT assessing the effect of chest tube size and analgesia on pain and clinical efficacy related to pleurodesis in people with MPE – TIME 1 (UK, USA, Canada).ParticipantsInclusion criteria: aged > 18 years, symptomatic MPE clinically determined to require pleurodesis (histocytologically confirmed pleural malignancy or typical features of pleural malignancy visualised during thoracoscopy or pleural effusion in the context of histologically confirmed cancer elsewhere). MethodsOpen‐label, multicentre, parallel group RCT of VATS pleurectomy and talc pleurodesis (either slurry or poudrage) in mesothelioma (UK).ParticipantsInclusion criteria: aged > 18 years; confirmed or suspected MPM with pleural effusion; fit enough for VATS pleurectomy. MethodsMulticentre RCT of intrapleural bleomycin and tetracycline in MPE (USA).ParticipantsInclusion criteria: exudative MPE (confirmed by cytology or pleural biopsy); ECOG Performance Score 0–2. MethodsSingle‐centre RCT of pleurodesis with doxycycline and C parvum in MPE (Finland).ParticipantsInclusion criteria: pleural effusion refractory to repeat aspirations; pleural malignancy – all cell types (histocytologically confirmed or confirmed malignancy elsewhere). MethodsSingle‐centre RCT evaluating intrapleural bleomycin vs interferon alfa‐2b in the palliative treatment of malignant effusion (Italy).ParticipantsInclusion criteria: cytologically confirmed MPE requiring ≥ 2 thoracenteses in preceding 4 weeks; ≥ 3 L drained in the preceding 4 weeks; adequate pulmonary re‐expansion on CXR after thoracentesis; last systemic treatment administered ≥ 6 weeks prior to enrolment; no further chemotherapy options; KPS > 40. MethodsRCT comparing the effect of streptokinase on pleurodesis therapy in multiloculated MPE (Turkey).ParticipantsInclusion criteria: multiloculated MPE. MethodsMulticentre RCT comparing pleurodesis using bleomycin with mitoxantrone (Germany). Paper in German.ParticipantsInclusion criteria: symptomatic, cytologically confirmed MPE; life‐expectancy > 3 months; WHO Performance Score 0–2 MethodsSingle‐centre RCT comparing talc instillation with pleural drainage only in the treatment of MPE (Denmark).ParticipantsInclusion criteria: histologically confirmed MPE (all cell types) causing respiratory distress, which is progressive and resistant to conventional therapy. MethodsRCT investigating the effectiveness of silver nitrate vs tetracycline for pleurodesis in MPE (Iran).ParticipantsInclusion criteria: cytologically or histologically confirmed MPE, anticipated survival > 1 month, dyspnoea secondary to the effusion. MethodsSingle‐centre RCT evaluating VATS talc poudrage and talc slurry in MPE (Brazil).ParticipantsInclusion criteria: biopsy or cytology confirmed MPE (all cell types); recurrent and symptomatic effusion; CXR confirming lung expansion of > 90% after thoracentesis; KPS ≥ 70. MethodsSingle‐centre RCT evaluating 3 different doses of silver nitrate for pleurodesis in MPE (Brazil).ParticipantsInclusion criteria: recurrent and symptomatic MPE (with pleural histological or cytological confirmation); previous CXR showing full lung expansion (> 90%) after chest drainage; KPS > 40; written consent. MethodsMulticentre RCT comparing IPCs with talc slurry pleurodesis for MPE (Australia, New Zealand, Singapore, Hong Kong).ParticipantsInclusion criteria: histocytologically confirmed pleural malignancy or recurrent exudative pleural effusion with no alternative cause in the setting of histocytologically confirmed extrapleural cancer. MethodsSingle‐centre RCT comparing intrapleural talc and mepacrine given via a chest tube after thoracoscopy (Sweden).ParticipantsInclusion criteria: recurrent, symptomatic pleural effusions, known or suspected to be due to malignancy; eligible for thoracoscopy and pleurodesis. MethodsSingle‐centre RCT of short‐term vs long‐term drainage before tetracycline pleurodesis of MPE (USA).ParticipantsInclusion criteria: moderate‐to‐large MPE, confirmed by cytology or pleural biopsy, causing respiratory symptoms; expected survival > 1 month; KPS > 40%. MethodsMulticentre RCT comparing daily IPC drainage with alternate day drainage in achieving autopleurodesis for people with MPE (USA).ParticipantsInclusion criteria: aged > 18 years, recurrent symptomatic pleural effusion in the setting of known malignancy with positive fluid cytology or pleural biopsy or recurrent effusion with no other identifiable cause, symptomatic improvement after therapeutic thoracentesis, recurrent symptoms with recurrence of pleural effusion. MethodsRCT evaluating the effects of intrathoracic perfusion of Endostar with chemotherapy in the management of MPE (China).ParticipantsInclusion criteria: pathological or cytologically confirmed diagnosis of lung adenocarcinoma, KPS 1–2, estimated survival > 3 months, measurable primary and metastatic disease allowing for an objective judgement of any therapeutic effect, medium‐to‐large MPE confirmed by USS or CT and who had not received intrathoracic chemotherapy within the last month, no chemotherapy contraindications, normal liver/kidney/heart function, normal routine blood tests. MethodsSingle‐centre RCT of rapid vs standard pleurodesis with oxytetracycline (Turkey).ParticipantsSymptomatic MPE, confirmed on cytology or pleural biopsy. MethodsSingle‐centre RCT of talc insufflation vs talc slurry for symptomatic MPE (Hong Kong).ParticipantsInclusion criteria: established, symptomatic MPE (all cell types); dyspnoea improved after tube thoracostomy or large volume thoracentesis. MethodsMulticentre RCT of bleomycin, OK‐432 and cisplatin plus etoposide pleurodesis in MPE (Japan).ParticipantsInclusion criteria: cytology or histology confirmed MPE associated with newly diagnosed NSCLC; aged ≤ 75 years; ECOG Performance Score 0–2; full lung re‐expansion after chest drainage; adequate bone marrow reserve, liver and renal functions. MethodsRCT of tetracycline pleurodesis vs placebo of the same pH as tetracycline (USA).ParticipantsInclusion criteria: biopsy confirmed malignancy; recurrent pleural effusion; expected survival > 1 month; KPS ≥ 40%. MethodsSingle‐centre RCT of intrapleural Ad‐p53 and cisplatin, compared with cisplatin alone in MPE due to lung cancer (China).ParticipantsInclusion criteria: MPE due to lung cancer confirmed by CT, thoracic ultrasound and cytohistological examination; expected survival > 3 months; KPS > 60. MethodsProspective RCT of talc vs bleomycin pleurodesis for symptomatic MPE (USA).ParticipantsInclusion criteria: MPE (all cell types); life‐expectancy > 1 month. CALGB: Cancer and Leukemia Group B; CR: complete response; CT: computer tomography; CXR: chest x‐ray; DHHS: Department of Health and Human Services; ECOG: Eastern Cooperative Oncology Group; EQ‐5D‐5L: 5‐level EQ‐5D; FEV1: forced expiratory volume in one second; Fr: French; GA: general anaesthetic; IPC: indwelling pleural catheter; ITT: intention to treat; IV: intravenous; KE: klinische Einheit (clinical unit); KPS: Karnofsky Performance Score; LTFU: loss to follow‐up; MBS: Modified Borg Scale; MPE: malignant pleural effusion; MPM: malignant pleural mesothelioma; NCI: National Cancer Institute; NSAID: non‐steroidal anti‐inflammatory drug; NSCLC: non‐small cell lung cancer; PR: partial response; QoL: quality of life; RCT: randomised controlled trial; SF‐36: 36‐item Short Form; TMP: thoracoscopic mechanical pleurodesis; USS: ultrasound scan; VAS: visual analogue scale; VATS: video‐assisted thoracoscopic surgery; VEGF: vascular endothelial growth factor; WCC: white cell count; WHO: World Health Organization; WHOQOL‐BREF: World Health Organization Quality of Life: Brief Version. Characteristics of excluded studies [ordered by study ID]StudyReason for exclusionStudy not truly randomised (high risk of bias for sequence generation). Participants allocated to treatment groups using alternation.Unable to differentiate between participants with benign and malignant disease in the results section. Also, not truly randomised (high risk of bias from randomisation method as allocated to treatment groups based on the last digit of their hospital number).Unclear from text if truly randomised – participants given number on entering study – allocated to bleomycin if number was odd and allocated to povidone group if number was even. Study authors emailed for clarification but no response.Study not truly randomised. Participants allocated to treatment groups based on the day of the calendar month. High risk of bias for sequence generation. Pilot data (not randomised) and randomised data presented grouped together. Unable to differentiate out the non‐randomised data. No contact details available for study authors.Not truly randomised (high risk of bias for sequence generation and allocation concealment. Additional information obtained from author who explained participants allocated to each arm consecutively).Participants with pleural effusions and ascites included, but unable to differentiate between them in the results section.Unable to differentiate between pleural, pericardial and peritoneal effusions in the results. No response from study authors.High risk of bias for sequence generation and allocation concealment (not randomised). We were unable to contact the authors for further clarification.Study not randomised (high risk of bias for sequence generation). Participants allocated to bleomycin group if met a list of criteria, otherwise given mitoxantrone.Study not truly randomised (high risk of bias for sequence generation). Participants allocated to treatment groups based on the month of their diagnosis with MPE.Feasibility study to determine whether sufficient numbers could be recruited for a future multicentre RCT to test the impact of pleural elastance directed indwelling pleural catheter or talc slurry pleurodesis management. Excluded from review as does not meet inclusion criteria (study does not give outcome data from comparison of different methods of managing malignant pleural effusion). Participants with pleural and peritoneal effusions included in the study and unable to differentiate them in the results.Excluded due to inclusion of a child in study. An attempt was made to contact the authors by email to obtain data for adults only but no reply was received. Not randomised (high risk of bias for sequence generation and allocation concealment), therefore excluded. MPE: malignant pleural effusion. Characteristics of studies awaiting assessment [ordered by study ID]MethodsRCT comparing the time to pleurodesis in people with MPE receiving doxycycline + IPC vs IPC alone (OPUS).ParticipantsMPEInterventionsIPC + doxycycline: doxycycline 500 mg in 50 mL saline via IPC. MethodsRandomised study comparing highly agglutinative staphylococcin plus cisplatin with cisplatin alone.Participants74 participants with MPE and ascites.InterventionsUnclear from abstract how agents were delivered.OutcomesReduction in effusion/ascites volume MethodsRandomised study comparing the therapeutic effect and safety of bevacizumab combined with cisplatin on MPE of people with NSCLC.Participants54 people with NSCLC and MPE.InterventionsControl group: intrathoracic injection of cisplatin 75 mg/m2 twice, each cycle 21 days. MethodsRCT of pleural perfusion of nedaplatin and cisplatin in MPE due to NSCLC.Participants68 participants with lung cancer associated with MPE.InterventionsParticipants randomised into 2 groups. MethodsRCT of intrapleural adriamycin and Nocardia rubra cell wall skeleton compared with adriamycin alone.Participants55 participants with MPE due to lung cancer.InterventionsAgents given via tube thoracostomy. No other details available.OutcomesTreatment response.NotesIn Japanese. Unable to translate. MethodsTrial comparing bleomycin, OK‐432 and cisplatin + etoposide in MPE due to NSCLC.ParticipantsMPE due to previously untreated NSCLC.InterventionsIntrapleural bleomycin, OK‐432 and cisplatin + etoposide.OutcomesProgression‐free survival.NotesIn Japanese. Unable to translate. No details in abstract as to whether it is randomised or the number of participants in the study. MethodsRandomised study evaluating the efficacy and safety of tranexamic and bleomycin for pleurodesis in MPE.Participants63 people with MPE.InterventionsRandomised to receive tranexamic acid, bleomycin or tranexamic acid + bleomycin via chest drain.OutcomesPleurodesis success, complications.NotesAbstract. Contacted authors for further information, which is pending at the time of review completion. MethodsRCT comparing intrapleural Pseudomonas aeruginosa, with cisplatin and interleukin‐2.Participants90 participants with MPE.InterventionsAgents administered through intrathoracic infusion. No other information available.OutcomesClinical efficacy and adverse reactions.NotesWritten in Chinese and unable to obtain a translation. Only abstract available in English. MethodsRCT of intrapleural Ya‐Dan‐Zhi's grease (YDZ) and cisplatin in MPE.Participants72 participants with MPE.InterventionsRandomly divided between 3 groups: MethodsRCT comparing intrapleural doxycycline and bleomycin.Participants34 participants with MPE requiring repeated thoracentesis.InterventionsParticipants received either intrapleural doxycycline or bleomycin.OutcomesFluid volume, adverse effects, response to treatment (on CXR and clinical examination), survival.NotesIn Korean. Only abstract available in English. Unable to obtain a translation. MethodsRCT evaluating the effect of intrapleural highly agglutinative staphylococcin combined with nedaplatin, compared to nedaplatin alone.Participants58 participants with MPE.InterventionsParticipants randomised to 2 groups. MethodsRCT comparing cisplatin and lentinan in MPE.Participants64 participants with MPE.InterventionsRandomised into 2 groups: MethodsRCT comparing matrine injection (yanshu) combined with intrapleural cisplatin for treatment of haematological malignancies complicated by pleural effusion.Participants46 participants with haematological malignancy complicated by pleural effusion.InterventionsParticipants randomly divided into 2 groups. CXR: chest x‐ray; IPC: indwelling pleural catheter; KPS: Karnofsky Performance Score; MPE: malignant pleural effusion; NSCLC: non‐small cell lung cancer; RCT: randomised controlled trial. Characteristics of ongoing studies [ordered by study ID]Trial name or titleThe Australasian Malignant Pleural Effusion (AMPLE) Trial 3: a randomised study of the relative benefits of combined indwelling pleural catheter (IPC) and talc pleurodesis therapy or video‐assisted thoracoscopic surgery (VATS) in the management of participants with malignant pleural effusion.MethodsMulticentre, international RCT comparing IPC and talc pleurodesis to VATS for the management of MPE.ParticipantsInclusion criteria: people with symptomatic MPE, predicted survival > 6 months, ECOG score 0–1. Trial name or titleMesoTRAPMethodsFeasibility study that includes a pilot multicentre, RCT comparing VAT partial pleurectomy/decortication with IPC in people with trapped lung and pleural effusion due to MPM. ParticipantsInclusion criteria: trapped lung requiring intervention in people with MPM with pleural effusion, aged > 18 years, expected survival > 4 months, suitable and willing to undergo VAT partial pleurectomy/decortication or IPC insertion. {"type":"clinical-trial","attrs":{"text":"NCT02583282","term_id":"NCT02583282"}}NCT02583282 Trial name or titleA study to compare the efficacy and safety of intrapleural doxycycline vs iodopovidone for performing pleurodesis in malignant pleural effusion.MethodsRCT comparing doxycycline and iodine pleurodesis.ParticipantsInclusion criteria: recurrent, symptomatic MPE with dyspnoea improvement follow thoracentesis.InterventionsParticipants randomised to receive doxycycline 500 mg slurry via chest drain or 20 mL 10% betadine via chest drain.OutcomesPleurodesis success, defined as absence of effusion re‐accumulation on CXR at 30 days and relief of symptoms.Starting date2015Contact [email protected] details as listed on clinical trials registry. Confirmation received from author that study is continuing to recruit. Trial name or titleOPTIMUMMethodsMulticentre RCT comparing whether outpatient management of MPE with an IPC and pleurodesis improves QoL compared with inpatient care with a chest drain and talc pleurodesis.ParticipantsInclusion criteria: MPE, WHO Performance Score 0–2, expected survival > 3 months. Trial name or titleEfficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE).MethodsMulticentre RCT designed to evaluate whether use of thoracic ultrasound in hospitalised people with MPE before and during the first 24–72 hours post‐talc administration, accurately identifies pleural adherence early in treatment, permitting shorter hospital stay without adversely affecting pleurodesis success.ParticipantsInclusion criteria: confirmed MPE requiring pleurodesis. Trial name or titleA randomised comparative phase 3 trial of pleurodesis in malignant pleural effusions: sterile graded talc vs. OK‐432 (WJOG8415L).MethodsRCT to compare efficacy and safety of graded talc and OK‐432 in pleurodesis for MPE.ParticipantsInclusion criteria: histocytologically confirmed symptomatic MPE, previous chest tube drainage, life‐expectancy > 30 days, aged > 20 years. Trial name or titlePivotal multi center, randomized, controlled, single‐blinded study comparing the silver nitrate coated indwelling pleural catheter to the uncoated PleurX catheter for the management of symptomatic, recurrent, malignant pleural effusions.MethodsRCT to determine whether a silver nitrate‐coated IPC is safe and effective in treating MPEs compared to approved catheters.ParticipantsInclusion criteria: symptomatic MPE requiring intervention, aged > 18 years, ≥ 1 ipsilateral pleural effusion causing dyspnoea that responded to thoracentesis where the lung expanded and the dyspnoea was improved, sufficient pleural fluid to allow safe insertion of an IPC, negative pregnancy test if appropriate, participant or carer is able to perform home drainage of the pleural effusion (UK participants will have drainage managed by home‐care nurses). Trial name or titleA Trial of Intra‐pleuraL bacterial immuno‐Therapy in mesothelioma (TILT): a feasibility study using the 'trial within a cohort' methodology.MethodsRCT investigating intrapleural bacterial immunotherapy in MPM using the 'Trial within a Cohort' (TwiC) methodology. Participants are recruited from an existing observational cohort (the ASSESS‐meso study).Participants24 eligible participants are identified from the cohort, of whom 16 participants are randomly selected to be offered either OK432 or BCG. BCG: Bacillus Calmette‐Guérin; CT: computer tomography; CXR: chest x‐ray; ECOG: Eastern Cooperative Oncology Group; EORTC QLQ‐C30: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EQ‐5D‐5L: 5‐level EQ‐5D; FACT‐L: Functional Assessment of Cancer Therapy – Lung; IPC: indwelling pleural catheter; KPS: Karnofsky Performance Score; MPE: malignant pleural effusion; MPM: malignant pleural mesothelioma; QoL: quality of life; RCT: randomised controlled trial; RECIST: Response Evaluation Criteria in Solid Tumors; VAS: visual analogue scale; VAT‐PD: video‐assisted thoracoscopic partial pleurectomy/decortication; VATS: video‐assisted thoracoscopic surgery; WHO: World Health Organization. Differences between protocol and review2016 reviewThe wording of the background and methods sections have been improved to make them more concise, minimise repetition and to reflect the recently published literature. In the original protocol, we stated we would use risk ratios for dichotomous outcomes; however, we elected to use odds ratios instead, since network meta‐analysis models are more readily available for these. The protocol stated that the size of the study would be assessed to look for bias associated with small‐study effects. This was not performed, as size in itself should not affect the study results and inclusion of sample size in 'Risk of bias' tables would be against the advice in the Cochrane Handbook for Systematic Reviews of Interventions (), and training provided by the Cochrane Bias Methods Group. The protocol combined blinding of participants and personnel and outcome assessment into a single domain. However, in light of new guidance from Cochrane, this was separated into 'blinding of participants and personnel' and 'blinding of outcome assessment', as per the Cochrane Handbook for Systematic Reviews of Interventions (). The protocol stated we would evaluate mortality in the short, medium and long term. However, due to a paucity of evidence at all these different time points, an overall assessment was done using the available study data closest to three months after the intervention. The wording of the planned sensitivity analyses has been amended for clarity. For clarity, we added 'a network meta‐analysis' to the title. Post‐hoc, we chose to perform a sensitivity analysis of the main network excluding talc poudrage and IPCs in order to remove the effect of mode of administration to identify which agent may be best delivered via a standard chest tube. 2020 updateWe further updated the wording of the background sections to reflect recent literature. We performed a search for ongoing studies on clinical trial registries, and extracted information on study funding sources and study author conflicts of interest statements, in line with current Cochrane standards. We added "methods to optimise IPC use including IPC drainage regimen and combined talc administration via IPC" to the list of types of interventions because data from newer studies, which have investigated whether daily IPC drainage or talc slurry via IPC may result in fewer pleurodesis failures in comparison to standard IPC use (with drainage based on symptoms), is included in this review. We expanded the interventions of direct interest to include 'IPC (both daily drainage and without daily drainage) and talc administered via IPC' to reflect the different ways in which IPCs are studied in more recent literature. We included that 'for studies evaluating IPCs, we judged that an effective pleurodesis was achieved when there was cessation of pleural fluid drainage or device removal due to cessation of drainage, or both' to reflect a more specific and clinically relevant definition of pleurodesis failure relating to IPC use. This was used in preference to the other definitions of pleurodesis failure, listed in the hierarchy of preferences, in participants receiving an IPC. In the 'Methods', for unit of analysis issues we added that 'in meta‐analysis of continuous outcomes, we pooled differences in change from baseline, rather than differences in final values ()' in keeping with Cochrane Handbook for Systematic Reviews of Interventions guidance. In the 'Methods', we added that 'for continuous outcomes, where baseline and final values were reported without a standard deviation of change score or correlation coefficient, we imputed correlation coefficients based on other studies in order to estimate the standard deviation of change' in keeping with Cochrane Handbook for Systematic Reviews of Interventions guidance. Although the use of network meta‐analysis was mentioned in the published protocol, further details have been included to clarify the methodology. This includes details on prior distributions and methodology used to quantify heterogeneity and check for inconsistency. Further, for the main analyses, we plotted the mean residual deviance contributions of each data point under the inconsistency versus network meta‐analysis models. This allows identification of specific data points for which the inconsistency model has improved fit, that is, data points that are potentially inconsistent with the network (). These changes are based on the protocol template from the Comparing Multiple Interventions Methods Group, which was not available when we wrote our original protocol. In 'Sensitivity analyses', we added 'analysis only including studies which administered pleurodesis through a chest tube (any size)', and slightly amended our criteria for low‐risk studies to 'analysis only including studies at a low risk of bias (maximum of one domain assessed as high risk of bias)' to ensure the sensitivity analysis for studies at low risk of bias included only the most robust data, to give a greater level of certainty in the estimate of the effect. We added that 'we performed a post‐hoc sensitivity network meta‐analysis evaluating only pleurodesis agents delivered via a chest tube (as opposed to being given at thoracoscopy). We removed the trials evaluating talc poudrage and IPC use from the main network and repeated the analysis. We performed an additional post‐hoc pair‐wise meta‐analysis comparing ipsilateral repeat invasive pleural intervention rates (where data were available).' We performed sensitivity analyses of direct evidence on pleurodesis failure using fixed‐effect meta‐analysis models, since pooled effect estimates from random‐effects models give relatively more weight to smaller studies, which is often considered undesirable. Within the patient acceptability secondary outcome, we considered that the risk of requiring a repeat invasive pleural procedure for symptomatic re‐accumulation of pleural fluid is an important factor when selecting an initial management strategy for MPE. Therefore, we performed a post‐hoc direct meta‐analysis of requirement for a repeat ipsilateral invasive pleural intervention. We added an assessment of the certainty of the body of evidence and include 'Summary of findings' tables, which present outcomes from the main network meta‐analysis for pleurodesis failure, adverse events (fever and pain) and mortality. Where sufficient data enabled direct meta‐analysis of breathlessness improvement and repeat invasive pleural intervention for the most commonly used interventions, we also included this information in the summary tables. Contributions of authorsThe protocol was written collaboratively by AOC, HEJ, RB, NP, NAM. AD and AOC screened the titles and abstracts and obtained the full‐text papers for the 2020 update. Screening of titles and abstracts up to 2016 was by AOC only. AD, AOC, NAM assessed the full‐text articles for inclusion. AD, AOC, NP, RB and NAM performed the data extractions. AD and AOC entered the data into Review Manager (and RevMan Web for 2020 update) and undertook the direct pair‐wise comparisons. HJ performed the network meta‐analysis and provided statistical support. AD and AOC drafted the final report, which was reviewed and amended by all the authors. AOC and NAM are responsible for future updates. Sources of supportInternal sources
External sources
Declarations of interestAD: none known. HJ: none known. RB was the trial co‐ordinator for the TAPPS and IPC‐Plus studies (; ), but did not perform the data extractions, or any assessments of risk of bias or GRADE, for these studies for the purposes of this review. NJP: none known. NM was a member of the trial steering committee for TIME‐1 and TIME‐3 trials (; ). NM is a co‐author for one of the included studies (). However, he did not perform the data extractions, nor any assessments of risk of bias or GRADE, for these studies for the purposes of this review. North Bristol NHS Trust received unrestricted research funding from CareFusion, to run the IPC‐Plus trial () (2012 to 2016) for which NM was the chief investigator. NM also received honoraria from CareFusion for medical advisory board meetings (2015 to 2019). AOC was involved in co‐ordinating and recruiting to the TIME‐3 trial (). She also recruited to the TAPPS trial (), and assisted with the data analysis. She did not perform the data extraction, nor any assessments of risk of bias or GRADE, for these studies for the purpose of this review. ReferencesReferences to studies included in this reviewAgarwal 2011 {published and unpublished data}
Alavi 2011 {published data only (unpublished sought but not used)}
Bagheri 2018 {published data only (unpublished sought but not used)}
Bayly 1978 {published data only}
Bhatnagar 2018 {published data only}
Bhatnagar 2020 {published and unpublished data}
Bjermer 1995 {published data only}
Boshuizen 2017 {published and unpublished data}
Clementsen 1998 {published data only}
Crnjac 2004 {published data only}
Davies 2012 {published and unpublished data}
Demmy 2012 {published and unpublished data}
Diacon 2000 {published and unpublished data}
Dresler 2005 {published and unpublished data}
Du 2013 {published data only (unpublished sought but not used)}
Emad 1996 {published data only}
Evans 1993 {published data only (unpublished sought but not used)}
Fentiman 1983 {published data only}
Fentiman 1986 {published data only}
Gaafar 2014 {published data only (unpublished sought but not used)}
Goodman 2006 {published and unpublished data}
Groth 1991 {published data only}
Haddad 2004 {published and unpublished data}
Hamed 1989 {published data only (unpublished sought but not used)}
Hillerdal 1986 {published data only}
Hojski 2015 {published data only (unpublished sought but not used)}
Ibrahim 2015 {published data only (unpublished sought but not used)}
Ishida 2006 {published data only (unpublished sought but not used)}
Kasahara 2006 {published data only}
Keeratichananont 2015 {published data only (unpublished sought but not used)}
Keeratichananont 2018 {published data only}
Kefford 1980 {published data only}
Kessinger 1987 {published data only}
Koldsland 1993 {published and unpublished data}
Kuzdzal 2003 {published data only (unpublished sought but not used)}
Leahy 1985 {published data only}
Loutsidis 1994 {published data only}
Luh 1992 {published data only}
Lynch 1996 {published data only}
Mager 2002 {published and unpublished data}
Martinez‐Moragon 1997 {published data only}
Maskell 2004 {published and unpublished data}
Masuno 1991 {published data only}
Mejer 1977 {published data only}
Millar 1980 {published data only}
Mishra 2018 {published data only (unpublished sought but not used)}
Mohsen 2011 {published data only}
Muruganandan 2018 {published data only (unpublished sought but not used)}
Neto 2015 {published data only (unpublished sought but not used)}
Noppen 1997 {published data only}
Okur 2011 {published and unpublished data}
Ong 2000 {published data only}
Ostrowski 1989 {published data only}
Ozkul 2014 {published data only (unpublished sought but not used)}
Paschoalini 2005 {published data only}
Patz 1998 {published and unpublished data}
Putnam 1999 {published data only}
Rafiei 2014 {published data only (unpublished sought but not used)}
Rahman 2015 {published data only}
Rintoul 2014 {published and unpublished data}
Ruckdeschel 1991 {published data only}
Salomaa 1995 {published data only}
Sartori 2004 {published data only}
Saydam 2015 {published data only (unpublished sought but not used)}
Schmidt 1997 {published data only}
Sorensen 1984 {published data only}
Tabatabaei 2015 {published data only (unpublished sought but not used)}
Terra 2009 {published data only (unpublished sought but not used)}
Terra 2015 {published data only (unpublished sought but not used)}
Thomas 2017 {published and unpublished data}
Ukale 2004 {published and unpublished data}
Villanueva 1994 {published data only}
Wahidi 2017 {published data only}
Wang 2018 {published data only (unpublished sought but not used)}
Yildirim 2005 {published and unpublished data}
Yim 1996 {published data only}
Yoshida 2007 {published data only (unpublished sought but not used)}
Zaloznik 1983 {published data only}
Zhao 2009 {published data only (unpublished sought but not used)}
Zimmer 1997 {published data only (unpublished sought but not used)}
References to studies excluded from this reviewCaglayan 2008 {published data only}
Dryzer 1993 {published data only}
Elayouty 2012 {published data only (unpublished sought but not used)}
Engel 1981 {published data only}
Gust 1990 {published data only}
Kleontas 2019 {published and unpublished data}
Kwasniewska‐Rokicinska 1979 {published data only}
Lissoni 1995 {published data only (unpublished sought but not used)}
Liu 2017 {published data only (unpublished sought but not used)}
Maiche 1993 {published data only}
Manes 2000 {published data only}
Martin 2019 {published data only}
Nio 1999 {published data only}
Ogunrombi 2014 {published data only (unpublished sought but not used)}
Tattersall 1982 {published data only}
References to studies awaiting assessmentAmjadi – OPUS Trial {published data only (unpublished sought but not used)}
Bo 1998 {published data only}
Chen 2015 {published data only}
Cong 2010 {published data only}
Fukuoka 1984 {published data only}
Miyanaga 2011 {published data only}
Mohamed 2013 {published data only}
Song 2013 {published data only}
Sun 2002 {published data only}
Won 1997 {published data only}
Xu 2010 {published data only}
Yu 2003 {published data only}
Zhuang 2012 {published data only}
References to ongoing studiesAMPLE 3 {published data only}
MesoTRAP {published data only}
{"type":"clinical-trial","attrs":{"text":"NCT02583282","term_id":"NCT02583282"}}NCT02583282 {published data only}
OPTIMUM {published data only}
SIMPLE {published data only}
Sterile‐graded talc versus OK‐432 {published and unpublished data}
SWIFT {published data only}
TILT {published data only}
Additional referencesAmerican Thoracic Society 2000
Bielsa 2008
Bjorkman 1989
Brims 2012
Burrows 2000
Chaimani 2013
Chaimani 2015
Clive 2014
Covidence [Computer program]
Deeks 2011
Dias 2013
Dias 2018
DiBonito 1992
Dipper 2019
Donegan 2013
Higgins 2003
Higgins 2011a
Higgins 2011b
Higgins 2019
Iyer 2019
Jansen 2013
Lan 1997
Lee 2003
Lunn 2000
Mishra 2015
Mummadi 2015
NICE 2019
Olfert 2017
Psallidas 2018
Rahman 2010
RevMan Web [Computer program]
Roberts 2010
Rodrîguez‐Panadero 1989
Rodrîguez‐Panadero 2008
Salanti 2012
Salanti 2014
Sears 1987
Sivakumar 2019
Sterne 2011
Tan 2006
Tremblay 2006
Warren 2008
WHO 2016
Williamson 2012
|